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Abstract
Irreversible dental problems such as dental carries and periodontal disease create a plethora of general and oral health issues.
Although there are solutions to treat these different problems, an emphasis has been placed on finding a solution to these points
with the help of bioengineering and stem cells. Using stem cells to treat these problems could result in a more permanent fix
than the methods dentists employ now.Two novel approaches to fixing irreversible dental problems via stem cell therapy are tooth
tissue regeneration and whole tooth replacement.This paper reviews the advantages and disadvantages of using dental pulp stem
cells, stem cells from human exfoliated deciduous teeth, periodontal ligament stem cells and stem cells of the apical papilla for
these novel techniques. Ultimately, these methods provide a promising future for dental patients, particularly with the use of stem
cells from of the apical papilla.
Introduction
Methods
The tooth is a complex ectodermal organ consisting of various
hard tissues as well as soft connective tissue. The hard tissues
found in the tooth include: enamel, dentin, and cementum. Teeth
also contain soft connective tissues like pulp and a periodontal
ligament composed of fibrous connective tissue with both vascular and neural sections. Whole tooth loss and oral diseases
such as dental carries, oral trauma, periodontal disease create
many problems that impact proper oral function. Issues with
enunciation, mastication, occlusion and general health issues are
known to be induced by tooth loss or the onset of oral disease.
(Oshima et. al, 2014)
Currently, there are many procedures using artificial materials to replace missing or damaged teeth. Dental implants,
bridges, dentures and crowns all help to replace missing teeth,
however, many believe that the optimal replacement is to regrow tooth tissue or an even an entire tooth in place of the
missing tooth.
Due to extensive, active research in embryonic development,
stem cell biology, and tissue engineering, regenerative therapy
is a promising method for the restoration of function in missing or damaged organs including teeth. There are numerous
tooth-tissue derived stem cells that have been found to aid
in the development of new teeth allowing for the evoution of
teeth regeneration techniques. Tooth-tissue regenerative therapy involves transplanting a bioengineered tooth germ grown
in vitro via stem cells. At the time of implantation, these bioengineered specimens must contain all the components of a
naturally growing tooth in order to be able to function as one
in the future. Whole tooth replacement transplants a complete,
bioengineered tooth to replace the missing tooth. Many believe
that tooth replacement via stem cell therapy will be the treatment of choice for missing or severely damaged teeth. Several
other methods have been proposed to replace missing teeth
including three-dimensionally bio engineered teeth and the
cell-aggregation method. Additional reports have been released
regarding fully functional bioengineered teeth with correct tissue orientation and the masticatory capabilities of regular teeth.
This review will discuss the most recent findings on tooth tissue
engineering and whole tooth regeneration, and will provide the
most viable method for the near future.

This review is based on the analysis of scientific articles and original
works found on the internet. Several different internet databases
were used including Touro college’s online library and PubMed.

Discussion:Tooth Development
To ensure the success of tooth regeneration techniques, it is
important to first understand how a biological tooth is formed
and attempt to mimic those natural steps in the lab. As a tooth
develops, it undergoes four distinct morphological phases;
the initiation, bud, cap, and bell stages (Yildrim, 2013). During
initiation, support structures such as the alveolar bone and
periodontal ligament begin to develop. The tooth germ is first
observed as a thickening and propagation of the cells of the
oral epithelium and these cells form a bud that extends to the
dental mesenchyme. The dental epithelium continues to undergo extensive proliferative activity, eventually forming a cap-like
structure and completing tooth development.
During tooth development, the cells differentiate into three
different sections: the inner and upper layers and the central
cell layer that forms the stratum intermedium and stellate reticulum. As they do so, the enamel knot signaling center can
be identified. At this point, ectomesenchymal cells of the dental
papilla condense, giving rise to both the dentine and pulp of
the tooth. The dental follicle forms around the dental papilla
and enamel, giving rise to the periodontal tissues. The final bell
stage is heavily defined by the continued proliferation and tissue
differentiation. In this process, the inner epithelial cells adopt
a cube shape and produce a considerable amount of glycogen,
while the cells of the stratum intermedium produce alkaline
phosphatase and the stellate reticulum adopts a star shape, encircled by the outer epithelial layer.
As the tooth continues to grow and differentiate, odontoblasts from dental mesenchyme differentiate and build up the
dentin matrix, while ameloblasts from epithelial cells produce
the enamel matrix. Once the crown of the tooth has formed,
tooth root structures start to develop from Hertwig’s epithelial
root sheath, creating periodontal ligament, dentin, cementum
and alveolar bone.
Throughout the entire tooth development, the only portion
that does not have regenerative properties is the dental enamel.
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Enamel is the only mineralized tooth tissue sourced from the
dental epithelium. All other mineralized tooth tissue, such as
dentin, periodontal ligament, alveolar tissue and cementum have
some form of regenerative properties.These tooth tissues originate from neural crest-derived dental ectomesenchyme. Dental
stem cells are believed to play an important role in the regenerative properties of these tissues (Dannan 2009).

Dental Stem Cells
Unlike other cells found in the body, stem cells have unique
capabilities. They are unspecialized, yet can produce specialized
cell types, even after prolonged periods of inactivity. Stem cells
are able to proliferate and can be isolated based on unique cell
surface markers. It is important to note that in vitro culture conditions may alter the cells, thus causing the cells to behave in a
different manner than they would have in vivo. There are two
categories of stem cells that can be used: embryonic or somatic
stem cells. Being that the use of embryonic stem cell is ethically
controversial, researchers work with strictly somatic, or adult
human stem cells for clinical application. Somatic stem cells are
easily accessible and without the controversy of their embryonic
counterparts, making them the optimal choice for use in dentistry.
There are several types of stem cells that can be found in
teeth. Dental stem cells are found in the periodontal ligament,
apical papillae, and the pulp of both adult and children’s teeth.
Although these stem cells differ in their growth rate in culture,
cell differentiation and gene expression, they most likely share
a common lineage. Dental stem cells are derived from neural
crest cells and all have generic mesenchymal stem cell-like properties. (Volponi et. al, 2010)

Dental Pulp Stem Cells
Dental pulp stem cells (DPSCs) are a mesenchymal type of stem
cell located in the center of the tooth. Dental pulp stem cells
are considered a great candidate for stem cell therapy for many
reasons. DPSCs are easily accessible for collection and have a
low morbidity once extracted.They are also known to generate
more dentin than other stem cells, being easily conserved via
cryopreservation (Yan, et. al. 2010). There are various methods
to isolate DPSCs from the dental pulp including size-sieved
isolation, stem cell colony cultivation, magnetic activated cell
sorting (MACS), and fluorescence activated cell sorting (FACS).
In addition, DPSCs were found to generate a dentine structure
in vivo and differentiate in vitro (Gronthos et.al, 2000). These
features make DPSCs a prime source of stem cells for 3-dimensional tooth regeneration.

Stem Cells from Human Exfoliated
Deciduous Teeth
Stem cells from the pulp of human baby teeth, also known as
stem cells from human exfoliated deciduous teeth (SHED),
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were found to differentiate into non-dental mesenchymal cell
derivatives in vitro, produce dentine, and induce bone formation. SHED differs from DPSCs with respect to their higher
rate of proliferation, sphere-like cell clustering and, most importantly, their inability to produce a dentin-pulp-like complex. It is
believed that the reason for these differences is due to SHED
being a multipotent stem cell that is less mature than DPSCs.
SHED were reported to not be able to differentiate into osteoblasts, yet managed to form an osteoinductive template, thus
leading to new bone formation. Following transplantation, SHED
were found to aid in bone formation and generate dentin. SHED
were found to be a highly proliferative cell population, capable
of differentiating into various cells such as neural and glial cells
as well as odontoblasts. Although there are better types of stem
cells for use in dentistry, due to its penchants for widespread
differentiation there is still much potential for SHED stem cells
in other areas of regenerative medicine, such as in the brain and
nervous system. (Miura et. al, 2003).

Periodontal Ligament Stem Cells
The periodontal ligament (PDL) has been viewed as a potential
source of stem cells for a long time. The PDL is a connective
tissue that acts as a shock absorber during chewing and is
found between the cementum and the inner wall of the alveolar socket, anchoring both to each other. These stem cells have
characteristics of mesenchymal stem cells and have potential
to be used in periodontal regeneration. It is important to note
that unlike other stem cells, PDLSCs do not have a unique cell
marker that differentiates them from mesenchymal stem cells.
Therefore, PDLSCs are not an optimal choice for stem cell research and dental regeneration (Zhu and Liang, 2015).

Root Apical Papilla Stem Cells
Stem cells of the apical papilla (SCAP) are found by the tips of
growing tooth roots. These cells are only present during root
development, prior to the eruption of the tooth. Stem cells of
the apical papilla were reported to differentiate into both adipocytes and odontoblasts. When compared to the proliferative
potential of DPSCs in vitro, SCAP were noted to proliferate at
a higher rate, making them a very promising source of stem cells
for stem cell therapy. Current implant-based methods to replace whole teeth have failed to reproduce the necessary root
structure, causing jaw-bone resorption around the implant due
to the force of chewing (Volponi et. al, 2013). When combined
with periodontal ligament stem cells and transplanted into mini
pigs, researchers noted formation of periodontal ligament and
dentine. These results suggest that the necessary technology to
implant a biological root and place an artificial dental crown on
it has been attained.
Another point of advocacy is that SCAP can be harvested
without the ethical issues of stem cell harvesting in embryos.
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In addition, an important attribute of SCAP is that they are
believed to be the source of root dentin, while DPSCs are
the source of the replacement odontoblasts. SCAP could be
distinguished from other mesenchymal stem cells in a number
of ways. The most significant difference is that while all other
mesenchymal stem cells test negatively for hTERT (human telomerase reverse transcriptions) activity, SCAP were found to
test positive for it. This suggests that there is a difference in the
genetic lineage of stem cells from the apical papilla compared
to that of other dental stem cells. SCAP seem to come from an
early population of progenitor cells and may be a better option
for tissue regeneration (Huang et. al, 2008).

Using Dental Stem Cells for Tooth Tissue
Regeneration
When stem cells isolated from the apical papilla of human teeth
and human periodontal ligament were transplanted into mice
and mini pigs, the successful regeneration of the root and periodontal complex capable of supporting a crown was achieved.
Being that pigs have an orofacial tissue organization similar to
humans, the successful regeneration of a bio root and transplantation into pigs shows the tremendous potential of this method
for use in humans. Unlike other experiments to regenerate
tooth tissue, this method used human stem cells and not stem
cells from mice or pigs, proving that human stem cells were
capable of producing the above mentioned successful results
(Sonoyama et. al, 2006).

Whole Tooth Regeneration
Whole tooth regeneration is another approach to fix the issues associated with irreversible tooth damage. This method of
tooth regeneration attempts to grow a whole tooth in vitro
and transplant it into the mouth. To successfully regenerate a
whole tooth, the same process that the tooth undergoes when
it is first formed in the developing embryo must be replicated.
Organogenesis of the tooth takes place by the interaction of
mesenchymal and epithelial progenitor stem cells. Once the
bioengineered tooth germ is produced in vitro, it may be transplanted it into the area of tooth loss, thus regenerating a new
tooth. The biggest challenge is to develop a technique that will
allow for the mesenchymal-epithelial stem cell interaction while
in vitro. So far, there are several suggested methods that will
allow scientists to use dissociated stem cells to bioengineer a
tooth germ (Oshima et. al, 2014).

The Scaffold Method
The first method which allows for the necessary mesenchymal-epithelial stem cell reaction, is using a biodegradable scaffold.
Scaffold technology has provided us the with a method to regenerate specific tissue by sowing cells on degradable materials. The
scaffold method has been used to generate tissues in cartilage

and bone regeneration therapies. Experiments using a collagen
sponge as the scaffold material have reported successful formation of small teeth.These lab-grown teeth had all the characteristics found in biological teeth including dentin, enamel and dental
pulp as well as forming the correct shape and size (Young et. al,
2002). Despite the scaffold method’s ability to regenerate teeth,
there are some significant problems with this technique. It has a
low frequency of tooth formation. This approach fails to provide
the many precise intercellular reactions, causing irregularities in
the created tooth tissues, such as in the enamel-dentine complex.
For proper tooth structure, there needs to be many precise junctions between the enamel, cementum and dentine for normal
tooth development. These complex junctions are the result of
very specific mesenchymal-epithelial stem cell tissue interactions,
resulting in a very precise combination of ameloblasts, cementoblasts and odontoblasts, a process the scaffold method has yet to
mimic perfectly (Thesleff, 2003).

The Cell Aggregation Method
A second approach is known as the cell aggregation method.
This procedure is used to reconstruct bioengineered organ
germ and has been able to produce the proper mesenchymal-epithelial cell interaction during the developmental process
that the scaffold method has failed to produce. Recent studies have reported that transplanted bioengineered mammary
gland stem cells successfully caused organ regeneration in vivo
with the proper structure and cellular arrangement (Zheng et.
al, 2005). The cell aggregation method was also used to successfully regenerate hair follicles (Zheng et. al, 2005). There has
been much research done using the cell aggregation method to
successfully regenerate teeth with correct structures. Currently,
this technique has only been able to create teeth with the proper structure, but to date, only at a low frequency. Although the
cell aggregation method replicated the organogenesis of biological teeth partially, a method that has a higher frequency of
success is being sought (Nakao and Tsuji, 2008).

The Organ Germ Method
The interaction between the epithelial and mesenchymal stem
cells in the embryo gives rise to the organ germ. It can be concluded from this that to properly reproduce organs, one needs
to reproduce the steps and conditions that created them in the
first place. Both tooth and whisker follicle germs were used as
a source of the disassociated epithelial and mesenchymal stem
cells. Although there has been successful regeneration of organs
in the past, they were all produced in vitro.The organ germ method allows for the regeneration of teeth in vivo as well as in vitro.
Self-reorganization of the mesenchymal and epithelial
stem cells is the first step in multicellular aggregation. Selfreorganization is accomplished by these stem cells moving and
adhering themselves to select cells until there is the necessary
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equilibrium.After the proper cell configuration has been accomplished through self-reorganization, the next step is the initiation
of organogenesis by the mesenchymal and epithelial stem cells.
These stem cells regulate the morphogenesis and differentiation
as well. It is important to note that the frequency of successful
self-reorganization and tissue regeneration is dependent on the
source of the stem cells used in this procedure.
In research performed by Nakao, the organ germ method
successfully produced tooth germ with the correct structure,
resulting in transplantation that yielded tooth growth. Similarly,
when growing whole teeth in vitro and then transplanting them,
the bioengineered teeth were able to attach themselves to the
mouth and form both nerve fibers and blood vessels from the
implanted stem cells. This method used completely disassociated mesenchymal and epithelial stem cells to generate the necessary tooth germ resulting in successful tooth transplantation
both in vivo and in vitro.
When the experiment was first conducted, single cells from
the incisor tooth germ at cap stage from the lower jaws of
mice were used. These explants failed to produce a complete
tooth, yet managed to generate bone or keratinized oral epithelium-like structures. The explants that failed to form cell
compartmentalization at high cell density, failed to produce
the correct tooth structure as well. To form a tooth with the
correct cell compartmentation of epithelial and mesenchymal
stem cells, the cells that could compartmentalize at high density were then collected and injected into the adjacent areas
via a collagen gel drop. After just one day, there was already
evidence of tooth germ formation with the correct compartmentalization of stem cells. This bioengineered tooth germ
was then transplanted into sub renal capsules in mice. After
transplantation, the formed tissue was observed histologically
and was found to contain odontoblasts, dentin, enamel, dental
pulp, Tomes’ process, root analog, alveolar bone, periodontal
ligaments and blood vessels in the same layout as natural teeth.
This transplantation produced successful results 100% of the
time in 50 different transplants.
Analysis of the regenerated teeth showed mRNA for specific
markers for periodontal ligaments and ameloblasts. To find out
if tooth germ taken from bioengineered teeth would also produce the same successful results, the origin of the mesenchyme
and epithelium cells from the tooth germ of GFP-transgenic
mice were analyzed. The mesenchymal cells derived from GFPtransgenic mice were found to contain dental pulp and odontoblasts as well as produce alveolar bone and periodontal follicles,
which are normally derived from dental follicles. The epithelial
cells from these mice produced ameloblasts. It was also determined that bio engineered tooth germ did not develop into
teeth as frequently as natural tooth germ. This is a distinct indication that the developmental stage of the natural tooth germ
is vital for successful regeneration of tooth germ.
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To prove that bioengineered tooth germ successfully produces teeth in vitro with the correct cell types, time-course
images were observed. These images proved that the tooth
germ successfully produced the necessary cell types in proper
fashion. After successfully growing a tooth in the renal capsule,
the next step was to check if it can be successfully transplanted
and develop into a fully functioning tooth. Bioengineered teeth
were allowed to grow in the sub renal capsule for a duration of
two weeks. After transplanting the tooth into the oral cavity of
a mouse, there were successful results. There was formation of
a correct tooth structure with all the components that natural
teeth have including dental pulp, dental root, enamel, dentin, and
periodontal ligaments. The size of these regenerated teeth was
found to be within a 1.1-fold increase, thus ensuring that we
have attained a method for successful whole tooth replication
with the proper proportions as well as with the necessary components. (Nakao et. al, 20007)
Although these results provide us with a viable method to
regenerate teeth successfully in mice, there are still many things
that need to be investigated before this method can be considered for successful whole-tooth regeneration in humans. There
are a few more things that this experiment did not determine,
such as the hardness of the regenerated tooth and its response
to mechanical stress (Ikeda et. al, 2008).
Although there have been no reported cases of transplanting a tooth grown with the organ germ method into a human,
there have been studies that prove that teeth grown in this
manner and implanted in mice exhibit the appropriate hardness
and normal function. To determine whether the regenerated
teeth were as hard as natural teeth, the Knoop hardness test
was performed. It is used to determine the hardness of brittle
materials. By testing multiple times throughout the growth of
the bioengineered teeth, the result values showed the same
significant increase in dentin and enamel hardness as is found in
natural teeth between three and nine weeks, proving that they
can successfully take the place of missing teeth.
In order to determine if the regenerated tooth successfully
replaces the missing tooth, the regenerated tooth’s response
to mechanical stress must be examined. It is believed that in
order to regrow a fully functioning tooth, the tooth must interact with the oral and maxofacial regions by means of the
periodontal ligament. This is because the periodontal ligament
is known to induce alveolar bone remodeling when under mechanical stress (Ikeda et. al, 2008). Histochemical analysis of
the periodontal ligament revealed a connection between the
tooth and alveolar bone, showing the successful interaction
between the tooth and the oral and maxofacial regions via the
PDL. When the regenerated tooth was subjected to mechanical stress, localization of osteoblasts and osteoclasts occurred.
These cells have been found when the PDL of normal teeth
was subjected to mechanical stress as well, proving that the
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regenerated tooth is able to properly respond to mechanical
stress. (Ikeda et. al, 2008)
There are those that believe the successful regeneration of
teeth in mice does not translate into successful results in regenerating human teeth. Unlike humans, mice are known to only
grow molars and incisors separated by a toothless region known
as the diastema. Mice also only possess one set of teeth that grow
continuously throughout their life.Thus, mice may not be the best
model for tooth regeneration in humans (Huysseune and Thesleff,
2004). Being that whole teeth were successfully regenerated in
the diastema as well as in the lower jaw-bone of mice there is
evidence to suggest that despite notable differences between
human and mouse mouths, the regeneration of teeth in mice is
not exclusive to mice and may be done in humans as well.

Conclusion
Although there have been no reports of successful whole tooth
regeneration in humans, scientists appear to be on the right track. The
research presented above indicate that although the cell aggregation
method is a promising technique to regenerate whole teeth, there is
still much work to be done before this will be the treatment of choice
to replace missing teeth. Being that a bio root composed of human
stem cells has been reported to be successfully transplanted into
mini pigs, there is strong reason to believe that this method may be
applied to humans in the near future. This review highlights differences
between mice and humans that may affect the success of regeneration
in humans. Despite there being extensive research and roadblocks
ahead in the development of tooth regeneration techniques, progress
and success with model organisms has introduced an element of hope
for science to provide cures and resolutions to damaging oral diseases
and encourage improved overall dental health.

References

Dannan A. Dental-derived Stem Cells and whole Tooth Regeneration:
an Overview. Journal of Clinical Medicine Research. 2009;1(2):63-71.
doi:10.4021/jocmr2009.03.1230.
Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human
dental pulp stem cells (DPSCs) in vitro and in vivo. Proceedings of
the National Academy of Sciences of the United States of America.
2000;97(25):13625-13630.
Huang GT-J, Sonoyama W, Liu Y, Liu H, Wang S, Shi S. The Hidden
Treasure in Apical Papilla: The Potential Role in Pulp/Dentin
Regeneration and BioRoot Engineering. Journal of endodontics.
2008;34(6):645-651. doi:10.1016/j.joen.2008.03.001.

Miura M, Gronthos S, Zhao M, et. al. SHED: Stem cells from human
exfoliated deciduous teeth. Proceedings of the National Academy of
Sciences of the United States of America. 2003;100(10):5807-5812.
doi:10.1073/pnas.0937635100.
Nakao K, Morita R, Saji Y, et. al. The development of a bioengineered
organ germ method. Nature Methods. 2007;4(3):227-230. doi:10.1038/
nmeth1012.
Nakao K, Tsuji T. Dental regenerative therapy: Stem cell transplantation
and bioengineered tooth replacement. Japanese Dental Science Review.
2008;44(1):70-75. doi:10.1016/j.jdsr.2007.11.001.
Oshima M, Tsuji T. Functional tooth regenerative therapy:
Tooth tissue regeneration and whole-tooth replacement.
Odontology. 2014;102(2):123-36. https://search.proquest.com/
docview/1553301568?accountid=14375. doi: http://dx.doi.org/10.1007/
s10266-014-0168-z.
Sonoyama W, Liu Y, Fang D, et. al. Mesenchymal Stem Cell-Mediated
Functional Tooth Regeneration in Swine. PLoS ONE. 2006;1(1).
doi:10.1371/journal.pone.0000079.
Thesleff I. Epithelial-mesenchymal signalling regulating tooth morphogenesis. Journal of Cell Science. 2003;116(9):1647-1648. doi:10.1242/
jcs.00410.
Volponi AA, Kawasaki M, Sharpe PT. Adult Human Gingival Epithelial
Cells as a Source for Whole-tooth Bioengineering. Journal of Dental
Research. 2013;92(4):329-334. doi:10.1177/0022034513481041.
Volponi AA, Pang Y, Sharpe PT. Stem cell-based biological tooth repair
and regeneration. Trends in Cell Biology. 2010;20-206(12-6):715-722.
doi:10.1016/j.tcb.2010.09.012.
Yan M,Yu Y, Zhang G, Tang C,Yu J. A Journey from Dental Pulp Stem
Cells to a Bio-tooth. Stem Cell Reviews and Reports. 2010;7(1):161171. doi:10.1007/s12015-010-9155-0.
Yildrim S. Dental pulp stem cells. New York, NY: Springer Science
Business Media, LLC; 2013.
Young C, Terada S,Vacanti J, Honda M, Bartlett J,Yelick P. Tissue
Engineering of Complex Tooth Structures on Biodegradable Polymer
Scaffolds. Journal of Dental Research. 2002;81(10):695-700. doi:10.1177
/154405910208101008.
Zheng Y, Du X, Wang W, Boucher M, Parimoo S, Stenn KS.
Organogenesis From Dissociated Cells: Generation of
Mature Cycling Hair Follicles From Skin-Derived Cells.
Journal of Investigative Dermatology. 2005;124(5):867-876.
doi:10.1111/j.0022-202x.2005.23716.x.

Zhu W, Liang M, Periodontal Ligament Stem Cells:
Current Status, Concerns, and Future Prospects. Stem
Cells International. https://www.hindawi.com/journals/
sci/2015/972313/cta/. Published March 16, 2015. Accessed May
11, 2017.

Huysseune A, Thesleff I. Continuous tooth replacement: the possible
involvement of epithelial stem cells. BioEssays. 2004;26(6):665-671.
doi:10.1002/bies.20039.
Ikeda E, Morita R, Nakao K, et. al. Fully functional bioengineered
tooth replacement as an organ replacement therapy. Proceedings
of the National Academy of Sciences. http://www.pnas.org/content/106/32/13475.full. Published June 30, 2008. Accessed May 12, 2017.

9
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Abstract
The 21st century continues to produce major advancements in prosthetic limb technology. Specifically, improvements to the myoelectric prosthesis have helped numerous upper limb amputees, especially transhumeral patients. Targeted muscle reinnervation
surgery has allowed for more seamless control of the prosthetic device by creating new control centers for the unused nerves
of the residual arm. Additionally, improvements in pattern recognition technology have enabled transhumeral amputees to gain
more natural control of the prosthesis and consequently better imitate a biological limb. Another important development is in
regards to the configuration and placement of electromyography electrodes on the amputee’s body. Using high-density electrodes
implanted totally beneath the patient’s skin have dramatically improved accuracy and performance of the electromyography
readings. One of the most current and promising developments has been targeted sensory reinnervation. Preliminary studies have
shown that this surgery can provide a dual flow of both motor and sensory information simultaneously between the patient’s
residual limb and the prosthesis. Studies also indicate that using osseointegration surgery to connect the prosthetic device directly
to the patient’s bone has improved its performance and made it more comfortable for the user. Finally, by undergoing extensive
training and rehabilitation under the guidance of therapists knowledgeable with upper limb prostheses, transhumeral amputees
can gain remarkable skills in prosthetic limb locomotion. Further advancement is required but research continues at a quick pace
in improving prosthetic devices so that one day they can truly replace biological limbs.
Introduction
In 2005, there were 1.6 million amputees residing in the US,
with that number expected to double by the year 2050. Of that
number, 41,000 people live with major upper extremity limb
loss (Ziegler-Graham, et. al. 2008). The loss of a limb is a devastating experience but an amputee’s quality of life can be dramatically improved with the use of a prosthetic device. Creating
a truly functional prosthetic has been, and continues to be, a
tremendous challenge. The importance of providing patients
with advanced prosthetics and thereby enabling them to function normally can’t be understated. This is especially true for
upper limb amputees (ULAs) who are severely inhibited in accomplishing even simple everyday activities. For example, transhumeral amputees require a prosthetic device that can provide
full function of the elbow, wrist, and hand. The objective of this
paper is to familiarize the reader with the current prosthetic
technology, as well as discuss the areas where further advancements are required in order to equip transhumeral amputees
with the full range of motion, sensory input, and practicality of
a true biological limb.

Methods
Research papers and articles were obtained primarily through
databases such as ProQuest, Ebsco, and PubMed accessed
through the Touro College library. Google Scholar was also
used to search for pertinent material. Relevant keywords were
used to mine for source material and the references found
within them were further retrieved as additional sources. The
librarians of Touro College were also extremely helpful in gaining access to articles which aren’t publicly available via the web.

Available Upper Limb Prosthesis
Prosthetic limbs can be classified into the following two categories: body-powered and myoelectric. The former uses harnesses and straps attached to the patient’s residual limb and
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body to move the artificial prosthesis. In the case of a transhumeral amputee, manually locking the joints would be necessary
to switch between functions, such as movement of the elbow,
wrist, and hand. The terminal device is usually a mechanical
hook, but can be interchanged for many useful tools to fit the
patient’s specific task. The approximate cost of such a device
is about $7,000 (Resnik, et. al. 2012). This form of prosthetic,
while inexpensive and simple to use, is limited by the patient’s
own strength. Additional disadvantages include limited ability to perform relatively simple movements, moving only one
joint at a time, and having an inhuman-like appearance. Even so,
body-powered prostheses are still widely used by about 30% of
ULAs today (Ostile, et. al. 2012). Most patients, however, will
choose to use the more advanced, battery powered myoelectric prosthesis. One of the great advantages of this prosthesis is
its ability to bypass the amputee’s limited strength and instead
use an external, artificial power source to enable movement.
Additionally, the myoelectric prosthesis uses electromyography
(EMG) signals to control the operation of the artificial limb, unlike the manual body-powered prosthetic.This is possible due to
the neuro-muscular system which remains intact in the ULA’s
residual arm even after amputation (Sudarsan, Sekaran, 2012).
It’s this EMG signaling which allows the myoelectric prosthesis to interact so seamlessly with its wearer. Unfortunately, the
cost of a transhumeral myoelectric prosthesis can be as high as
$100,000 (Resnik, et. al. 2012).

EMG Signaling in Myoelectric Prostheses
The nervous system is made up of billions of neurons, all
connected throughout the body. These neurons act as a communications pathway through the means of electrical signals
and neurotransmitters at synapses. An electromyograph measures the strength of the action potentials with the use of an
electrode placed at target skeletal muscle. Skeletal muscle is
composed of contractible bundles of cells attached to bone.

Upper Limb Prosthesis: A Functional Replacement for the Biological Limb?

The muscle’s contractions control skeletal movement, usually
induced voluntarily by impulses transmitted through the neuronal network to the motor neurons. The transmission occurs
through the depolarization of the muscle fibers to generate
an electric current, thus allowing the EMG signals to be measured (Raez, et. al. 2006). When an amputee is fitted with a
myoelectric prosthetic, electrodes that measure EMG activity
are placed at a single pair of flexion and extension muscles on
the residual limb. A ULA’s myoelectric prosthesis then retrieves
the EMG signals generated by these two muscles to promote
locomotion. However, the prosthesis is limited to controlling
only one joint at a time. To switch from one joint to another (e.g. elbow to wrist), the patient must co-contract a pair of
muscles, thereby signaling to the prosthesis to switch joints. A

Figure 1 Conventional myoelectric control for
transhumeral amputation. (Cheesborough, et. al. 2015).
common pair used by a transhumeral amputee is the biceps
brachii and triceps brachii. Alternatively, a patient may also use
a remote controlled by shoulder or foot movement to switch
joints. The strength of the EMG signal produced at these sites
determines the prosthesis’s velocity. For example, the amputee
may use a biceps contraction to close the prosthetic hand, and
a triceps contraction to open it, thereby promoting movement
singularly controlled by the patient’s nervous system. However,
this becomes increasingly less intuitive with higher levels of amputation due to diminished levels of residual muscles available
in the arm. For example, transhumeral amputees must use the

biceps/triceps to control all distal prosthetic functions, as depicted in figure 1 (Cheesborough, et. al. 2015). Operation of the
terminal device, wrist, and elbow needs to be done sequentially which besides being a very slow and cumbersome process,
also requires much cognitive oversight because the same biceps/triceps need to move even the arm muscles not natively
controlled by them (Kuiken, et. al. 2004, Carlsen, et. al. 2014).
To allow for more seamless use of the myoelectric prostheses,
an innovative surgery termed targeted muscle reinnervation
(TMR) was introduced.

Targeted Muscle Reinnervation
The concept of targeted muscle reinnervation surgery was
first introduced in the year 2004 to help a patient with bilateral
amputations of the shoulders gain further control of the prosthesis (Kuiken, et. al. 2004). TMR surgery utilizes nonfunctional muscles as amplifiers for the patient’s dormant nerves that

Figure 2 Normal anatomy of the human body (Kuiken, et. al. 2009).
were originally attached to the amputated limb.This enables the
nerves to produce signals in those muscles, thus providing a
source for intuitive prosthetic locomotion. For example, conventional control of a myoelectric prosthesis for a ULA with a
transhumeral amputation is with EMG signals from the biceps
brachii, as well as from the triceps brachii. Granted, this may
provide intuitive control of elbow flexion and extension, but not
forearm supination/pronation, nor hand opening/closing. These
movements require cumbersome mode switches because the
limited residual muscles must control physiologically unrelated
movements. (Cheesborough, et. al. 2015, Carlsen, et. al. 2014,
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Kuiken, et. al. 2009, Zhou, et. al. 2007). Luckily, however, the median, ulnar, and radial nerves of the upper arm remain intact
even after amputation (see figure 2), and consequently motor
commands for the missing limb continue to travel through the
residual nerves. Through TMR surgery, these nerves can be
transferred to innervate other muscles in the body. Specifically,
the median nerve is transferred to the short head of the biceps muscle to allow for hand closing (or pronation), while the
distal radial nerve innervates the lateral head of the triceps to
provide signaling for hand opening (or supination), as depicted
in figure 3 (Carlsen, et. al. 2014). Ergo, through the use of TMR
surgery patients will have gained four myoelectric electric sites
in place of the standard two (figure 4). This allows for very intuitive control of the prosthesis; attempting to flex/extend the
elbow causes the native contraction of the long head of biceps/

each can be sacrificed as a recipient signal amplifier. This would
not sacrifice the intuitive elbow flexion/extension signals that’s
provided by the remaining biceps/triceps muscles with native
innervation via the musculocutaneous and radial nerves, respectively. Additionally, the four distinct EMG signals can be used to
simultaneously control multiple joints, thus avoiding the traditional and tedious mode switching which is normally required
(Cheesborough, et. al. 2015). While this use of TMR greatly increases a patient’s control of the prosthesis, it’s still limited to
two simultaneous degrees of freedom: elbow flexion/extension
and hand opening/closing. Further movements like wrist rotation still require cumbersome and unintuitive mode switches.
However, by applying pattern-recognition techniques together
with TMR surgery, substantially more motor control can be
extracted from the reinnervated muscles (Zhou, et. al. 2007).
Unfortunately, a difficulty that remains even post TMR surgery
is separating the distinct amplitudes of the surface EMG signals
on different muscles so that the prosthesis can recognize the
intended movements of the amputee (Schultz, Kuiken, 2011).
Additionally, further study is required to perfect the safety and
long-term efficacy of TMR surgery, as well as making it more
widely available to the masses.

Pattern-Recognition Techniques

Figure 3 Anatomy of a transhumeral amputee (Kuiken, et. al. 2009)
triceps, while attempting to close/open the hand activates the
short head of the biceps/lateral head of triceps which have been
newly innervated by the median/radial nerve, respectively. Since
there are more than one head to the biceps and triceps, one of

Targeted muscle reinnervation provides a rich source of motor
control information. In traditional TMR surgery, the median nerve
is transferred to control hand closing, and the radial nerve to control hand opening. In contrast, a non-amputee’s body will normally
use these nerves to innervate dozens of muscles in the forearm,
wrist, hand, and fingers. The goal of pattern-recognition techniques is to enable an amputee to control all these movements
in the myoelectric prosthesis simply and dexterously. High-density
electrode arrays are placed over the patients reinnervated target
muscles as the muscles attempt many different motions involving
the elbow, wrist, hand, and fingers.The specific patterns produced
by the combined EMG signals are processed by software which

Figure 4 Conventional myoelectric control for transhumeral amputation, with targeted muscle reinnervation. Patients use natively innervated
biceps and triceps to control the elbow and reinnervated biceps and triceps to control the hand (Cheesborough, et. al. 2015).
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deciphers which specific movement is being performed, hence
the name “pattern-recognition”. Detailed mappings of EMG amplitudes across the reinnervated muscle site of a TMR patient show
distinctive patterns of activity as the subject attempts a variety of
thumb, finger, and wrist movements.The pattern-recognition software has been shown to be 95% accurate in predicting a patient’s
16 intended arm movements (8 degrees of freedom). To highlight,
without pattern-recognition the conventional myoelectric control
methods can only use EMG amplitude at specific myoelectric control sites, and ergo can’t take advantage of the true complexity of
information. Accordingly, the muscles reinnervated by the median
and radial nerves operate only hand opening/closing. However, by
using pattern-recognition software, information can be extracted
about the subject’s desire to perform wrist flexion/extension/
rotation, and even movement of the thumb, index finger, or digits (Zhou, et. al. 2007). Further investigation was accomplished in
2009 that demonstrated pattern-recognition control for real-time
use of myoelectric prostheses (Kuiken, et. al. 2009). A very brief
explanation of how pattern-recognition techniques works is as
follows: patients provide example contractions for each of the
prosthesis movements (e.g., elbow supination, hand close, etc.),
and the algorithm learns which EMG patterns correlate to each
intended movement. Thus, when a patient later desires to move
the prosthesis, the algorithm predicts the desired movement from
the previously learned pattern of EMG signals (Cheesborough,
et. al. 2015). This starkly contrasts to conventional EMG readings
in that pattern-recognition doesn’t simply use EMG signal amplitudes, but rather utilizes numerous EMG recordings to globally
classify the patient’s intended movements. The use of pattern
recognition enables TMR patients to significantly outperform conventional nonpattern-recognition in the following two tasks: 1) a
box and blocks task, and 2) a clothespin relocation task. Both of
these tasks are validated and standardized measures of gross hand
function first developed by occupational therapists. The box and
blocks task requires the patient to move one inch blocks from
one compartment to another during an allotted time period, while
the clothespin task requires the movement of clothespins from a
horizontal bar to a vertical bar also during an allotted time period
(Mathiowetz, et. al. 1985, Kuiken, et. al. 2004, Miller, et. al. 2008).
Patients moved 40% more blocks and completed clothespin relocation in 25% less time when using pattern-recognition over
conventional myoelectric control. Additionally, patients’ personal
preference favored pattern-recognition over conventional control
(Hargrove, et. al. 2013).

Electromyography Electrode Configuration
Though TMR surgery, along with advanced pattern-recognition,
can provide vast amounts of neural information, it requires the
use of a high density (HD) electrode array with over 125 electrodes placed over the reinnervated muscles. The placement of
these electrodes is clinically challenging, and even after placement,

the input of electromyography signals is slow. Preliminary studies show that by using advanced electrode selection algorithms,
the number of electrode placements can be radically reduced
to just a dozen. These electrodes can provide sufficient neural information to classify the user’s intended movements with
99.1% accuracy in regards to 8 basic joint movements (elbow,
wrist rotation, wrist flexion/extension, hand open/close). In a
16-class analysis which includes 8 additional finger movements,
the classification accuracy was 93%. It’s important to note that
as the number of applied electrodes decreases, exact electrode
placement becomes increasingly more integral. Thereupon,
it’s important to keep electrodes stably located over muscles,
while being cautious to place them in the most accurate positions possible (Huang, et. al. 2008). Further studies show that
by increasing electrode distance, as well as their orientation in
regard to muscle fibers, pattern-recognition performance can
be improved in the event of electrode shift (Young, et. al. 2011,
Young, et. al. 2012). EMG signals are an integral mechanism for
helping ULAs to gain full use of their myoelectric prosthesis.
Therefore, ensuring that accurate readings can be obtained repeatedly and accurately is essential.

Implanted EMG Sensors
Though advancements in electrode configuration have greatly
enhanced the accuracy of readings, they still have severe limitations such as poor skin contact (thus causing electrode liftoff),
skin impedance changes due to sweating, lack of repeatable
electrode placement due to day-to-day donning, as well as wire
breakages (Weir, et. al. 2009, Pasquina, et. al. 2015). Hence, developing methods to solve these multitudes of issues are of the
upmost importance. One method showing great promise is the
use of fully implanted sensors beneath a patient’s skin to ensure
accurate EMG readings. These sensors are cylindrically shaped,
and about 16 mm long (Figure 5). Each of these tiny sensors
are capable of magnetically transmitting vast amounts of data
directly to the retrofitted prosthesis. Furthermore, the ability
to place these electrodes directly within residual limb muscles
allows for stronger and more reliable signals that remain static
despite body movement and sweating. Additionally, in the case
of a transradial amputee these implanted electrodes present
the possibility to record data from superficial and deep muscles
simultaneously, allowing for more intuitive control by providing signals from the actual muscles responsible for hand and
wrist locomotion prior to amputation (Pasquina, et. al. 2015).
Unfortunately, a major technological issue with this system that
still requires further research is reducing power consumption,
and thus enabling the patient to have a portable prosthesis
which can last a full day of use without the need for recharging
(Schultz, Kuiken, 2011).
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Targeted Sensory Reinnervation
No prosthesis can be called a true replacement of a biological limb without providing sensory feedback to its user. Tactile
sensation is one of the earliest developed and basic human
senses, providing a rich source of information about environ-

Figure 6: Schematics of a TR surgery. Green, arm nerves; blue, skin
sensory nerves; dotted lines, nerves routed beneath muscles. (A)
skin nerves were cut, and the distal ends were sewn to the hand
nerves to provide neural conduits for the regenerating nerve fibers.
(B) Diagrams of skin sensation provided by each nerve in the
normal hand (Adapted from Kuiken, et. al. 2007b)
Figure 5 (A) Size example of an implantable electrode. (B) The
prosthetic. (C) The magnetic coil built into the prosthetic frame that
powers and receives EMG information (adapted from Pasquina, et.
al. 2015).
mental stimuli. However, even when a patient uses an advanced
myoelectric prosthesis they’re still reliant on their limited visual
feedback, wherefore hindering natural control of the prosthesis.
Surprisingly, one of the reasons why body-powered prostheses continue to see widespread use is because the wearer can
sense its movement through the cables attached to his body
(Marasco, et.al. 2009). Therefore, proving tactile sensory information to the amputee is integral in providing a lifelike prosthesis. Unexpectedly, a potential source for proving this feedback
was first discovered accidentally, as an unintended result of TMR
surgery on a bilateral shoulder disarticulation amputee. After
undergoing TMR surgery to transfer his residual brachial plexus
nerves to the pectoralis muscles, touching the skin overlying
the reinnervated muscles produced sensation in different areas
of his phantom limb (Kuiken, et. al. 2004). With this knowledge,
the targeted reinnervation surgery was extended to include
reattaching sensory nerves as well, dubbed targeted sensory reinnervation (TSR). In the reinnervation surgery of a short-transhumeral amputee, the distal ends of the patient’s supraclavicular and intercostobrachial cutaneous nerves were attached
to the ulnar and median nerves, respectively (see figure 6). Six
months after the operation, the patient reported sensation in
her phantom hand when her reinnervated pectoralis muscles
were stimulated. All modalities of cutaneous sensation were
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present including graded pressure, thermal feedback, vibration,
and edge detection (i.e. sharp vs dull). Stimulation of each of
these sensations within the reinnervated region was interpreted by the patient as occurring in her missing hand (Kuiken, et.
al. 2007a). Further studies have similarly shown how sensory
feedback can be felt by an amputee post targeted reinnervation
surgery (Kuiken, et. al. 2007b, Schultz, et. al. 2009). However, the
above mentioned studies have been limited mainly to patients
with shoulder-level amputations who underwent targeted reinnervation surgery to reinnervate the brachial plexus to the
pectoralis muscle group. Since a transhumeral amputee still
needs the residual nerves to innervate the upper arm it’s unfeasible to simply transfer the brachial plexus to reinnervate the
pectoralis muscle group. To help solve this issue, a recent study
has attempted to extend the scope of TSR surgery to a transhumeral patient. By using an improved variation of the TSR surgery,
along with an incorporated sensory feedback device, a patient
can now feel, and accordingly coordinate, the strength of force
applied by the myoelectric prosthesis when handling an object,
without auditory or visual stimuli. Previously, TMR patients simply obtained sensory reinnervation directly on top of the reinnervated muscle sites, which can lead to over-crowding when
placing all the necessary hardware and EMG sensors. Hence,
the ability to place the reinnervated sensory site distant from
the reinnervated muscle site, but close enough to be viable, is a
tremendous advancement in creating a viable sensory feed-back
system for myoelectric prosthesis users. During the TSR surgery,
the transhumeral patient’s median and ulnar nerve are located
and their high sensory nerve content fascicles isolated. These
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Figure 7: A fascicle of the median nerve (blue) is coapted to the
intercostobrachial cutaneous nerve while a fascicle of the ulnar
nerve (red) is connected to the cutaneous branch of the axillary
nerve. (Herbert, et. al. 2014)
fascicles are dissected out of the main nerve trunk, transected
distally, and coapted to the interocostobrachial cutaneous nerve
and axillary nerve, respectively (see figure 7). The remainder of
the nerve trunks are used to reinnervate portions of biceps and
triceps as done in a classical TMR surgery. In addition to creating
two spatially separated wide spread areas with discrete sensation for individual digits in the two nerve territories, called hand

maps (see figure 8), the patient is able to utilize this sensory
feedback to execute tasks while operating a myoelectric training arm, without having to rely on visual guidance or auditory
cues. Furthermore, the above mentioned over-crowding problem is alleviated with this innovative surgical technique, as the
sensory fascicles are directed to cutaneous areas distant from
the muscle electrode sites. In the aforementioned study, the patient showed sensory feedback when gripping and releasing a
ball, detected the difference between small and large blocks, as
well as their difference in stiffness. Additionally, the patient discriminated between levels of applied force to the reinnervated
area. Finally, the study demonstrated the ability to have a dual
flow of motor and sensory information simultaneously between
the patient’s residual limb and the prosthesis. Additionally, further research is required to create a portable and wearable
device that can viably transfer all the sensory and motor information between the prosthesis and its wearer. This was a single
case study of a transhumeral patient and further investigation
is required to test the efficacy of TSR with a real myoelectric
prosthesis, as well as whether the sensory pathways will remain
long-term (Herbert, et. al. 2014, Zuo, Olson, 2014).

Osseointegration
An unfortunate occurrence amongst amputees is prosthesis

Figure 8:Transfer sensation for the median and ulnar nerve territories, mapped on transhumeral residual limb at 15 months post-operatively.
The dots are 1 cm apart (Herbert, et. al. 2014).
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abandonment which can occur when patients refrain from
wearing their prosthetic device due to problems including lack
of comfort, stability, and durability. Mean rejection rates as high
as 45% and 35% were observed for body-powered and electric
prostheses respectively in pediatric populations, while adult
populations had somewhat lower rates of 26% and 23%, respectively (Biddiss, Chau, 2007). However, by performing an osseointegration surgery which directly attaches the prosthesis to
the patient’s bone, one avoids the need for an unwieldly socket.
This enables the prosthesis to always fit firmly, comfortably, and
correctly, consequently giving the patient a more natural prosthetic limb to mimic the amputated biological one. The implant
system includes a threaded titanium implant, which is inserted
intramedullary into the transhumeral amputee’s humerus bone,
as depicted in figure 9 (Jönsson, et. al. 2011). As of yet, the FDA
has not approved osteointegration trials for ULAs in the US,
though one European group has successfully implanted devices
in over 100 patients around the world (Cheesborough, et. al.
2015). Important to note is that after the osseointegration surgery, the patient must adapt to having a permanent appendage
abutting from the limb.

Figure 9: Transhumeral osseointegration patient being fitted with a
prosthetic device (A-C) (Jönsson, et. al. 2011).

Rehabilitation and Prosthesis Training
Prosthesis training during rehabilitation directly affects an individual’s level of function, and thus providing post-op amputees
with proper instruction on how to use their prosthetic limb
is vital. Training with therapists knowledgeable in upper limb
prosthetic components and control is a significant portion of
prosthetic rehabilitation leading to functional success of the
ULA (Carlsen, et. al. 2014). Important to note is that fitting
a patient with a congenital upper limb absence within 11
months of age leads to a greater acceptance than when fitted
at an older age. Similarly, individuals fitted with a prosthetic 3
months after injury are less likely to reject the prosthetic device than patients fitted 6 months after surgery (Biddiss, Chau,
2007). Consequently, it’s important to fit the patient with a
prosthetic device and start the rehabilitation process as soon
as possible. The rehabilitation process can be classified into a
three-phase process. Phase one promotes healing of the residual limb wound, starting at the time of injury and continuing
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until all wounds have successfully closed and are infection free.
The length of time spent in this phase varies depending on the
extent of the patient’s injury, but approximately three weeks
after injury phase two begins and introduces pre-prosthetic
training. The rehabilitation goal of pre-prosthetic training is to
prepare the patient to receive a correctly fitting and functional prosthesis. This begins upon wound closure and ends with
procurement of a preparatory training prosthesis. Patients
will receive physical therapy to achieve improved flexibility
and strength, as well as to educate them in avoiding incorrect
postures that may lead to overuse injury of the upper body.
Additionally, they learn how to perform activities of daily living,
like writing, with just one hand when the prosthesis is unavailable. The third and final phase begins prosthetic training with
the goal of the prosthesis becoming an integrated part of the
patient’s life. The therapy’s focus is to help the amputee master
the mechanical actions required for prosthetic control and
eventually achieve independence in all activities of daily living.
To help further this goal, the patient is fitted with varied types
of prosthetic devices to gain experience accomplishing many
different tasks so as to gauge and refine his skill sets when operating diverse types of prostheses. Hence, many patients will
own multiple prosthetic devices and will use them accordingly
for different tasks. The amputees are also trained in how to
care for their prosthetic devices, to put on and remove them
by themselves, as well as perform even complicated activities
of daily living (Smurr, et. al. 2008). The rehabilitation for a post
targeted muscle reinnervation surgery patient is somewhat
more complicated, since each nerve that’s being used for reinnervation contains numerous motor neurons. These neurons
control many muscle fibers that work in conjunction to create
nerve actions and thereupon move the body. For example, the
radial nerve innervates hand extensor muscles, wrist extensor
muscles, and supination muscles. However, a surgeon can’t be
certain exactly which nerve fibers will reinnervate the new target muscle. Hence, the patient must first attempt to perform
all the actions controlled by the transferred nerves in order
to see which will actually develop and innervate the muscle.
The first noticeable reinnervation will usually occur at about 3
months after surgery. At this point, the patient can finally begin
exercises to strengthen the reinnervated muscle over the next
few months, followed by the patient learning to elicit strong,
reliable EMG signals for the myoelectric prosthesis to receive.
Whenever possible, the most intuitive movements that yield
strong and reliable EMG signals will be used to move the prosthesis. As an example, the patient’s attempt at extension of
the phantom hand (radial nerve) hopefully will produce the
strongest and most physiological appropriate signal for prosthetic hand opening, therefore making prosthesis movement
intuitive for the subject. Over the long rehabilitation process,
it’s integral for the success of the patient that the occupational
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therapists, physical therapists, and prosthetists understand the
principles of TMR, peripheral nerve distribution, specifics of
the surgery, as well as the different possible post-op outcomes
for each patient (Stubblefield, et. al. 2009). This will enable an
amputee to truly gain the most from his prosthetic device and
thereby return to functioning as fully and naturally as possible.

Conclusion
Science continues to make great strides in advancing prosthesis
technology and thus increasing the quality of life of countless
amputees. Electromyography signaling and targeted muscle reinnervation surgery continues to pave the way for leading edge
prosthetic limbs. Advanced pattern recognition software is constantly being improved and perfected, while targeted sensory reinnervation surgery stands at the forefront of current scientific
research in providing upper limb amputees with truly advanced
replacements for their amputated biological limbs. Of course,
additional work is needed to improve the control algorithms so
that the amputee may interact seamlessly with his myoelectric
prosthesis. Additionally, further study is needed to test the efficacy of wireless, implantable EMG electrodes. Osseointegration
surgery remains a promising new method to comfortably suspend a transhumeral amputee’s prosthesis. Additionally, targeted
sensory reinnervation helps produce a real-time, dual flow of
mechanical and sensory information between the prosthesis
and its wearer. One of the biggest challenges remaining is to
create a way to minimize power consumption of the prosthesis,
while still providing its wearer with all the technology needed
to provide the full range of motor output and sensory input of
a real limb. Additionally, the life-time cost of providing a patient
with a prosthesis can be astronomical and further advancements are needed to lessen the cost so that it can be a viable
clinical option. The human body is a wonder and even a simple
task like typing on a keyboard is truly a wonderment of seamless
interaction of neurons and muscles. Hence, though a current
myoelectric prosthesis is indeed an advanced appendage, it’s
still far less advanced than one’s natural biological limb. Overall,
however, the future seems extremely hopeful in one day providing a transhumeral amputee with a fully functional prosthetic
limb to truly replace a lost biological one.
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Abstract
The scientist who discovered penicillin and its use as an antibiotic, Alexander Fleming, also raised concerns about bacterial resistance. As he predicted, in the twenty first century, the overwhelming use of antibiotics has led to both drug- and multi-drug resistant bacteria.This paper attempts to investigate the antibacterial potential of silver nanoparticles against drug resistant bacteria.
By using Touro’s online library database, the efficacy of silver nanoparticles as a potential antibacterial agent was comprehensively
researched. Using transmission electron microscopy and the disk diffusion method, silver nanoparticles have been found to exert
bactericidal effects by adsorbing to the cell surface and by entering the cell. The small size of the particles confers it with a high
surface area which thus enables the silver nanoparticles to effectively interact with the cell membrane and thereafter enter into
the cell. Moreover, the dose and shape of silver nanoparticles affects their antibacterial properties. While it has been found to
be dose dependent, there is controversy regarding which shaped particle, sphere or triangular, has the greatest ability to damage
the cell membrane, transport systems, DNA, and proteins, in addition to generating reactive oxygen species. Most studies have
found the particles to be nontoxic at low levels, but some uncertainty still exists. In addition, silver nanoparticles seem to have a
synergistic effect with the simultaneous use of antibiotics. Further research must be done before silver nanoparticles can be used
as a new and effective antimicrobial agent.
Introduction and Background
On February 27th 2017, the World Health Organization
(WHO) published a list of the top twelve resistant bacteria that
greatly endanger human health (Press Association, 2017). Drug
resistant and multi-drug resistant bacteria are one of the most
serious public health threats the world faces today. Antibacterial
resistance is the ability of bacteria to survive even in the presence of antibiotics. The development of antibiotics has made a
great impact on the medical field by enabling doctors and health
professionals to successfully combat many diseases. However,
with the rise of the use of antibiotics, drug resistance has
evolved, and according to WHO statistics, 700,000 people die
annually from infections and diseases that have resulted from
such resistant bacteria (Press Association, 2017).

Method
The research discussed in this paper was compiled from various published articles obtained from Touro’s online database
including Proquest as well as PubMed’s database to research
the actions of antibiotics, drug resistant bacteria, and the use of
silver nanoparticles against drug resistant bacteria.

A. Antibiotics and their mechanism of action
Antibiotics are natural or synthetic agents that fight and inhibit
the growth of bacteria. Antibiotics are grouped into different
classes based on their mechanism of action, and they can either
disrupt the cell membrane, or they can inhibit cell wall synthesis,
protein synthesis, DNA replication and repair, RNA synthesis,
or various metabolic pathways.

1. Inhibition of Cell Wall Synthesis
Bacterial cell walls are comprised of peptidoglycan, the cytoplasmic
membrane, and in gram negative bacteria, the outer membrane.
The peptidoglycan, the strongest layer of the cell wall, is a netlike
arrangement of glycan and peptide strands. The biosynthesis of
the peptidoglycan is catalyzed by thirty different enzymes (Shah,
2015). Transglycosylases and transpeptidases are two enzymes

which aid in the final steps of the cell wall synthesis by adding
new peptidoglycan units to extend the sugar chain and by linking the amides of the peptide strands, respectively (Walsh, 2000).
Numerous antibiotics, like the B-lactam class of antibiotics, target
different steps in the synthesis of the peptidoglycan. Penicillins
and cephalosporins act as pseudo-substrates for the penicillin
binding proteins (PBPs), the active site of the transpeptidases, in
order to prevent the cross-linking of the PG. The cross-linking
action of the transpeptidases is responsible for the strength of
the PG, and without it, the bacterial cell wall is significantly weaker and therefore more prone to lysis. When B-lactam antibiotics
bind to the PBPs, the oxygen from the serine residue located near
the PBP attacks the B-lactam ring and forms a penicilloyl-enzyme
complex. The serine is then acylated by the b-lactam which thus
inactivates transpeptidases (Walsh, 2000). Consequently, transpeptidases can no longer bind to the substrate, and therefore the
enzyme cannot complete the cross linking action (Andersson, et.
al. 2001) (Bockstael, Aerschot, 2009).
Vancomycin is a drug that belongs to the glycopeptide class of
antibiotics. Like the B-lactams, vancomycin targets the synthesis
of the cell wall. However, rather than targeting the enzymes
involved in the production of the PG, vancomycin targets the
substrate by making five hydrogen bonds with the D-ala-D-ala
terminus of each uncross-linked peptidoglycan (Lange et. al.
2007). By blocking the substrate of both the transpeptidases
and transglycosylases, vancomycin and other glycopeptides inhibit the cross linking of the peptidoglycan, resulting in a weaker
cell wall that is subject to osmotic lysis (Walsh, 2000)

2. Disruption of the Cell Membrane
The cell membrane of bacterial cells are semipermeable membranes that are comprised of phospholipids, carbohydrates, and
proteins. Antibiotics like polymyxins and lipopeptides have the
ability to disrupt the bacterial cell membrane. Polymyxins like
colistin are cationic cyclic peptides that bind to the phospholipids in the bi-layer. By interacting with the negatively charged cell
membrane (Taneja, Kaur, 2016), colistin disrupts the bacterial cell
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membrane by displacing divalent ions, like calcium and magnesium, from the lipids present on surface of the cell.The disruption
of the cell membrane causes cell leakage and ultimately cell death
(Biswas, et. al, 2012) (Bockstael, Aerschot, 2009). Similarly, aminoglycosides can also displace these divalent ions to increase the
membrane’s permeability, resulting in the leakage of intracellular
content and cell death (Lange, et. al. 2007).
Furthermore, daptomycin, a lipopeptide, can also disrupt the
cell membrane. However, rather than displacing calcium and
magnesium ions, daptomycin forms pores in the membrane by
inserting its tail into the membrane. Consequently, there is a
potassium efflux, and as potassium ions leave the cell, cell depolarization occurs (Shah, 2015) (Bockstael, Aerschot, 2009).
Besides for causing cell depolarization, daptomycin can also
inhibit the production of lipoteichoic acid which is responsible for regulating both cell division and cell shape (Bockstael,
Aerschot, 2009).

3. Inhibition of Protein Synthesis
In addition to targeting the synthesis of the cell wall and cell
membrane, other antibiotics exert their effects by inhibiting
bacterial protein synthesis. Ribosomes are essential to the synthesis of proteins as they translate the genes from mRNA into
proteins through the three steps of initiation, elongation, and
termination. The bacterial 70S ribosome has two subunits: the
50s subunit and the 30s subunit. While the large 50s subunit
contains a 5S rRNA, a 23S rRNA and 36 proteins, the smaller 30S subunit is comprised of 16S rRNA and 21 proteins.
Antibiotics can exert their effects by targeting either the 30S or
the 50S subunit (Bockstael, Aerschot, 2009).

Targeting the 30S Subunit
The 30S subunit contains the site where the codons are recognized by their corresponding tRNA anticodons. Transfer RNAs
help with the process of translation by acting at either the A site,
the P site, or the E site (Lange, et. al. 2007).
Aminoglycosides like gentamicin and tobramycin interact with
the 16s RNA located in the 30S subunit. By hydrogen bonding
with the substituents on the aminoglycoside cyclitol ring in the
16s RNA located at the A site, mistranslation occurs, and as a
result abnormal proteins are produced. These aberrant proteins
are then incorporated into the bacterial cell wall, ultimately resulting in a weak cell wall which is associated with cell leakage and
further penetration of the drug into the cell (Lange, et. al. 2007)
(Bockstael, Aerschot, 2009).
Tetracyclines bind to the 30s subunit (Lange, et. al. 2007) to
prevent the elongation step of protein synthesis. By blocking the
substrate of the incoming tRNAs, these antibiotics prevent new
amino acids from being added to the growing amino acid chain
(Shah, 2015).
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Targeting the 50S Subunit
While the antibiotics discussed above inhibit protein synthesis
via the 30S subunit, many other drugs have the ability to affect
protein synthesis through the 50S subunit. The 50S subunit is
associated with peptidyl transferase activity as well as the formation of peptide bonds (Bockstael, Aerschot, 2009).
Chloramphenicol, a broad spectrum antibiotic that is used
against both gram positive and negative bacteria, binds to the
23s RNA on the 50S subunit. This class of drugs inhibits the formation of peptide bonds by preventing the tRNAs from binding
to the A site (Bockstael, Aerschot, 2009).
The antibiotic class of macrolides binds to the 23S rRNA.
Consequently, the exit tunnel that helps transport the peptide
away from the peptidyl transferase center is blocked.
Lincosamides, like clindamycin, attack both the A site and P site
located in the peptidyl-transferase center (Lange, et. al.2007).
As a result, lincosamides inhibit the initiation of peptide chain
synthesis and detach tRNAs from the ribosome (Bockstael,
Aerschot, 2009).
Streptogramins affect protein synthesis and the action of the
peptidyl transferase center activity by binding to the 23S subunit
on the 50S ribosome. There are two types of streptogramins,
Type A and Type B. While type A prevents the step of elongation by blocking the substrate of the peptidyl-transferase center,
type B stimulates the premature release of incomplete peptide
bonds by inhibiting peptide bond synthesis (Bockstael, Aerschot,
2009).
Oxazolidinones act by targeting the 50S subunit. The drug
linezolid binds to the 23S subunit located on the 50S ribosome.
By binding to this subunit, the formation of the complex between tRNA, mRNA, and the ribosome is blocked which thus
inhibits the formation of the first peptide bond. If the complex
is already formed, oxazolidinones can exert their effects by preventing the translocation of the peptidyl RNA from the A site to
the P site (Bockstael, Aerschot, 2009).

4. Inhibition of Metabolic Processes
Some antibiotics can interfere with various metabolic processes that are vital to the survival of bacteria. Folate and folic
acid are essential for the synthesis of purines, thymidines, and
some amino acids (Lange, et.al. 2007). The folic acid pathway
is catalyzed by dihydropteroate synthetase and dihydrofolate
reductase, two enzymes which aid in the production of 7, 8
dihydropteroate and tetrahydrofolate, respectively (Shledon Jr.,
2005). Drugs like sulphonamide and trimethoprim block different steps in this folic acid pathway, and while sulphonamide
competitively binds to p-aminobenozic acid in order to prevent
the actions of dihydropteroate synthetase, trimethoprim binds
to the enzyme dihydrofolate reductase to prevent the reduction
of dihydrofolic acid to tetrahydrofolic acid (Bockstael, Aerschot,
2009) (Sheldon Jr., 2005).
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5. Inhibition of DNA Replication

1. Enzymatic Degradation or Alteration

Topoisomerases I, II, III, and IV are enzymes that are essential
for DNA replication in bacterial species (Walsh, 2000). Bacterial
DNA is negatively supercoiled, and during DNA replication,
topoisomerase II, DNA gyrase, removes positive supercoils,
breaks the double bond, and decreases the linking number by
two. Furthermore, during DNA replication, topoisomerase IV
unlinks the daughter chromosomes (Bockstael, Aerschot, 2009).
Topoisomerases II and IV are vital for DNA topology, replication, and decatenation, and quinolone antibiotics target these
enzymes. By interacting with the complex formed between DNA
and DNA gyrase, quinolones make conformational changes that
affect the activity of both topoisomerases II and IV, and as a result,
DNA replication is blocked (Bockstael, Aerschot, 2009).
The process of transcription, the transferring of genes from
DNA to mRNA, is mediated by the multi-subunit enzyme RNA
polymerase. The antibiotic rifamycin targets DNA transcription
by binding to the beta subunit of RNA polymerase. Rifamycin
blocks the entry of the first nucleotide, thereby blocking the
action of RNA polymerase and inhibiting mRNA synthesis
(Bockstael, Aerschot, 2009).

Some bacterial species can resist a wide array of drugs by enzymatic degradation and alteration. By producing an enzyme that
destroys an antibiotic, bacterial species can cause various antibiotics to become ineffective. Antibiotics like penicillins, carbapenems, and cephalosporins all contain a B-lactam ring which binds
to PBPs on the peptidoglycan to prevent cross linkage of the
cell wall (James, 1999). In response, various bacteria produce
different classes of B-lactamases to hydrolyze the four membered B-lactam rings and thereby inactivate these antibiotics
(Sibanda, Okoh, 2007).
Similar to the B-lactamases, the aminoglycoside modifying
enzymes (AMEs) are enzymes that cause bacterial resistance to
aminoglycosides. Some microorganisms can produce enzymes
that modify drugs. Aminoglycosides like kanamycin, gentamicin,
streptomycin, and neomycin can either be acylated, adenylated,
or phosphorylated by aminoglycoside acetyltransferase, adenyltransferase, and phosphoryltransferase. Consequently, the modified antibiotics can no longer exert their antibacterial effects
(James, 1999) (Gabani, et. al 2012).

2. Alteration of Targets

Fig. 1 Primary targets site for major classes of antimicrobial agents

B. Mechanism of Resistance
Resistance can be classified as either intrinsic or extrinsic.
Intrinsic resistance is resistance that is inherent to a specific
species of bacteria. For example, the bacteria belonging to the
genus of Enterobacter, Klebsiella, and Escherichia coli are all resistant to methicillin, clindamycin, and vancomycin (James, 1999).
Various species of bacteria all differ in the variation of their
cell walls, efflux pumps, and biofilms, all of which lends itself to
different bacteria’s innate resistance to certain drugs (Sheldon
Jr., 2005).
Extrinsic or acquired resistance, on the other hand, arises
when bacteria acquire new resistance to numerous drugs via
different mechanisms. Resistant bacteria can degrade and modify
enzymes, alter the targets of antibiotics, change the permeability
of their cell wall, or alter metabolic pathways to prevent drugs
from penetrating and affecting their cells (Sheldon Jr., 2005).

In order to have a combative effect on bacteria, antibiotics must
bind to their intended receptors. Therefore, in response to various antibiotics, bacteria can reduce the affinity of the antibiotics
by modifying the structure of the drugs’ active site. Different bacterial species like methicillin-resistant Staphylococcus aureus and
Streptococcus pneumoniae produce new penicillin binding proteins, PBP2a and PBP2b respectively, in the presence of antibiotics.
These modified active sites have a lower affinity for B-lactams
which, in turn, prevent the drugs from properly binding and having
an antibacterial effect (James, 1999). Furthermore, substituting at
least one amino acid in the PBP can result in a lower affinity of the
drug, and as a result the bacterial cell wall is not destroyed by the
antibiotic (Gabani, et. al. 2012) (Sibanda, Okoh, 2007).
In different species of bacteria, the N^6 amino group of an adenine
residue located in 23S rRNA is methylated, and as a result bacterial resistance to macrolides, lincosamides, and streptogramin
B arises. The mechanism behind this resistance is associated with
the reduced affinity of the binding sites that results from conformational changes from the methylation (Sibanda, Okoh, 2007).

3. Alteration of Permeability
In addition to altering the targets of antibiotics, drug resistant
bacteria can modify the permeability of their cell wall in order
to prevent or decrease the entrance of various drugs into the
cell. A drug’s concentration in the bacterial cell determines the
efficacy of the drug on the pathogen, and it is through both
porins and efflux pumps that drug resistant bacteria have the
ability to decrease the amount of drug that reaches the cell
(Lange, et.al. 2007) (James, 1999) (Sheldon Jr., 2005).
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Porins
Porins are protein channels that exist solely in the outer membranes of gram negative bacteria. These channels are highly
specific, and depending on size, shape, and charge, certain molecules can pass through to the inside of the cell. Being hydrophilic
molecules, antibiotics easily enter the cell through these protein
channels. Research has shown that when bacteria lose porins in
their outer membrane, drug resistance emerges since less of the
antibiotic can enter into the cell. For example, when the amount
of OPrD porins were decreased in Pseudomonas, the imipenem
class of antibiotics could not enter the bacterial cell. Similarly,
resistance to imipenem and meropenem occurred after the
amount of 29-kDa Porins was reduced in Acinetobacter baumannii. Multi-drug resistant bacteria like Klebsiella pneumoniae also display resistance to cephalosporins and carbapenems
after losing OmpK35 and OmpK36, outer membrane proteins
(Santajit, Indrawattana, 2016).

Efflux Pumps
Efflux pumps actively transport drugs out of the bacterial cell
thereby decreasing the intracellular concentration of different
antibiotics. There are five different categories of efflux pumps
that exist in either gram positive or gram negative bacteria. The
ABC, RND, MFS, SMR, and Multidrug and toxic compound extrusion family transporter efflux pumps all bind to the drug in
the phospholipid bilayer, and thereafter export it out of the cell
to different locations. While gram positive bacteria transporters
work by pumping the drug out of the cell across the cytoplasmic
membrane, gram negative efflux pumps can either extrude the
antibiotic across the membrane and into the periplasmic space, or
directly into the external medium. As these efflux pumps quickly
extrude the antibiotics out, the concentration of antibiotics cannot accumulate to a high enough level to have an antibacterial
effect (Zgurskaya, 2002) (Lomovskaya, Watkins, 2001).

4. Altered Metabolic Pathway
Resistant bacteria have come up with alternate routes to obtain
metabolic products that are blocked by antibiotics.The folic acid
pathway produces pyridine thymidylate, an essential molecule in
the synthesis of DNA. In order to circumvent antibiotics that
target the folate pathway, Enterococcus either uses folinic acid
from its host cell, or mutates to have the ability to produce
thymine (Mambrio-Jones, Hoek, 2010) (Sheldon Jr., 2005).

Discussion:
C. Combating Drug Resistance
According to statistics, it is predicted that an estimated 10
million people will die from drug-resistant bacterial infections
by 2050 if no viable solution is discovered (Press Association,
2017). Therefore, finding effective treatments for drug resistant
bacteria is of extreme importance. Over the last few years,
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much research has been done to determine proper treatments
for such deadly infections. This paper will discuss the effectiveness of silver nanoparticles against drug resistant bacteria.

1. Silver Nanoparticles
Silver is widely known for its antimicrobial properties, and
therefore, silver nanoparticles (Ag NPs) have been widely
studied as a potential antibacterial agent against drug-resistant
bacteria. Various studies on different strains of bacteria were
performed to uncover the antibacterial effects of Ag NPs. More
specifically, the studies focused on the size, dose, and shape of
these silver particles coupled with the potential toxicity they
pose to human cells.
There are various methods to create nanoparticles. Ag NPs
can be synthesized into different shapes and sizes via physical
processes like laser ablation, evaporation, and condensation, or
through chemical processes like hydrazine, sodium borohydride,
and green synthesis (Nurani, et.al. 2015).

1. Mode of Action of Silver Nanoparticles
After determining the bactericidal properties of silver nanoparticles, the mechanism behind their antimicrobial effects was
studied. Various studies using transmission electron microscopy
(TEM) and other methods verified that Ag NPs have the ability to
cause damage to bacterial cells through a wide array of different
mechanisms.
A Kirby-Bauer sensitivity test was performed, and by using various antibiotic discs with different silver resistant bacterial strains,
the zone of inhibition was measured. It was found that the bacteria showed modified susceptibility to cephalosporins, glycopeptides, aminoglycosides, and fluoroquinolones, thereby indicating
the mechanism of action of Ag NPs. Based on the action of these
antibiotics and the bacteria’s altered zone of inhibitions, this study
showed that these particles interact with the cell wall, proteins,
and DNA (Lara et. al. 2010).
Because of their small size, silver nanoparticles have the ability
to attach to the surface of the cell membrane and disrupt its
function. The positive charge of the Ag NPs allows them to electrostatically interact with the negatively charged membrane (Lara,
et.al. 2011). As transmission electron microscopy has shown with
E. coli cell membranes, silver nanoparticles disrupt the cell membrane, increase the cell’s permeability, and ultimately cause cell
death (Dakal, et. al. 2016) (Mambrio-Jones, Hoek, 2010).
Furthermore, silver has a high affinity for sulfur and phosphorus (Nurani, et.al. 2015). Therefore, Ag NPs can also adsorb to
the cell membrane by interacting with thiol (SH) groups on the
cell membrane. As a result of this interaction, a new bond between sulfur and silver (S-Ag) is formed, and the creation of
this new bond blocks both respiration and the electron transfer. Ultimately, this results in the collapse of the proton motive
force. Without the proton motive force, the cell membrane
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is disrupted and cell leakage followed by cell death ensues
(Mijnendonckx, et. al. 2013).
Moreover, after weakening the cell membrane, these particles have the ability to penetrate the bacteria (Lara, et.al. 2010)
(Mijnendonckx, et.al. 2013). Additionally, in gram negative bacteria, porins help facilitate the entry of Ag NPs into the cell. Once
inside, these Ag NPs interact with various molecules resulting in
further cell damage (Dakal, et. al. 2016).
Ag NPs have a significant effect on DNA replication. Silver
particles interact with thiol groups resulting in conformational
changes that ultimately inhibit the activity of various enzymes
(Mijnendonckx, et.al. 2013). Furthermore, when silver particles
bind to the guanine base, pyrimidine dimerization occurs, and
DNA replication is inhibited. Silver particles can also affect protein production and translation by interacting with and subsequently denaturing ribosomes (Dakal, et.al. 2016).
Moreover, silver nanoparticles are oxidized into silver ions
upon entering the bacterial cell. Ag ions cause damage and cell
death by interacting with lipids, proteins, and DNA. Silver ions
also interact with nucleosides in addition to forming complexes
with nucleic acids. Furthermore, these ions bind and dimerize
DNA and RNA, block the expression of proteins and enzymes
involved in ATP production, and generate free radicals (Lara,
et.al. 2010) (Mijnendonckx, et.al. 2013).
Reactive oxygen species can be endogenously produced from natural metabolic processes like aerobic respiration. Metal ions, like
silver, have the ability to catalyze the generation of free radicals
in the presence of oxygen (Mambrio-Jones,Hoek, 2010), and spin
resonance measurements have shown that silver ions increase
the production of reactive oxygen species (Mijnendonckx, et.al.
2013) (Mambrio-Jones, Hoek, 2010) (Kim, et. al. 2007). These free
radicals then act upon the mitochondrial membranes to induce
necrosis and cell death. Furthermore, ROS oxidize lipids, nucleic
acids, and proteins, thus disrupting the level of homeostasis by
inducing oxidative stress and cell damage.
In addition to increasing the production of ROS, silver particles
also decrease the levels of glutathione, an antioxidant, by reducing
it into glutathione disulfide. Moreover, NPs inhibit the action of
NADPH-dependent flavoenzyme, catalase, glutathione peroxidase,
and superoxide dismutase, anti-oxidative enzymes that quench free
radicals. These enzymes are dependent on thiol groups, but since
silver ions interact with thiol groups, these enzymes cannot properly quench the reactive oxygen species (Mijnendonckx, et.al. 2013)
(Dakal, et.al. 2016).
Phosphorylation and dephosphorylation are important signaling
processes in bacterial growth. Phosphorylated proteins guide DNA
replication and recombination, metabolism, and bacterial cell cycle.
Silver nanoparticles block this signaling pathway to prevent the
production and action of phosphorylated proteins. Furthermore,
phosphorylated tyrosine kinases aid in the transport of exopolysaccharide and capsular polysaccharides. Therefore, to prevent

bacterial growth, Ag NPs can also dephosphorylate these tyrosine
residues (Dakal, et. al. 2016) (Shirvastava, et.al. 2007).

Effects of Silver Nanoparticles on Gram Positive
and Gram Negative Bacteria
A great deal of controversy exists regarding the efficacy of silver
nanoparticles in both gram negative and gram positive bacteria.
In some studies, the Ag NPs had an equal effect in both types of
bacteria, rendering silver as a potential broad antibacterial agent
(Lara, et. al. 2010). However, other studies found that these particles are more effective in gram negative bacteria.This phenomenon is attributed to the differences in the composition of the
cell wall in both gram positive and gram negative bacteria. The
peptidoglycan in gram positive bacteria is very thick, averaging
around 20-80 nm, and rigidly cross linked. Because of this thick,
rigid membrane, there are fewer sites for the silver to adhere to,
making it harder for the particles to adsorb and penetrate the
cell. On the other hand, the cell wall of gram negative bacteria is
composed of a much thinner, roughly 7-8 nm, and weaker PG. In
addition, the membrane of gram negative bacteria contains the
lipopolysaccharide (LPS). Because of its negative charge, the LPS
increases the silver nanoparticles’ ability to successfully bind to
the cell’s surface. The thinner and weaker PG coupled with the
negatively charged LPS makes gram negative bacteria more susceptible to silver nanoparticles (Feng, et.al. 2000) (Shirvastava,
et.al. 2007) (Dakal. et.al. 2016).

2. Size of Silver Nanoparticles
Particle size, shape, and dose all contribute to the efficacy and
toxicity of silver particles. Extensive research has been done in
attempt to uncover the antibacterial effects of different sized
Ag NPs. Using the disk diffusion method, one study compared
the efficacy of different sized nanoparticles against both gram
positive and gram negative bacteria. The relationship between
size and efficacy of Ag NPs has been extensively researched, and
it was concluded that the two are inversely related; the smaller the diameter of the particle, the more effective it is against
drug-resistant bacteria. The efficacy of smaller nanoparticles
compared to larger NPs can be attributed to the relationship
between surface area and size. Surface area and particle size is
inversely related; the smaller the particles are, the larger their
surface area is (Rai, et. al. 2014). As a result of the increased
surface area, the smaller particles can interact with the bacterial
cell more efficiently (Rai, et.al. 2009) (Haider, Kang, 2015).

3. Dose of Silver Nanoparticles
After determining the mode of action of Ag NPs, researchers
began to study the dose required to have a bactericidal effect. By
using various doses, 0.0, 6.25, 12.5, 25.0, and 50.0 mM, against different strains of bacteria, it was found that dose and antibacterial
effect were directly related; the higher the dose of the Ag NPs,
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Figure 2
(Dakal, et.al. 2016)
1.	The mode of action of Ag NPs:
2.	Adsorption to cell surface
3.	Penetration into the cell to cause damage to various biomolecules
4.	Generate ROS
5.	Affect signaling processes

which contains numerous facets (Mambrio-Jones, Hoek, 2010)
(Raza, et.al. 2016) (Pal, et.al. 2007) (Mijnendonckx, et.al. 2013).
However, other research found contradictory results. Using
the disk diffusion method, the zone of inhibition of Pseudomonas
aeruginosa was measured with the use of five different sized
and shaped particles: S1, S2, S3, S4, and S5, was measured. While
S1, S2, S3, S5 were all sphere shaped varying in size, S4 was
triangular shaped. After placing the particles in the center of
the sampled bacteria on an agar plate, the zone of inhibition of
S2, the smallest sphere particle, was 1.5 mm, while the zone of
inhibition for the triangular shaped particles was 1.4 mm. This
demonstrated that the smallest sphere particle had a greater
effect than the triangular shaped one (Raza, et.al. 2016). Using
x-ray diffraction, it was determined that the smaller spherical
shaped particles also contained high atomic density facets that
are found in triangular shaped Ag NPs which evidently contributed to the sphere’s greater bactericidal effect. Furthermore,
the sphere shaped Ag NPs acted as acids and interacted with
bases, sulfur and phosphorus containing compounds, to cause
damage to both the cell membrane and DNA (Raza, et.al. 2016).

5. Toxicity of Silver Nanoparticles

Figure 3:
(Morones, et.al. 2005)
TEM analysis of:
a) Bacterial cells before treatment of Ag NPs
b & c) Cells after use of Ag NPs
NPs attach to the surface of cell and penetrate inside the cell.
the more effective they were.The highest dose, 50.0 mM, was the
most successful at killing bacteria (Lara, et.al. 2010). Furthermore,
the dose required to have a combative effect was found to be
bacteria specific for each genus (Morones, et. al. 2005).

4. Shape of Silver Nanoparticles
In addition to amount and size, shape also plays a role in the
efficacy of the silver nanoparticles against drug-resistant bacteria.
Facets are flat surfaces that are present on geometric shapes.
Because of their large densities, facets have a higher surface
reactivity, and therefore Ag NPs with more {111} facets, facets
that are cut through the x, y, and z planes, have a greater effect
against bacteria (Mambrio-Jones, Hoek, 2010). Some research has
shown that triangular shaped particles are more effective than
both sphere and rod shaped particles at combating drug resistant
bacteria. The increased surface area and antibacterial effect of
triangle shaped particles can be due to their geometric structure
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The toxicity of any antimicrobial agent is a major issue of concern, and despite silver particles’ potential to act as an antimicrobial agent, at certain levels, silver nanoparticles can be toxic
to all mammals, including humans. Research has shown that Ag
NPs stimulate an immune response and induce apoptosis via the
JNK and ROS signaling pathways. As indicated by the levels of
glutathione, silver particles induce oxidative stress by decreasing the amount of the glutathione in the body. Additionally, due
to their high surface area, Ag NPs can also generate free radicals
from the respiratory chain. This imbalance between ROS and
antioxidant levels results in damage to both lipids and proteins
(Arora et.al. 2008) (Mambrio-Jones, Hoek, 2010). Silver NPs
also interact with the mitochondria to increase oxidative stress
and to disrupt ATP production, ultimately causing damage to
DNA. Ag NPs also affects protein folding. This increased stress
in the cell leads to cytotoxicity and apoptosis. Furthermore, Ag
NPs can enter the nucleus and induce genotoxicity by causing
DNA mutations, base damages, and strand breaks. Finally, these
particles induce carcinogenesis by activating different signaling
cascades and inflammatory responses (Dakal, et.al 2016).
In a few studies, it was found that the dose of Ag NPs needed
to induce apoptosis was different from the dose required to stimulate necrosis, 0.78-1.56 vs. 12.5 μg. Therefore, it was concluded
that a safe dosing range of silver can be determined (MambrioJones, Hoek, 2010). However, a contradictory conclusion was
reached by AshaRani et. al who found silver nanoparticles can be
toxic to humans at any dose (AshaRani et.al. 2009) (MambrioJones, Hoek, 2010). Therefore, due to this discrepancy, further
research in regards to the toxicity of Ag NPs must be conducted.

Silver Nanoparticles and Drug Resistant Bacteria

6. Resistance to Silver Nanoparticles
As is the case with antibiotics, bacterial resistance to silver is a
major concern. When bacteria are exposed to silver nanoparticles, it results in the natural selection of bacteria, thus causing
bacterial resistance to silver particles.
Bacterial resistance to silver NPs can be encoded in the plasmid or in the chromosome as it is seen in both Salmonella and E.
coli respectively (Mambrio-Jones, Hoek, 2010). In Salmonella, the
resistance to silver ions is attributed to nine genes on the plasmid.
Furthermore, resistance is also associated with the SilCBA and
SilP efflux pumps, the SilE and SilF periplasmic binding proteins,
and in Escherichia coli porin loss. However, resistance to silver
nanoparticles as a result of a one point mutation is not very common because of the complexity of silver’s actions (Chopra, 2007).
Additionally, since silver nanoparticles have a high surface area,
they can aggregate and combine together, causing them to lose
their antibacterial effect (Nurani, et.al. 2015) (Beyth, et.al. 2015).
Furthermore, because of its high surface energy, Ag NPs can become contaminated by the air, and therefore Ag NPs are synthesized with either chitosan, alginate, or gelatin, biodegradable
polymer matrixes, to prevent their oxidation (Nurani, et.al. 2015).

7. Combination of antibiotics and AG NPs
The synergy of two drugs or compounds has the potential to
successfully combat drug-resistant bacteria by acting through
different mechanisms. Therefore, after determining the bactericidal effect of silver nanoparticles, many researchers attempted
to determine the effects of the use of Ag NPs in conjunction
with the use of antibiotics against different strains of bacteria.
To determine the synergy of Ag NPs with drugs, silver particles
were used with amoxicillin against samples of E. coli. By comparing the minimum inhibitory concentration of various doses
of silver nanoparticles alone, the use of different amounts of
amoxicillin by itself, in addition to the combined effects of both
silver NPs and amoxicillin, the advantages of combination therapy was identified.
The combined effect of amoxicillin and Ag NPs was seen
to have a greater bactericidal effect than each of them alone.
Furthermore, when the two were administered together, a lower
dose of both amoxicillin and silver nanoparticles were needed to
stimulate an antibacterial effect as opposed to when each one
was given alone (Allahverdiyev, et. al. 2011) (Li, et. al 2005).
The success for this synergy can be attributed to a few different theories. With combination therapy, the two compounds or
drugs that are used usually target different steps, pathways, or
enzymes. Therefore, if bacteria resist the action of one antibiotic, the other compound can still exert its antimicrobial effects
through a different non-resistant mechanism.
Additionally, in non-resistant bacteria, the synergy of the two
can be attributed to the chelation reaction that occurs between
both the hydroxy and amino groups of the B-lactam and the Ag

NPs. The binding between the silver and the amoxicillin in addition to the binding between the antibiotic with other drug particles resulted in the formation of a new compound. This newly
synthesized antimicrobial agent, containing silver on the inside
and amoxicillin on the outside, attaches to the surface of the cell
membrane and causes more damage because of the synergy of
the two compounds. Additionally, the amoxicillin disrupted the
cell wall which increased the penetration of the Ag NPs into the
cell. Moreover, from this chelation reaction, silver nanoparticles
prevent DNA from unwinding, thus resulting in further damage
to bacterial DNA (Li, et. al. 2005) (Allahverdiyev, et. al. 2011).
Furthermore, silver nanoparticles can be used as a drug carrier. While antibiotics are usually hydrophilic, silver nanoparticles
are hydrophobic. Therefore, these nanoparticles can interact
with the hydrophobic bacterial cell membrane more easily than
antibiotics, enabling the transport of hydrophilic antibiotics to
the bacterial cell surface (Li, et. al. 2005).

Figure 4
(Li, et. al. 2005)
The formation of a new antimicrobial agent through the chelation
reaction between amoxicillin and silver nanoparticles

Figure 5
(Allahverdiyev, et. al. 2011)
The mechanism of action of the combination of B-lactam antibiotics
with silver nanoparticles is shown: The newly formed antibacterial
agent interacts with and destroys the surface of the cell.The Ag NPs
also prevent DNA from unwinding.

Conclusions
This paper attempted to explain the mechanism of action and
mechanism of resistance of antibiotics and drug resistant bacteria, respectively.As antibiotic resistance continues to emerge, researchers are constantly searching for new antimicrobial agents.
Silver nanoparticles have gained much attention as a possible
tool in combating drug resistant bacteria, and studies have proven the efficacy of Ag NPs to induce cell damage and cell death.
However, despite the growing potential of silver nanoparticles,
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further research must be conducted before implementing silver
nanoparticles into clinical trials as a promising way of replacing
or supplementing the currently used antibiotics.
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Abstract
The development of a new drug requires research and evaluation before the drug is approved to enter the market. One of the
factors determining the efficacy of a drug is the aqueous solubility of the drug. A current problem in today’s pharmaceutical
industry is the low aqueous solubility of many useful drugs. A drug with a low aqueous solubility will not readily be absorbed by
the body. The low aqueous solubility of a drug is often due to the drug’s hydrophobic character. Drug enhancement methods are
necessary to avoid the obstacle of drug insolubility and many methods have been developed. This paper focuses on the use of
cyclodextrins and their derivatives as a drug carrier to increase the solubility of poorly soluble drugs. Cyclodextrins have both
hydrophobic and hydrophilic character and are capable of encapsulating a hydrophobic drug molecule and forming guest-host
complexes. The cyclodextrin’s cylindrical shape allows the guest molecule, the drug, to be kept within the hydrophobic interior
while the exterior of the cyclodextrin is hydrophilic and soluble in aqueous solution. This complex improves the drug solubility
and ultimately the bioavailability of insoluble drugs. In this paper the complexation of four drugs with cyclodextrin was studied;
ibuprofen, imatinib, praziquantel and camptothecin. In each case the aqueous solubility of the poorly soluble drug was increased
with the use of cyclodextrins.
Introduction
The development of a drug is a process of converting a biologically active compound into a product that is safe and effective, it
is a long and expensive process. The performance of a drug, the
efficiency of the drug in carrying out the desired action, is dependent on the drug’s properties. Chemical and physical properties
of a drug determine the drug’s ability to react with the necessary
components along the path to achieving the desired effect. One
of the factors determining a drug’s performance and effectiveness
is the aqueous solubility of the drug (Gareth, 2007).

Solubility of a Compound
IUPAC defines solubility as the composition of a saturated
solution in terms of the amount of solute in proportion to
solvent (McNaught, Wilkinson, 2006). Solubility is the term
used to describe a solid, liquid, or a gas’s ability to dissolve in
a solvent. Aqueous solubility of a molecule changes depending
on the electrostatic charge of the molecule and the degree of
ionization. The dipoles in the water molecules are attracted to
the charged molecules forming a shell around the molecule and
solvating it (Trevor et.al. 2015).
Solubility of a compound depends also on its structure and
polarity. Polar groups can hydrogen bond with water molecules
and be solvated, nonpolar groups are insoluble in aqueous solution. Therefore, the aqueous solubility of a compound increases
as the number of polar groups on the compound increases. In
addition, if the polar groups on a compound have the ability to
ionize in water, the compound will be further soluble. Lipid soluble compounds are those with more nonpolar groups and they
may contain functional groups such as benzene rings, ethers and
esters. Amphipathic compounds with polar and non-polar parts
are soluble in both aqueous and lipid solvents (Gareth, 2007).

Drug Solubility
Solubility is a fundamental property that must be considered
when evaluating a drug. The solubility of a drug can range from
fully soluble, like ethanol in water, to poorly soluble, often referred
to as insoluble (Clugston, Fleming, 2000). The Biopharmaceutics
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Classification System (BCS), is a guide from the U.S. Food and
Drug Administration and is used to regulate and classify drugs
based on aqueous solubility and membrane permeability. Class
I drugs have high aqueous solubility and high membrane permeability, Class II drugs have low aqueous solubility and high membrane permeability, Class III have high aqueous solubility and low
membrane permeability, and Class IV drugs have low aqueous
solubility and low membrane permeability. Solubility of a drug is
determined based on the drug’s solubility over a pH range of 1 to
7.5 and is considered very soluble if the highest dose strength is
soluble in <250 ml of water.The membrane permeability of a drug
is measured by the extent of absorption and a drug is considered
highly permeable when the absorption in humans is > 90% of an
administered dose (FDA, BCS, 2016). Since cells typically contain
65% water, a drug must be water soluble to be effective. A drug
must be absorbed before entering the bloodstream in order for
the drug to be transported via the systemic circulation to its site
of action. The more soluble the drug the greater amount of absorbed drug in the bloodstream. More drug in the bloodstream
increases the gradient between the bloodstream and the extracellular fluid, in this way diffusion of the drug from the blood to
the extracellular fluid will be facilitated (Trevor et. al. 2015). In
addition, the more water soluble the drug the higher the bioavailability (Gareth, 2007).The amount of drug that is absorbed by the
bloodstream, divided by the amount that was administered, is the
bioavailability of that drug administered in that specific manner.
Drug absorbed / drug administered = bioavailability of the drug
(Trevor et. al. 2015).
Oral drugs are the most common form of drug administration.
They are easy to administer, are less specific in their sterility requirements, they are most cost effective, have a high patient compliance, and there is flexibility in the dosage form. For this reason
many pharmaceutical companies prefer to produce bioequivalent
oral drugs.The difficulty with oral bioequivalent drugs is their low
aqueous solubility and therefore low bioavailability. Oral drugs
must first dissolve in the aqueous gastric fluid in order to be
transported to the site of action.Therefore, solubility of a drug is
an important factor in determining the concentration of a drug
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that is required to achieve a desired response. More than 40% of
pharmaceutical developments are poorly soluble in water. Low
solubility of a drug slows the absorption rate, decreasing the bioavailability. Thus, solubility enhancement methods are necessary.
Increasing a drug’s solubility is a challenge faced by the drug development industry, especially the solubility of oral drugs (Savjani
et. al. 2012). Increasing the solubility of Class II drugs that have
low solubility and high permeability would be very productive.
The rate limiting step for Class II drugs, according to the BCS, is
the insolubility of the drug, therefore increasing the solubility will
increase the bioavailability of those drugs.
There are many methods that are currently used to increase
the solubility of new chemical entities (NCE’s). There are physical and chemical modifications that can be made to a drug to
increase its solubility. Particle size reduction can be employed, as
well as solid dispersion, nanosuspension, colloidal particles, and
changes to the crystal form. Additionally, chemical changes to pH
as well as complexation and salt formation affect the solubility
(Savjani et. al. 2012).
Other methods include the use of surfactants, micelles, liposomes and inclusion complexes (Gareth, 2007). These methods
utilize the hydrophobic effect in increasing the solubility of a molecule. Cyclodextrins and cyclodextrin derivatives form inclusion
complexes with insoluble drugs. Inclusion complexes apply guesthost chemistry in the formation of the complex. This paper will
focus on cyclodextrins and cyclodextrin derivatives as a method
to increase the solubility of a poorly soluble drug.

of six, seven, or eight glucose units.The cyclodextrin ring form is
composed of α-D-glucopyranoside units with 1→4 linkage like
in amylose (Gareth, 2007). When glucose is degraded by the enzyme glucosyltransferase, a product of the chain splitting can undergo an intramolecular reaction to form cyclic molecules, cyclodextrins. Each glucose molecule in the cyclodextrin contains
two secondary alcohols and a primary alcohol. Alpha (α), beta
(β), or gamma (γ) cyclodextrins, depending on whether they
contain six, seven, or eight glycosyl units respectively, are classified as natural cyclodextrins. Chemically derived cyclodextrins
are hydroxypropyl-β-cyclodextrin, randomly methylated-β-cyclodextrin, and sulfobutylether-β-cyclodextrin. These derivatives are often preferred due to their enhanced physiochemical
and biopharmaceutical properties (Gidwani,Vyas, 2015).

Cyclodextrin Synthesis
B. macerans is the microbe responsible for the formation of
cyclodextrins. A method to synthesize cyclodextrins is to treat
starch with amylase from Bacillus macerans. A crude product
of cyclodextrin is then obtained with about 60% αCD, 20%
βCD, and 20% γCD. The product also contains small amounts
of other materials including proteins. To purify the different

Methods
This study was completed by analyzing various articles collected from databases including Touro Library and PubMed. The research collected mainly explored cyclodextrins and their ability
to form guest-host complexes.

Discussion:
Cyclodextrin and Cyclodextrin Derivatives
Cyclodextrins (CD’s), and their derivatives are amphipathic molecules capable of forming guest-host complexes with drug molecules. The complex improves the drug solubility and ultimately
the bioavailability of insoluble drugs. Cyclodextrins are used as a
drug delivery system because of their potential to change physical, chemical and biological properties of a drug by forming a
guest-host complex (Gareth, 2007). From a microscopial point
of view, each guest molecule is micro-encapsulated leading to
changes in the chemical and physical properties of the molecule.
Cyclodextrins and their derivatives can improve the solubility of
a molecule, modify a liquid substance to a powder, and mask a bad
taste, smell or color of a drug (Chaudhary, Patel, 2013).

Cyclodextrin Structure
Cyclodextrins are cylindrical oligosaccharides typically made up

Figure 1 Cyclodextrin Structure (Brewster, Loftsson, 2007)

Figure 2 Top – bottom: α, β, γ CD derivatives (Gidwani,Vyas, 2015)
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cyclodextrin derivatives, various forms of glucosyltransferases
are genetically engineered.These glucosyltransferases are active
towards the production of specific cyclodextrin derivatives.The
glucosyltransferase enzymes distinguish the six, seven, or eight
glucopyranose units from the non-reducing end of an amylose
and alter the linkage to produce a specific cyclodextrin derivative (Brewster, Loftsson, 2007).

Hydropathy of Cyclodextrin
Cyclodextrins are amphipathic molecules. They have hydrophobic and hydrophilic character. Cyclodextrins have a hydrophobic interior and hydrophilic exterior. The polar exterior of the
cyclodextrin forms hydrogen bonds with the aqueous solution.
The hydrophobic effect drives the non-polar portion of the cyclodextrin inwards, away from the aqueous solution, forming a
hydrophobic cavity. This property enables the cyclodextrin to
form guest-host inclusion complexes with hydrophobic molecules (Chaudhary, Patel, 2013).
Cyclodextrins can encapsulate many molecules. The nonpolar hydrophobic molecule interacts with the nonpolar groups
in the interior of the cyclodextrin, while the polar hydroxyl
groups on the exterior surface of the cyclodextrin are hydrophilic. Hydrophobic molecules the size of one or two benzene
rings can fit into the cyclodextrin cavity. The cyclodextrins in
the complex increase the aqueous solubility of the guest molecule, often a drug. The interactions between the cyclodextrin
and the drug form the inclusion complex, the cyclodextrin host
molecule with the guest drug (Tiwari et. al. 2010).

Cyclodextrin-Drug Complex
A number of forces are responsible for the complex formation;
hydrogen bonding, van der Waals interactions, release of conformational strain, and exclusion of high energy water bonds
in the cyclodextrin cavity. Thermodynamic interactions are the
main drive in the formation of the cyclodextrin-guest complex.
Thermodynamically, the interaction between the cyclodextrin
host, the guest molecule, and the solvent, must overall be favorable in order for the reaction to proceed (Chaudhary, Patel,
2013). The cyclodextrin complex formation is usually enthalpy
driven. In an aqueous solution the cyclodextrin cavity contains
polar water molecules that are readily exchanged for non-polar hydrophobic guest molecules. The water molecules situated
inside the non-polar environment of the cyclodextrin cavity do
not have a full complement of hydrogen bonds and are higher
in energy than the water molecules outside the cyclodextrin.
Liberating the water molecules that are enthalpy-rich, high in
energy, is a driving force for the complexation. Sterically, the
size and certain functional groups of the guest molecule determine the ability of the guest to fit into the cyclodextrin cavity.
Additionally, the complex formation is dependent on the chemical properties of the guest molecule (Brewster, Loftsson, 2007).
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The formation of the cyclodextrin-drug complex can be
achieved through several methods. The kneading method is
a simple and inexpensive method and is therefore the most
commonly used method for preparing the complex (Savjani et.
al. 2012). This method converts the cyclodextrin into a paste
by saturating the cyclodextrin or cyclodextrin derivative with
water or hydroalcoholic solution. The drug is then added to the
paste and the mixture is kneaded. The kneading can be done either in the laboratory or using machines for large scale achievement of the complex. An additional method, the lyophilization/
freeze-drying technique, works with a solution of cyclodextrin
and drug. The solvent in the solution is removed by freezing the
solution and then drying it by rapidly reducing the pressure,
generating a powder. The increased surface area of the powder
enables considerable interactions between the cyclodextrin and
the drug (Savjani et. al. 2012).
Cyclodextrins can increase the solubility of the guest molecule in three patterns when graphed with cyclodextrin concentration and drug solubility. AL profiles indicate a linear increase in drug solubility as the concentration of cyclodextrin
is increased. AP systems have a curve that deviates in a positive
direction from the linearity indicating that the cyclodextrin is
proportionally more effective at higher concentrations. AN
relationships have a negative deviation from the linearity indicating that at higher concentrations cyclodextrin’s effectiveness
decreases (Brewster, Loftsson, 2007).

Complex Dissociation
Once a product of drug-cyclodextrin is obtained, the complex
must dissociate to release free drug upon reaching the site of
action.When drug is encapsulated within the cyclodextrin there
are factors that cause the complex to dissociate and release
free drug. The drug and cyclodextrin interactions are non-covalent interactions that are in dynamic equilibrium, constantly
associating and dissociating. There are two important factors
concerning the complex’s non-covalent interactions; firstly the
complexation strength, defined by K, and secondly the complex
lifetime. In a 1:1 complex ratio of drug to cyclodextrin the complexation strength, the K constant, is defined by the equation:
K = kf / kt = [DCyD] / [Df] [CyDf] where kf and kt are the
forward and reverse rate constants, [DCyD] is the complex
concentration and [Df] and [CyDf] are free drug and free cyclodextrin respectively.
Dilution is a major factor assumed to play a role in the dissociation of the complex. 1000-fold dilution of a drug with a low
binding constant to cyclodextrin decreased the complexation
percentage from 98% to 5.7%. The fraction of complexed drug
decreased from 99.5% to 47.5% in the presence of 1000-fold
dilution of a drug with a high binding constant to cyclodextrin.
Therapeutically, the complexed drug is diluted either
in the plasma or in the aqueous extracellular fluid. A 1mL
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drug-cyclodextrin complex administered via intravenous injection is diluted in the plasma by a factor of 1:3,500, in the
extracellular fluid the factor is 1:21,000. Dilution alone is not
sufficient in orally administered drugs because the complex
resides in the gastrointestinal tract before reaching the site
of action.
Drug binding to plasma protein is another factor responsible
for complex dissociation. If a drug has the ability to bind to
plasma protein the complex would dissociate further to release
more free drug according to Le Chatelier’s principle. Drugs with
a high binding constant to cyclodextrin that have the ability to
bind moderately to proteins, in 1000-fold dilution, are further
dissociated and only 31.9% complexed drug remains. If the drug
binds more tightly to proteins the factor of complexed drug
decreases to 8.9%.
Furthermore, if a drug is lipophilic and can be taken up by tissue
more drug would be released from the complex.The cyclodextrin
would remain in the aqueous solution and drug would be taken up
by tissue. This mechanism is especially useful in drug administered
at a site that has insignificant dilution (Stella et. al. 1999).
The dissociation process is driven mainly by an increase of
water molecules in the surrounding environment and happens
relatively fast. In a dilute environment there is a concentration
gradient which shifts the equilibrium to the left, dissociating the
cyclodextrin and the drug, thereby releasing free drug to be
absorbed. In the body’s dynamic environment, it is not likely
that the drug will encounter another cyclodextrin with which
to form a complex and in this way it remains free in the solution
(Chaudhary, Patel, 2013).

Complexed Drug Pharmacokinetics
The effect of cyclodextrins on the pharmacokinetics of complexed drug must be considered before cyclodextrin complexation can be applied. Kurkov et. al. studied the effect of complexation on the pharmacokinetics of close to 200 drugs. The
results concluded that the hydroxypropyl-β-cyclodextrin does
not have a significant effect on the pharmacokinetics of the
drugs. However, although not altered, some drug is lost due to
the complexation. The hydrophilic cyclodextrins are excreted
unchanged by the kidneys and any drug still encapsulated is
excreted too. This is especially true when the drug has a high
binding constant to cyclodextrin (Kurkov et. al. 2012).

Toxicological Considerations
Orally administered cyclodextrins are not significantly absorbed in their intact form from the gastrointestinal tract. The
Cyclodextrins range from 1000 Da to over 2000 Da in molecular weight and are hydrophilic with significant hydrogen bonding
donors and acceptors, therefore they cannot be absorbed in
their original form. Natural α-cyclodextrin and β-cyclodextrin cannot be hydrolyzed by human salivary and pancreatic

amylases and in general oral administration is not associated
with significant adverse effects and is well tolerated. After IV
injection α-cyclodextrin is mainly excreted unchanged in the
urine. β-cyclodextrin is nephrotoxic when administered parenterally but non-toxic in the topical, buccal, rectal or oral form
and can be found in numerous marketed drugs. The metabolism
of γ-cyclodextrin is similar to that of starch and linear dextrins
and only small amounts are absorbed intact. After iv injection
the γ-cyclodextrin is mainly excreted unchanged in the urine
(Brewster, Loftsson, 2007).

Ibuprofen-Cyclodextrin

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID)
used to treat mild to moderate pain and fever. Ibuprofen works
by inhibiting cyclooxygenase, an enzyme that converts arachidonic acid to cyclic endoperoxides. Cyclic endoperoxides are
precursors to prostaglandins responsible for inflammation
(PubChem, 2004).
Ibuprofen is a poorly water soluble drug. Although it contains
a carboxylic acid functional group which can hydrogen bond
with water and be solvated, the alkyl groups and the benzene
ring are non-polar and make the drug poorly soluble. Ibuprofen
is complexed with cyclodextrin derivatives to increase its solubility (Hussein et. al. 2007).
Khaled Hussein, et al. conducted a study on the ibuprofen-β-cyclodextrin complex (Hussein et. al. 2007). A solid
complex of ibuprofen, MW 206.3 g/mol, and β-cyclodextrin,
MW 1,135.0 g/mol, was prepared. Using controlled Particle
Deposition (CPD) with supercritical carbon dioxide the ibuprofen-β-cyclodextrin complex was formed.The CPD method
dissolves the desired solution in supercritical carbon dioxide
which then enters the pores of the carrier at extremely high
pressure and precipitates following a rapid pressure drop.
The “n-hexane wash” method determined whether the complex was formed. β-cyclodextrin and its complexes are insoluble in n-hexane but the free drug is soluble. The supernatant
liquid that was insoluble was separated, dried and then analyzed
by high-performance liquid chromatography (HPLC). HPLC determined the product yield as well as the content of ibuprofen
in the complex. The inclusion yield of the complex was determined using the following equation:
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Percent of included ibuprofen= [complexed amount
of ibuprofen/free amount + complexed amount] x 100
49.83±3.65 inclusion yield % was calculated.
Infrared spectroscopy of pure ibuprofen showed all the
characteristic peaks including the carbonyl peak at 1,706 cm-1.
The complexed drug’s infrared spectroscopy had a very week
carbonyl peak indicating that the drug molecule was encapsulated inside the β-cyclodextrin. Morphological changes were
also observed. Pure ibuprofen is rough needle-shaped crystals
and β-cyclodextrin is parallelogram shaped. The shape of the
complexed particles appeared smaller in size and different than
pure drug or pure β-cyclodextrin. This observation adds to the
evidence of the ibuprofen-β-cyclodextrin complex formation.
The complex was tested for drug release using a flow system with a dissolution vessel at pH 5 and 37°C. A sample of
pure ibuprofen and a sample of complexed ibuprofen, each
containing 3mg ibuprofen, were added to the vessel. Samples
were taken from the dissolution fluid at set intervals and were
studied spectrophotometrically. Kw, the dissolution coefficient,
was calculated. Kw corresponds to the time when 63.2% of the
drug is dissolved.
The dissolution of pure ibuprofen in vitro at pH 5 showed
poor dissolution after 15 minutes and after 75 minutes. The
complexed drug had a significantly higher dissolution rate and
amount, due to the presence of the β-cyclodextrin. The dissolution rate of the complexed product was 0.086±0.002 min-¹,
the rate of pure ibuprofen was excluded from analysis since it
did not reach 63.2% within 72 minutes.The dissolved amount of
drug after 15 minutes was determined to be 71.9±3.62% for the
complexed prepared using the CPD method, and 22.0±3.56%
for pure drug. After 72 minutes, 93.5±2.89% of drug dissolved
from the ibuprofen-β-cyclodextrin complex and from pure
ibuprofen sample only 59.5±4.86% of drug dissolved. The complexed drug had a significant increase in aqueous solubility.

Imatinib-Cyclodextrin

Imatinib, known as Gleevec, is an oral tablet or a capsule used
for the treatment of Philadelphia chromosome positive chronic
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myeloid leukemia (CML) or gastrointestinal stromal tumors.
Imatinib works by inhibiting protein tyrosine kinase, the growth
factor receptor that causes unregulated cell growth of cancer
cells (PubChem, 2005).
Aqueous solubility of imatinib is charge dependent and varies
depending on the pH. The active compound, imatinib, can be
mono, di, tri and tetra protonated. The more protonated the
compound the greater the overall charge of the compound.
Increased charge increases the aqueous solubility.At a pH below
5.5 the formation of different protonated species of imatinib
results in a charged drug that is water soluble. However, the free
base form of imatinib is neutral, uncharged, and therefore poorly
soluble. To increase the aqueous solubility of the free base form
of imatinib, the drug was complexed with β-cyclodextrin and
with randomly methylated β-cyclodextrin (RAMEB). Szabolcs
Beni, et al. performed a study determining the effectiveness of
cyclodextrin and cyclodextrin derivatives in increasing the solubility of the neutral drug form (Beni et. al. 2007).
In a solution of Na2CO3 at a pH of 10.5, 2 mg of imatinib
was added to a 1 ml solution of varying concentrations of β-cyclodextrin, 0-13 mM. The mixture was shaken for two days at
25.0 ± 0.5°C and a complexed product of 1:1 stoichiometry
was formed.
The aqueous solubility of the free base form of imatinib was
enhanced by complexing it with β-cyclodextrin. At a pH of 10
the linear AL phase solubility diagram indicated the improvement in the solubility of the drug. With increased cyclodextrin
concentration, the solubility of the drug increased linearly, complexation increased the drug solubility tenfold.
Titration of pure imatinib with KOH precipitated above a
pH of 6.5. Titration of 1mM imatinib in the presence of fourfold β-cyclodextrin or randomly methylated β-cyclodextrin
(RAMEB) did not precipitate due to the complex’s effect on
the solubility. The most stable form of the imatinib-cyclodextrin complex formed with the neutral form of imatinib. This is
because the neutral imatinib is most hydrophobic and interacts
most with the hydrophobic interior of the cyclodextrin. The affinity of imatinib towards cyclodextrin decreased as the charge
on the drug increased.
¹H NMR chemical shift titration method quantified the
non-covalent molecular interactions. At a titration of pH 3.5 the
predominant imatinib species was the deprotonated form. The
mono and tri protonated forms were present in smaller quantities. Interactions between the imatinib forms and the β-cyclodextrin was evident. The data collected suggests that the benzamide fragment of imatinib is involved in the inclusion complex.
2D ROESY NMR spectra was recorded at the same pH to
verify the data. The evidence suggested that the imatinib inclusion proceeds through the narrower part of the cyclodextrin
host. For steric reasons the inclusion proceeds in an unusual
way, through the narrower part of the cyclodextrin. The result
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Figure 3 AL phase solubility diagram (Beni et. al. 2007)
of the study concluded that a tenfold increase in the imatinib
solubility was achieved with 12mM β-cyclodextrin complexation. The increased aqueous solubility of imatinib greatly increases the effectiveness of the anti-cancer drug.

of praziquantel the drug was complexed with β-cyclodextrin
and hydroxypropyl-β-cyclodextrin. A study was conducted to
determine whether this Class II drug can be complexed with cyclodextrin and behave like a Class I drug (Maragos et. al. 2009).
The praziquantel-cyclodextrin complexes were formed via
the kneading method. 0.080 grams of praziquantel was mixed
with cyclodextrin in varying ratios; 1:1, 1:2, and 1:4 molar ratios.
The complexed praziquantel-β-cyclodextrin reached equilibration within 12 hours and the praziquantel-hydroxypropyl-β-cyclodextrin complex reached equilibration after a 24 hour
period. Heating the samples at 70°C for an hour prior to the
experiment accelerated the reaction and also increased the formation of the praziquantel-cyclodextrin complex. The concentration of praziquantel in the binary system remained constant
while it was in a shaking bath at 25°C for 72 hours.

Praziquantel-Cyclodextrin

Praziquantel (PZQ) is a Class II drug, according to the BCS,
used for the treatment of schistosomiasis. The drug works by
causing severe spasm and paralysis to the worms’ muscles and
the worms are then destroyed in the intestines or passed in the
stool. It is classified as a Class II drug due to its high membrane
permeability but low aqueous solubility. The low aqueous solubility is due to its lipophilic character (PubChem, 2005).
As a Class II drug, a high dose of praziquantel is necessary in
order for it to be effective. Improving the aqueous solubility of
praziquantel can potentially result in the classification of the drug
as a BCS-Class I compound. To increase the aqueous solubility

Figure 4 Proposed imatinib-CD complex (Beni et. al. 2007)

Figure 5 Phase solubility diagrams of praziquantel
with cyclodextrin (Maragos et. al. 2009)
The aqueous solubility of the lipophilic drug had a 4-5-fold
increase upon complexation with cyclodextrin. Calculations
of the praziquantel solubility in 0.01 M cyclodextrin versus
the solubility of praziquantel without cyclodextrin calculated
a solubility enhancement factor of 4.5. Preheating the samples
at 70°C for one hour prior to the experiment increased the
solubility enhancement factor; a factor of 5.5 was calculated for
the praziquantel-β-cyclodextrin complex and 6.0 for the praziquantel-hydroxypropyl-β-cyclodextrin complex. Preheating the
sample before complexation enhanced the drug complexation
by increasing the dissolved amount of praziquantel that interacted with the cyclodextrin to form inclusion complexes.
The content of praziquantel in the product was determined
spectrometrically. The isoquinoline ring of the praziquantel inserted in the cyclodextrin cavity. The phase solubility diagrams
were linear. The praziquantel complexation was stronger with
β-cyclodextrin than with the hydroxypropyl-β-cyclodextrin
derivative as revealed by the complexation constants, K values,
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obtained from the diagram. Furthermore, the complexation enhancement as a result of preheating the sample was more significant in the hydroxypropyl-β-cyclodextrin complex as reflected
in the K values.
Praziquantel complexation with different molar ratios of
cyclodextrin was studied. The praziquantel complex with
β-cyclodextrin had the highest drug concentration in a 1:2
praziquantel-cyclodextrin ratio. The optimum praziquantel-hydroxypropyl-β-cyclodextrin complex molar ratio was 1:4. The
different behaviors of the cyclodextrin derivatives are a result of
hydrogen bond formation between the drug and cyclodextrin.
After complexation with β-cyclodextrin and hydroxypropyl-β-cyclodextrin the drug was reevaluated in terms of the
BCS. The solubility/dose ratio, in relation to the dose and intestinal content, was calculated using solubility values of praziquantel in the presence and absence of β-cyclodextrin and
hydroxypropyl-β-cyclodextrin. At a low dose of 150 mg the
praziquantel complexed with β-cyclodextrin or hydroxypropyl-β-cyclodextrin had a higher solubility/dose ratio than pure
drug.The solubility was increased while the dose decreased.The
low dose form of praziquantel, 150 mg, thus classified as a BCSClass I drug.

Camptothecin-Cyclodextrin

camptothecin increased linearly with the increasing concentrations of various cyclodextrins. Camptothecin in the β-cyclodextrin complex had the highest increase in solubility, increasing
by about six-fold. α-cyclodextrin increased the camptothecin
solubility three-fold and γ-cyclodextrin increased the drug’s solubility five-fold. Of the modified cyclodextrin, RDM-β-CD exhibited the greatest increase in camptothecin’s solubility. At 25%
weight / volume concentration of RDM-β-CD, the solubility of
camptothecin increased by a factor of 170. The methyl groups
significantly increase the solubilizing effect of this cyclodextrin
derivative by disrupting the intramolecular hydrogen bonding
and enlarging the cyclodextrin cavity.

Conclusion
Drug solubility is an important factor in determining the efficacy
of a drug. The low aqueous solubility of many pharmaceutical
developments is an area of constant research. This paper studied the effect of cyclodextrins on the solubility of poorly soluble
drugs. Cyclodextrins and their derivatives, by forming guesthost complexes, encapsulate an insoluble drug and increase its
aqueous solubility. The cyclodextrin carries the drug through
the aqueous solution and the complex dissociates upon reaching the site of action. The cyclodextrin drug carrier transports
the insoluble drugs without altering the drug or causing significant harm to the patient.
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Abstract
Over the past few years, awareness of the prevalence of obstructive sleep apnea has significantly increased. Indeed, sleep apnea
may be more common now with the increasing incidence of obesity and the growing number of elderly individuals in our population. How serious is this condition, and what are the potential long-term effects and consequences of obstructive sleep apnea
if left untreated? An overlap of many serious conditions with obstructive sleep apnea has been noticed. These conditions include
hypertension, heart disease and failure, stroke, diabetes, neurological diseases, depression, and a number of other serious health
concerns. The purpose of this paper is to understand what the effects of untreated obstructive sleep apnea might be, and to
determine if is reasonable to suggest that sleep apnea is the cause of, or at least a significant contributing factor to, the conditions
it is associated with. Research shows that sleep apnea itself does inflict enormous trauma on the body. This trauma is mainly in
the forms of hypoxia which leads to oxidative stress, vascular damage, and hyperstimulation of the sympathetic nervous system
which can lead to high blood pressure and subsequent heart disease and failure, and by causing repeated episodes of unnatural
intrathoracic pressure which can lead to a number serious health concerns and even sudden death. These findings demonstrate
that sleep apnea should not be viewed as an incidental condition alongside other serious health problems nor mainly as a side
effect of them. It should rather be seen as a contributing factor, if not the primary cause, of many consequential health issues.
Introduction

Methods

Untreated obstructive sleep apnea has been strongly linked to
many serious diseases and early mortality. It can be the underlying cause of certain diseases, and it can cause rapid progression
or early onset of others. Perhaps even more alarming, is that
many incidences of sudden death, especially heart attacks, have
been attributed to untreated obstructive sleep apnea. The basic
understanding of its severity is that untreated obstructive sleep
apnea inflicts significant and multi-faceted trauma on the body.
This trauma is mainly due to nightly deprivation of oxygen in
the blood, sleep deprivation, constant hyper stimulation of the
sympathetic nervous system, and enormous strain on the heart.
It is noteworthy that there are also secondary physical, mental,
and emotional health concerns associated with untreated sleep
apnea. In a random sample of several hundred individuals presenting to a sleep clinic with symptoms typical of sleep apnea,
it was observed that the vast majority of the patients subsequently diagnosed with obstructive sleep apnea had at least
one other serious health issue. The percentage of people with
additional health problems tended to be much higher among
those 40 years of age and older- i.e. in the individuals who had
gone through many more years of trauma to their bodies before
seeking treatment (personal observation, Chang, et.al. 2013).
It is also especially critical to explore the effects of untreated sleep apnea because it effects many more people than was
previously thought (up to 24% of adult men) (Peppard, et.al.
2000) and because there has been a steady rise in the diagnosis of sleep apnea with the increased incidence of obesity. In
addition to the obesity factor, it is now known that the general
aging process is a major risk factor in the development of sleep
apnea. Consequently, it may be prudent to study the diagnostic methods and treatment options for sleep apnea for those
involved in geriatric care (Adegunsoye, Ramachandran, 2012).
Several studies indicate that post-menopausal women are at
increased risk for developing obstructive sleep apnea because
the female sex hormones which help dilate the airway decrease
after menopause (Chang, et.al. 2013).This paper will explore the
question of how untreated sleep apnea effects the body and the
implications of these effects.

Relevant material was scoured mainly from the web, from conversations and correspondence with a veteran pulmonologist
and sleep specialist, and from personal experience observing
and interviewing patients and studying polysomnography data at
a sleep clinic over a period of about two months. Only materials
from authoritative sources were used. An effort was made to
gather information on the interaction between sleep apnea and
numerous medical conditions thus broadening the scope of the
paper. This was done in order get as full a picture as possible on
how sleep apnea may affect the body. Material on the effectiveness of treatment of sleep apnea was also considered pertinent
to understanding the mechanisms of this condition and are included in the discussion accordingly.
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Definition ofTerms
Sleep apnea: Sleep apnea is defined as a cessation of breathing
of ten seconds or more while asleep (Tsara, et.al. 2009). There
are two main types of sleep apnea: Obstructive Sleep Apnea, and
Central Sleep Apnea.
Obstructive Sleep Apnea (OSA): OSA is an anatomical condition where, while asleep, the muscles in the throat relax to an
extent that the airway collapses. Specifically, there may be several different muscles responsible for this. Sleep apnea is more
common in people who have a narrow airway. A narrow airway
can be genetic, it can be caused by inflammation, or it can be
due to obesity. (Obese individuals often have excess submucosal
adipose tissue which can build up around the airway thereby
causing the airway to compress.) Defects in, or damage to, the
face or neck in areas which affect the airway may also be a risk
factor for OSA. OSA can affect adults or children, but is more
common in adults (Tsara, et.al. 2009). OSA can be a factor in determining the cause of Sudden Infantile Death Syndrome (SIDS),
and a family history of OSA may be considered a risk factor in
SIDS (Thach, 2008).
Central Sleep Apnea (CSA): CSA is a condition where the
apneustic center in the brain stem fails to send nerve impulses
necessary for breathing. CSA can occur without an obstructed airway. However, OSA and CSA are often clinically related.

Consequences of Untreated Obstructive Sleep Apnea

When a patient who has CSA and OSA is treated just for the
OSA, the CSA part of the sleep apnea is often minimized or
even eliminated (Costanzo, et.al. 2015). It is possible that the
disordered breathing caused by the OSA may contribute to the
apneustic center malfunction- either directly or by a secondary
mechanism. CSA can also be accompanied by irregular breathing patterns. For example, the Cheyne-Stokes respiration is a
common symptom of primary CSA (Tsara, et.al. 2009, Costanzo,
et.al. 2015). (Cheyne-Stokes respiration is a breathing pattern
where there are rapid or deep breaths followed by a decrease
and secession of breathing. This is usually in a cycle which can
last anywhere from 30 seconds to two minutes.) CSA can also
be secondary to illness or trauma, and it can be caused by
certain medications and substances. It is noteworthy that if a
newborn has sleep apnea, it is often CSA (Tsara, et.al. 2009) and
may be a factor in determining the cause of SIDS (Thach, 2008).
Hypopnea: A hypopnea is a partial closure of the airway which
is often characterized by loud snoring. (The snoring is caused
by the fluttering of the air passage walls as they come in close
proximity while breathing.) This partial closing is classified as
a hypopnea when the obstruction is severe enough to cause
oxygen desaturation in the blood.
Polysomnography: A polysomnography is a sleep study. During
a sleep study, the individual is attached to electrodes and other
machinery which collect information about the person’s sleep.
This information will include how long the patient spent in each
phase of sleep, whether or not the patient has OSA or CSA, oxygen saturation or desaturation in the blood, breathing patterns,
and many other items of relevance. A polysomnography can be
used to diagnose sleep apnea.
Apnea-Hypopnea Index (AHI): An AHI is a score of how many
events of apnea and hypopnea occur per hour. For example, if
six times in the course of an hour, a patient stops breathing for
ten seconds or more and/or has an oxygen desaturation, then
the patient will have an AHI of 6 (or an event on average of
every ten minutes).
Sleep Disordered Breathing: Sleep disordered breathing is a
general term used to refer to any abnormal breathing issues
or abnormal breathing patterns which can occur when one is
asleep.
Continuous Positive Airway Pressure Machine (CPAP
Machine): A CPAP Machine is a medical device which blows air
through the nose to the back of the airway to keep it open while
a person is asleep. It is currently the most effective standard
treatment for sleep apnea.The machine can be adjusted to apply
more or less pressure as needed, and modern machines are
often self-adjusting. Other machines are available to treat more
complicated cases, but they too incorporate positive pressure
to treat the OSA component of any sleep disordered breathing.
There are surgeries which can be performed to help eliminate
OSA, but they are only about 50% effective. Some dental devices

have been developed to treat OSA, but they too are often insufficient as effective treatment (Peker, et.al. 2002).

Discussion
The most obvious area of concern with sleep apnea is the fact
that when breathing stops, oxygen doesn’t enter the lungs.
This, in turn, leads to oxygen desaturation in the blood. This
hypoventilation has been linked to a number of conditions such
as systemic hypertension (Peppard, et.al. 2000), pulmonary hypertension (average pressure in the pulmonary arteries greater
than 25mmHg (resting)) (Adegunsoye, Ramachandran, 2012),
polycythemia (high red blood cell count), heart problems, behavioral issues, emotional issues (Sheu, et.al. 2015), and birth
defects (Tsara, et.al. 2009, Adegunsoye, Ramachandran, 2012).
It has also been reported that early treatment is effective in
eliminating these negative effects, and it is therefore of paramount importance to recognize, diagnose, and treat sleep apnea
syndrome at the earliest possible opportunity (Adegunsoye,
Ramachandran, 2012).
Systemic hypertension can be due to numerous factors involving OSA. One factor is that the hypoxia may lead to a pressor
effect as an attempt by the body to get more oxygen (Peppard,
et.al. 2000, Tkacova, et.al. 2014). Another contributing factor to
hypertension is fluid and sodium retention due to sympathetic
nervous system activation of the renin angiotensin aldosterone
system effecting the kidneys (Bradley, Floras, 2003, Nishizaka,
et.al. 2004). Many patients with untreated OSA have swelling in
their legs (personal observation). It is noteworthy that administration of oxygen does not prevent the hypertensive effect of
untreated OSA (Leung, Bradley, 2001).
The increased risk for developing hypertension due to untreated OSA is present even in individuals diagnosed with mild
sleep apnea (AHI of approx. 5) (Peppard, et.al. 2000). The risk
for developing hypertension is, however, directly related to the
severity of the sleep apnea. Several studies show that individuals with more severe sleep apnea were more likely to develop
hypertension than those with milder sleep apnea (Peppard, et.al.
2000, Peker, et.al. 2002, Nieto, et.al. 2000). The likelihood of developing hypertension is present regardless of gender, race, or
ethnicity, and it is usually manifest in individuals middle age or
older (Nieto, et.al. 2000). Severity of sleep apnea is based on AHI
and on ODI (oxygen desaturation index) (Tkacova, et.al. 2014).
If treatment for OSA is initiated before the onset of hypertension, then chronic hypertension as well as other cardiovascular
disease may be avoided. Additionally, treatment for the OSA has
a much greater impact on lowering blood pressure than does
weight loss (Nieto, et.al. 2000, Tkacova, et.al. 2014, Lavie, et.al.
2000). Even in the event that hypertension has already set in,
studies show that it can be minimized significantly after approximately 9 weeks of treatment (Milleron, et.al. 2004). The association between sleep apnea and hypertension is so strong that
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sleep apnea should be seriously considered in the diagnosis and
treatment of high blood pressure (Lavie, et.al. 2000).
Many studies have demonstrated that endothelial cells are
severely damaged and impaired by hypoxic conditions, and
the extent of endothelial cell damage has also been associated
with the AHI index (Lui, et.al. 2013). The damage may occur in
the form of apoptosis of endothelial cells, in the form of cell
cycle arrest, and in a number of other ways which play a role in
many of the adverse effects of untreated sleep apnea (Iida, et.al.
2002). Endothelial cell damage and dysfunction is connected to
inflammation, atherosclerosis, renal damage, impaired vasodilation ability and nitric oxide production, and many other severe
health issues (Bruno, et.al. 2013). Additionally, oxidative stress
seems to be one of the main causes for endothelial cell damage.
The extent of oxidative stress is likewise directly correlated to
the severity of the sleep apnea (Del ben, et.al. 2012). It is extremely important to realize that the individual with untreated
OSA is at increased risk of arterial stiffness, which can lead to
heart disease and other severe health issues even if they experience very minimal symptoms (Kohler, et.al. 2008).
Hypoxia is known to cause an increase in reactive oxygen
species. The mechanism for this phenomenon is not clear, but
some studies suggest that this is due to the lack of a strong
electron acceptor in the absence of oxygen. When there are no
electron acceptors, the electrons have no place to go and therefore remain unbound as superoxide radicals or as other reactive oxygen species (ROS) (Kondoh, et.al. 2013). Compounding
this problem is the reperfusion following the apneic episode
which also causes an increase in ROS. Reperfusion may cause
an increase in ROS for two reasons. One is that cell function
has been impaired due to the lack of oxygen and is altogether
not running efficiently enough to rid itself of the ROS. Second
is that the sudden influx of oxygen overloads the cell which
cannot process it fast enough. Studies show that hypoxia and
subsequent reperfusion can cause damage to the epithelial lining of blood vessels.This damage can cause and/or contribute to
atherosclerosis (Sawatari, et.al. 2016).
Aside from the ROS caused by reperfusion, there are other
ROS released by a number of granular leukocytes in response
to hypoxemia. The increased presence of ROS is a general
danger to the body and has been linked to cancer and other
illnesses.This is especially a concern for cancers which originate
in endothelial cells because they are most directly affected by
ROS (Kondoh, et.al. 2013). This is especially the case when the
body experiences this kind of oxidative stress night after night
for years on end (Adegunsoye, Ramachandran, 2012, Milleron,
et.al. 2004). Proper treatment of OSA solves the problem of
oxidative stress and can help reverse some or all of the damage
caused by it (Del ben, et.al. 2012, Bayram, et.al. 2009).
Pulmonary hypertension in particular, is one cause for right
sided heart failure and has an especially grim prognosis if left
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untreated. Pulmonary hypertension can be caused by a number
of conditions, but its link to OSA and general sleep disordered
breathing is strong enough that the American College of Chest
Physicians recommends that patients presenting with pulmonary hypertension be evaluated for sleep disordered breathing.
The pathophysiology of pulmonary hypertension in sleep disordered breathing is that the hypoxia caused by the breathing
disorder in turn causes hypertrophy of the pulmonary arteries.
This hypertrophy decreases perfusion of blood in the lungs.The
situation is even more disastrous for individuals with emphysema or fibrosis of the lung. The heart tries to compensate for
the decrease in perfusion by working harder, and this attempted
compensation puts enormous strain on the right ventricle. This
strain is unsustainable and leads to right sided heart failure and a
subsequent general dyspnea even at rest. If left untreated, death
typically occurs within three years of diagnosis (Adegunsoye,
Ramachandran, 2012). The mechanism of how hypoxia causes
the initial hypertrophy of the pulmonary arteries needs elucidation, but it seems to be related to endothelial cell dysfunction.
(It is also noteworthy that obese individuals are more likely
to develop pulmonary hypertension with OSA (Adegunsoye,
Ramachandran, 2012).)
Aside from hypertrophy of the pulmonary arteries which
can cause pulmonary hypertension, there is the direct effect
of hypoxia in the form of pulmonary vasoconstriction. The reason for vasoconstriction during an hypoxic event is due to an
attempt by the body to keep ventilation and perfusion in sync.
In the absence of oxygen, vasoconstriction will lessen perfusion.
This, however, will also cause an increase in pulmonary artery
pressure. This pressure is primarily a concern while the individual is sleeping. However, about 20% of patients with elevated
pulmonary artery pressure while sleeping will eventually develop pulmonary hypertension even while awake. This may be because the increased blood pressure can directly cause damage
to blood vessels and result in the hardening and stenosis of
those damaged vessels.
Another area of concern in untreated OSA is the effect of
prolonged sympathetic nervous system stimulation. When
a person with OSA has an event, the body responds to the
obstructed breathing by activating the fight or flight response.
This occurs for each event- all night, every night. One effect of
this stimulation is vasoconstriction and an increased heart rateboth of which raise blood pressure. Eventually, this can lead to
chronic systemic and pulmonary hypertension (Adegunsoye,
Ramachandran, 2012).
Chronic systemic hypertension is known to negatively affect
cardiovascular health and increase mortality. It has also been
reported that hypertension in individuals with untreated OSA is
particularly difficult to control, and that in attempting to control
the high blood pressure, beta blockers are the most effective,
suggesting that a major contributing factor to the high blood

Consequences of Untreated Obstructive Sleep Apnea

pressure is sympathetic stimulation (Leung, Bradley, 2001).
Even in the absence of chronic hypertension development,
there is, concern of vascular endothelial dysfunction. Overstimulation of the sympathetic nervous system can, in of itself,
lead to vascular endothelial dysfunction. The pathophysiology of
the damage is, similar to what is found in patients with chronic
hypertension: Vasoconstriction creates more resistance in the
blood vessels. Resistance, especially if prolonged, can cause
damage to the vasculature and lead to hardening of the blood
vessels (Adegunsoye, Ramachandran, 2012). The damage can
be quite significant because the effects of sympathetic system
over-stimulation linger into the wake hours as well (Tkacova,
et.al. 2014).
The constant presence of catecholamine levels also puts the
untreated OSA patient at greater risk for thromboembolism
because high levels of catecholamines tends to lead to platelet
aggregation. This and other phenomena which can predispose
an individual to thromboembolism can be reversed with effective treatment. The reversal of which suggests that the hypercoagulability in individuals with OSA is indeed caused by the OSA
(Adegunsoye, Ramachandran, 2012).
There is a secondary problem associated with untreated OSA
of the sleep deprived individual. The way the body clears the
obstructed breathing is by jolting the person out of deep sleep
long enough to return muscle tone to the airway and open it
back up. This arousal from deep sleep is called a Respiratory
Effort- Related Arousal or RERA. A RERA can be present even
in the absence of a clinically defined apnea- for example if the
breathing stops for less than 10 seconds, or if there is no significant oxygen desaturation during an event (Tsara, et.al. 2009).
There are serious health risks associated with sleep deprivation
as well as physiological effects and secondary risks. Psychological
effects could include depression, apathy, and irritably. Secondary
risks could include general fatigue or falling asleep while driving
(Adegunsoye, Ramachandran, 2012).
Sleep deprivation and hypoxia are both known causes of inflammation. Inflammation is an independent factor in endothelial cell dysfunction and has also been linked to certain cancers
(Lui, et.al. 2013). Several factors which cause inflammation are
found in high levels in individuals with untreated OSA. Proper
treatment is effective in stopping the inflammatory response
(Adegunsoye, Ramachandran, 2012, Shamsuzzaman, et.al. 2003).
Another factor associated with OSA which causes sleep
deprivation is nocturia. Nocturia is a condition where an individual’s sleep is interrupted multiple times in order to empty the
bladder. The pathophysiology of this condition is that attempting to breathe with an obstructed airway causes an enormous
amount of intrathoracic pressure which results in a much larger
than usual volume of blood to enter the heart. In some individuals, this overfilling causes the release of atrial nauturetic peptide
(ANP). ANP in turn causes the kidneys to excrete more water.

The reason this system is activated is because the overfilling of
blood in the heart mimics the mechanics of increased blood
volume. Increased blood volume increases blood pressure. As a
result, the body, thinking that it has too much blood, will want
to get rid of the excess volume by way of diuresis (Umlauf, et.al.
2004). Patients with OSA report that their nocturia subsides
once they comply with effective treatment (Personal communication with patients).
In addition to the mimicking of increased blood volume which
causes the release ANP, ANP excretion is also increased due to
acidosis.The lack of oxygen caused by OSA can certainly lead to
at least a temporary acidosis, and this may further contribute to
nocturia. ANP also directly inhibits the excretion of vasopressin. Vasopressin normally plays a role in the decrease in urine
production while asleep. If vasopressin is inhibited, then urine
production will not decrease and the individual may experience
nocturia. In one study of carefully selected individuals diagnosed
with OSA, blood levels of ANP, as well as urine levels of ANP and
increased urine volume were directly correlated with untreated
OSA. It is also noteworthy that an elevated level of blood ANP
is related to mortality rates in patients with heart problems, and
a correlation between heart disease and untreated OSA has
been strongly established (Umlauf, et.al. 2004).
Nocturia is often associated with aging. This association is
due to the general aging process, and in men due to prostate
hypertrophy, and in women due to decreased bladder volume.
Aging is also a risk factor for OSA, and as such, its another
possible cause of the increase in nocturia with age in both men
and women. The connection between untreated OSA and nocturia is one way to explain why, in many individuals, nocturia is
not resolved with the treatment for benign prostate hypertrophy. It has also been documented that the incidence of sleep
apnea doubles in women post menopause- probably as a result
of low estrogen levels. This correlates well with the increase
in nocturia in women post menopause. Attributing nocturia in
post-menopausal women to untreated OSA may be more accurate than attributing it to a simple decrease in bladder volume.
The effects of over elimination of fluids and how this may affect
proper hydration and general fluid management in the body also
needs to be considered when evaluating the impact of nocturia
(Umlauf, et.al. 2004).
Many individuals with OSA are obese. Obesity is a risk factor
in OSA, but OSA can, in of itself, also cause weight gain. Weight
gain can be attributed to lack of physical activity. People with
OSA often experience chronic fatigue, and this can possibly
cause OSA patients to limit their physical activity. However, in
addition to this secondary cause for weight gain, OSA can be
directly responsible for altered metabolic factors which lead
to obesity. Leptin levels are often found to be at abnormally
high levels in obese individuals. Patients with untreated OSA
often have even higher levels of leptin than obese individuals.
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The current understanding is that leptin is found at high levels because of resistance to their appetite suppressing activity.
Patients with untreated OSA have sometimes been found to
have high levels of leptin and gain weight in the year prior to
diagnosis, and these patients tend to return to normal leptin
levels and lose the weight once proper treatment is undertaken.
It is also noteworthy that a high leptin level is considered a risk
factor for cardiovascular disease (Adegunsoye, Ramachandran,
2012, Shamsuzzaman, et.al. 2003, Milleron, et.al. 2004).
Another metabolic factor linked to OSA is impaired glucose tolerance. Insulin resistance has been directly correlated
to OSA, and several studies demonstrate that individuals with
OSA are several times more likely to develop diabetes mellitus
than those without OSA (Adegunsoye, Ramachandran, 2012,
Gottlieb, et.al. 2010, Bayram, et.al. 2009).
One of the most extensive areas of study concerning untreated OSA is the effect it has on the heart. In fact, about 50% of patients with heart failure have OSA, and medication for heart failure seems to have little, if no effect on alleviating OSA (Bradley,
Floras, 2003). In addition to the effect of pulmonary hypertension on the heart (discussed above), there are additional ways in
which untreated OSA can cause cardiac health problems. When
the body tries to breath while the airway is obstructed, an enormous amount of negative pressure is generated in the thoracic
cavity. This negative pressure pulls large amounts of blood from
the superior and inferior vena cava into the right atrium of
the heart, thus effectively increasimg afterload (Shekerdemian,
Bohn, 1999). The negative intrathoracic pressure increases venous return and distends the right ventricle which effectively
impairs left ventricular filling (Bradley, Floras, 2003). Additionally,
the negative pressure may prevent the left ventricle from relaxing and filling properly (Shamsuzzaman, et.al. 2003). These
mechanisms effectively decrease cardiac output (Adegunsoye,
Ramachandran, 2012, Mooe, et.al. 2001, Gottlieb, et.al. 2010).
Individuals with OSA can thus have high blood pressure due to
vasoconstriction from sympathetic nervous system stimulation
but decreased cardiac output due to impaired left ventricular
filling. Unnatural configuration of the heart and aortic stretching
are also caused by this large negative pressure. This stress on
the heart can cause either rapid or reduced heart rate, and
even complete sudden heart failure. The longer the apneic episode the greater the risk of cardiac malfunction (Adegunsoye,
Ramachandran, 2012).
Aside from rhythmic and filling problems for the heart, there
is also a risk for myocardial hypertrophy which can cause irreversible hypertension. The hypertrophy is caused by the constant strain on the heart muscle- just as constant strain on any
muscle leads to muscle growth. If the strain is primarily right
sided, then the hypertrophy will affect the right side of the heart.
If the strain is primarily left sided then it will affect the left side
of the heart. If the strain is on both sides then the entire heart
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can be effected. Hypertension caused by OSA can last beyond
the actual apnea episodes, and even in the absence of myocardial hypertrophy, this hypertension can last for many hours after
awakening (Peppard, et.al. 2000, Peker, et.al. 2002). However,
treatment for OSA can often reverse systemic and pulmonary
hypertension if myocardial hypertrophy has not yet set in. This
is one on the many reasons why it’s important to properly treat
OSA at the earliest opportunity (Adegunsoye, Ramachandran,
2012, Jean-louis et.al. 2010).
In addition to myocardial hypertrophy, there is concern
that untreated OSA may cause ion channel remodeling in the
heart. This condition can lead to sudden cardiac death (Chahal,
Somers, 2016). Gene expression effecting potassium ion channels was studied by examining mRNA associated with potassium ion channels. It was discovered that there was significant
altering of several potassium pump genes which may result in an
extended repolarization period. Potassium pumps are needed
to pump positively charged potassium ions across the myocardial cell membranes so that a new muscle contraction can begin.
If they don’t pump ions efficiently, then this period of repolarization will take longer. One potential problem with this is that
there is a danger of ventricular extrasystole (premature ventricular contraction). This kind of arrhythmia can cause sudden
cardiac death. The mechanism for how exactly the OSA causes
the altered gene expression has not been fully elucidated, but it
seems to be multifactorial, including stressors such has hypoxia,
sympathetic stimulation, and increased intrathoracic pressure.
Individuals who undergo treatment for OSA can reverse the
pathologic alterations to the potassium ion channels and regain
proper gene expression for potassium pumps that work correctly (Chahal, Somers, 2016, Bradley, Floras, 2003).
The risk of sudden cardiac death in patients with untreated
OSA is not limited to extrasystole due to ion channel malfunction. In fact, there are quite a few additional mechanisms
by which sudden cardiac death may occur. For example, during
REM sleep, there is a general increase in sympathetic stimulation. (This is in contrast to other stages of sleep where the
sympathetic nervous system is depressed.) The transition from
non-REM to REM thus creates a situation which increases oxygen demand. Experiencing an apnea, with the simultaneously
occurring hypoxia, is thus of greater consequence at this point
in the sleep cycle. This ensuing trauma to the heart can cause
arrhythmias (Chahal, Somers, 2016).
Sudden cardiac death is of even greater concern in the
morning hours because that is typically when the longest REM
period takes place and because the apneas at this point tend
to last for longer periods of time. In addition to the risk of
arrhythmias being increased during this longer REM period,
there is great risk of myocardial infarction or stroke at this
point as well (Mooe, et.al. 2001). In general, blood pressure
rises at different points in the sleep cycle. Individuals with
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untreated OSA often experience an even greater increase in
blood pressure- probably due mainly to the overstimulation
of the sympathetic nervous system. The risk for MI or stroke
is always increased with an increase in blood pressure, and as
such, these individuals will be in the most danger during REM
sleep. The longer REM and the prolonged apneas associated
with it have claimed many lives (Michael Katzoff MD, personal
communication May 2017).
Stimulation of the sympathetic nervous system can also result
in tachycardia which further puts a large demand for oxygen
on the heart at a time when the heart cannot get oxygen due
the apnea. This situation can be even more life-threatening in
patients with coronary artery disease (CAD) (Milleron, et.al.
2004). Additionally, a myocardial infarction or stroke is often
caused by a plaque rupture which is made more likely by the
increase in blood pressure and also because of the intrathoracic pressure caused by the obstructed airway (Chahal, Somers,
2016). In fact, 43-91% of patients who experience a stroke also
have sleep apnea (Leung, Bradley, 2001, Shamsuzzaman, et.al.
2003). It is noteworthy that the rise in intrathoracic pressure
has also been known to cause the rupture of an aortic aneurism
which is typically fatal (Chahal, Somers, 2016).
In patients with pre-existing coronary artery disease (CAD)
there is at least a 60-70% increase in sudden cardiac death or
myocardial infarction when the individual also has untreated
OSA. In addition to heart related problems there is an increase
in cerebral vascular complications such as stroke. The cerebral
vascular complications may result from the increase in the prothrombotic effect connected with untreated OSA as well as
from other factors effecting hemodynamics (Mooe, et.al. 2001,
Peker, et.al. 2002). Fortunately, proper treatment for OSA has
been shown to decrease the number of new cardiac issues or
at least to dramatically slow the rate of coronary artery disease
progression (Milleron, et.al. 2004, Peker, et.al. 2002, Jean-louis
et.al. 2010). It is likely that treatment would be similarly beneficial to cerebral vascular health (Gottlieb, et.al. 2010).
In general, the sympathetic system stimulation, which often
lingers throughout the day in untreated OSA individuals, is
known to increase platelet aggregation.This aggregation is detrimental to patients with CAD (Milleron, et.al. 2004). Additionally,
prolonged platelet aggregation as well as increased levels of fibrinogen, and general inflammation in individuals with untreated
OSA, may be a risk factor in developing a deep vein thrombosis
on top of the risk these factors pose to CAD (Milleron, et.al.
2004, Bayram, et.al. 2009).
It is noteworthy that many patients with nocturnal angina
experience relief when undergoing proper treatment for OSA.
This suggests that the cause of pain, which is normally due to a
lack of oxygen, is caused by the OSA and is effectively treated
with standard CPAP therapy (Peker, et.al. 2002).
Another area of recent study is the possible connection

between untreated OSA and dementia. One study found that
the correlation between sleep apnea and dementia may be affected by factors such as age, gender, and duration of the condition. The mechanism for the connection between untreated
OSA and dementia are not yet conclusive, but the connection
between hypoxia, which is a side effect of untreated OSA, and
neurological malfunction has been documented a number of
times. For instance, rats which were exposed to hypoxic conditions experienced a greater incidence of apoptosis in their
hippocampus, and advanced brain imaging showed reduced grey
matter in parts of the brain responsible for executive functions
and memory. Damage to these areas in humans may be a factor
in the cause of dementia (Svatikova, et.al. 2003, Ju, et.al. 2013).
Another disturbing finding is that rodents placed in hypoxic
conditions developed large amounts of cerebral amyloid plaque.
Similar results have been found in humans with levels of serum
amyloid A being two and a half times higher in patients with
untreated OSA (Svatikova, et.al. 2003, Ju, et.al. 2013). Cerebral
amyloid plaque is one of the hallmark findings in individuals with
Alzheimer’s disease. It was also found that there was significant
phosphorylation of the tau proteins. Tau proteins are abundant
in neural tissue and function in support of microtubules. When
they are over-phosphorylated, they can malfunction and cause
the structure of the cells in which they are found to become
pathologically altered. Additionally, microtubules function as a
sort of road or transport pathway for various particles within
the cell. The intracellular functions which rely on these transport pathways may stop working properly if the tau proteins
become over phosphorylated. Quite tellingly, another common
finding in Alzheimer’s disease is tau protein phosphorylation. In
lab mice, cerebral amyloid plaque buildup and tau phosphorylation has been connected to decreased memory function
(Daulatzai, 2015). It is also possible that the general damage to
the vasculature throughout the body due to hypoxia can be a
factor in dementia because the vasculature in the brain is negatively affected (Chang, et.al. 2013).
It has been shown that treatment of OSA in the early stages
of Alzheimer’s disease can aid in dramatically slowing its progression. One study demonstrated that with treatment of OSA
with CPAP machine, memory and mental processing speed improved in any stage of dementia. Treatment also helped reduce
or eliminate neuroinflammation. Additionally, the cardiovascular
improvements experienced with CPAP treatment have had positive impact on patients with neurological illnesses. Conversely,
some research indicates that the onset of mental decline may
begin as much as one decade earlier in individuals with untreated OSA (Emamian, et.al. 2016).
Another connection between sleep apnea and brain function
loss in humans is the presence of a common gene known as
APOE4 (apolipoprotein epsilon 4) which has been shown to
play a role in obstructive sleep apnea as well as being connected
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to the development of dementia. The association could be a
shared genetic fate, but it could also suggest that the gene is tied
mainly to the development of OSA which, if left untreated, could
lead to the damage which can cause dementia. Further studies
would be necessary to determine the exact nature of the correlation. The long-term effects of sleep deprivation caused by
sleep apnea should be considered when determining the longterm effects of untreated OSA on brain function (Chang, et.al.
2013).
A recent study has implicated untreated OSA as one possible
cause of Parkinson’s disease. The mechanisms seem most likely
to include the general oxidative stress caused by hypoxia and
reperfusion and the general inflammation characteristic of the
body’s response to untreated sleep apnea. There is even evidence to support the possibility that the blood brain barrier
may be interrupted as a result of cerebral vascular damage
which may allow molecules harmful to brain tissue to cross the
barrier and reach cells involved in Parkinson’s disease and other
neurological pathologies (Sheu, et.al. 2015).

to his pulmonology and sleep medicine practices and patiently
explained to me the foundational principals of OSA along with
many of its intricate details and its relationship to many bodily
systems which it can affect.

Conclusion

Chang WP, Liu ME, Chang WC, et al. Sleep apnea and the risk of
dementia: a population-based 5-year follow-up study in Taiwan. PLoS
ONE. 2013;8(10):e78655.Costanzo MR, Khayat R, Ponikowski P, et
al. Mechanisms and clinical consequences of untreated central sleep
apnea in heart failure. J Am Coll Cardiol. 2015;65(1):72-84.

Extensive research reveals that untreated obstructive sleep apnea
is extremely traumatic and damaging to the body. It has been
clearly linked to physical diseases in the heart, brain, endocrine
system, and vasculature, and it has been implicated as a cause for
psychological and emotion distress, as well as secondary hazards.
Mortality rates are consistently higher and earlier in individuals
with untreated OSA and as such, individuals presenting to their
health care providers with significant health issues associated
with OSA should be tested for it. It is extremely important for
health care providers to realize the severity of OSA and to understand that it can be present even in patients who experience
few of the symptoms commonly indicative of OSA. Even patients
with a relatively low AHI of about 4 or 5 are at risk because
the trauma to the body is consistent and repeated every time
the person sleeps, and this trauma has a tendency to have a cumulative effect on the body. Early diagnosis is key because the
negative effects of OSA can be eliminated with early treatment.
Treatment should be adamantly encouraged even in individuals in
whom permanent damage has already occurred because treatment can reverse some of the damage and certainly help stabilize
the patient and prevent the progression of further health issues.
Unfortunately, the symptoms of sleep apnea are not always connected immediately to the condition and are often written off as
symptoms of other medical or phycological issues. It is therefore
prudent of heath care practitioners to be mindful of sleep apnea
and diagnose it as early as possible.
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Abstract
The relationship between periodontal disease and cardiovascular disease has been the subject of much research in recent years.
The aim of this study is to review and analyze the relevant literature regarding this relationship, with an emphasis on determining
a presence of periodontal bacteria from the periodontal pocket in atheromatous plaques, and to explore the biological role of
inflammatory mechanisms that may link periodontitis and cardiovascular disease. Although there seems to be conflicting reports,
the overall consensus confirms the presence of periodontal bacteria, such as Porphyromonas gingivalis, in atheromatous plaques.
Additionally, the presence of systemic markers of cardiovascular disease in patients with periodontitis, such as acute phase
proteins, proinflammatory cytokines, and markers of procoagulant state, has been confirmed. These confirmations could indicate
a role for periodontal pathogenic bacteria in atherosclerosis disease process. Additionally, these findings give rise to possible
mechanisms linking the two diseases.
Introduction
As early as the early 1900’s, oral sepsis and tooth extractions
were suggested as causes of cardiac infection. However, due
to the lack of compelling scientific evidence, the idea of oral
disease as a cause of systemic illness was basically disregarded.
That focus was revived in the early 1990’s after reports of the
connection between periodontal disease (PD) and cardiovascular disease (CVD). Although many subsequent studies have
postulated positive associations between PD and CVD, others
have maintained that no such correlation exists. Additionally,
several potential mechanisms have been proposed describing
how PD could cause systemic inflammation, initiate or exacerbate atherogenesis, and possibly lead to cardiovascular catastrophes such as myocardial infarction (MI) or stroke. The purpose
of this article is to review the relevant articles, predominant
theories, and proposed mechanisms relating periodontitis and
atherosclerotic vascular disease. Specifically, does the inflammatory PD contribute causally to heart disease and stroke, or are
these two conditions coincidentally associated?

Methods
The information gathered in this paper has been collected from
numerous sources including databases such as GoogleScholar,
Touro Library, and PUBMED.The information was read, analyzed
and compared to determine each study’s validity and authority.

Results and Discussion:
Defining PD and CVD
CVD, or more specifically atherosclerotic vascular disease,
affects the heart and the blood vessels. Coronary heart disease (CHD)- also referred to as coronary atherosclerosis, or
simply heart disease- is a subset of CVD and is characterized
by dysfunction of the arteries supplying blood to the muscle
tissue of the heart, depriving it of sufficient amounts of blood.
Atherosclerosis, or the hardening and narrowing of the arteries,
silently and slowly blocks arteries, putting blood flow at risk.
CHD includes blockage of blood vessels (thrombosis) and can
eventually cause acute myocardial infarction (heart attack).
CVD is the number one cause of death in the United States and
other industrialized countries, and is among the major causes of
mortality worldwide. Traditionally, CVD has been attributed to
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risk factors such as treated and untreated systolic blood pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, and body-mass index. However, these factors only occur
in about half of all patients that experience heart attacks. For
example, 40% of CHD deaths occur in patients who have cholesterol levels that are lower than the population average. This
has led researchers to investigate additional causes of CHD, including bacterial induced inflammation (Taylor, et. al. 2009).
Periodontitis is a bacteria-induced, chronic inflammation of the
gingival tissue in response to dental plaque accumulation. PD
is always preceded by gingivitis, an earlier and less severe form
of gum disease, though not all cases of gingivitis will progress
to PD. Untreated PD leads to deepening of the gingival sulcus,
which evolves into a periodontal pocket, destruction of the connective tissue and bone supporting the teeth, including gingival
tissue, periodontal ligament, and alveolar bone. Clinical criteria
for PD include bleeding on probing, pocket depth and degree of
tooth attachment loss.

Evidence of Correlation Between CVD and PD
Many studies have been conducted assessing the possible connection between CVD and PD. The results have varied, and at
times proposed conflicting views. The fact that oral pathogens
can come to lesions far from the oral cavity has been proven
by Lockhart, et. al.. The authors showed how poor oral hygiene
or dental disease are risk factors for developing bacteremia
after a simple tooth brushing or after a single tooth extraction.
One hundred and ninety-four patients participated in the study.
The authors assayed blood samples before, during and after the
toothbrushing or single tooth extraction to identify Infective
Endocarditis (IE)- associated bacteria. The authors found that
oral hygiene and gingival disease indices were strongly correlated with IE-related bacteremia after toothbrushing. Patients with
a mean plaque and calculus score of 2 or more had an increased
risk of 3.78 and 4.43-times for developing bacteremia. Thus, we
see that it is easy for bacteria in the oral cavity to enter that
blood stream. This, as well as other similar studies, present a
strong basis for the idea that oral pathogens can make their
way to regions far from the oral cavity (Lockhart, et. al. 2009).
Additionally, many studies show that bacteremia is present after
oral examination and probing Loos, 2006).
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Siddeshappa, et. al. (2016) conducted a study to determine
whether nonsurgical periodontal therapy can impact various hematological parameters in patients with periodontitis.
Traditionally, the total number of white blood cells (leukocytes)
and erythrocyte sedimentation rates in peripheral blood has
been used as diagnostic measures to determine whether or
not a patient suffers from an infection or an inflammatory
disease. Leukocytes become more numerous through the innate immune system response to periodontal bacteremia. The
suggestion has been made that higher numbers of leukocytes
makes the blood more viscous. Additionally, cells may adhere to
the endothelial lining of the blood vessels causing decrease of
blood flow. Furthermore, periodontitis has been associated with
an increase in plasma fibrinogen and platelet activation which
increase the risk of atherosclerosis and CVD. The aim of the
study was to investigate the effect of nonsurgical periodontal
therapy on total leukocyte count (TLC), differential leukocyte
count (neutrophils, lymphocytes, eosinophils, basophils, and
monocytes), erythrocyte sedimentation rate (ESR), and the total
platelet count on patients with periodontitis. Thirty patients
were selected for the study.The results of this experiment were
that a decrease in clinical parameters of PD (ex. plaque index,
gingival index, etc.) was accompanied by a statistically significant
change in TLC, platelet count and ESR. The authors concluded
that there is a decrease in hematological parameters after nonsurgical periodontal therapy, which may also reduce the risk of
atherosclerosis (Siddeshappa, et. al. 2016).
In a similar vein, animals with experimentally induced periodontitis had more extensive accumulation of lipids in the aorta than
did those without t. There was a positive correlation between
the severity of PD and the extent of lipid deposition (Jain, et. al.
2003)., A study of 711 subjects, suggestaaed that tooth loss is a
marker of past periodontal disease, and is related to subclinical
atherosclerosis. Among those with 0 to 9 missing teeth, 46% had
carotid artery plaque, and among those with ≥10 missing teeth,
carotid artery plaque prevalence was about 60% (Desvarieux,
et al. 2003).
However, such correlations are vague and broad. The above
studies merely show increased atherosclerotic suseptability.
This can be due to an overall systemic increase of inflammatory
organisms. A more direct demonstration of correlation can be
had by discovery of specific periodontal oral cavity bacteria in
the atherosclerotic lesion. Such findings would show that inflammatory PD contributes causally to heart disease and stroke,
and that these two conditions are not merely coincidentally associated. Research in this area is more questionable, and not as
consistent in its results.
In a study conducted in 2004, 52 patients were studied who were
scheduled for carotid endarderectomy to ascertain the presence
of periodontal bacteria DNA, including that of Actinobacillus actinomycetemcomitans, Fusobacterium nucleatum, Porphyromonas

gingivalis, Prevotella intermedia, and Tannerella forsythensis, in
carotid atheromatous plaque. In subgingival plaque samples of 19
test patients,T. forsythensis, F. Nucleatum, P. intermedia, P. gingivalis
and A. actinomycetemcomitans were found. However, no periodontal DNA was detected by PCR in any of the carotid samples.
The authors concluded that the presence of periodontal DNA
in atheromatous plaques could not be confirmed by this study,
and thus no correlation could be established between species
associated with periodontal disease and putative bacteria contributing to atheromatous plaques (Cairo, et. al. 2004). This study
brings into question the causality relationship of periodontitis and
gingival disease to CVD.
Other studies have produced results indicating a small number of matching pathogens. A study was conducted to isolate
and identify bacteria from the periodontal pockets of different
patients and to compare them with the microorganisms detected in atheromatous plaques obtained from the same patients.
Clinical isolates were obtained from 12 patients with periodontal wounds and atheromatous plaques. These samples were
then used to identify periodontal bacteria using polymerase
chain reaction (PCR) assays. The results were as follows. From
the 12 patients studied, 9 presented different periodontopathic
species. In two patients Actinobacillus actinomycetemcomitans,
a gram-negative coccobacillus, was present in the periodontal
pockets and the respective atheromatous plaques. The authors
were unable to explain the mysterious absence of P. intermedia
and P. gingivalis growth in atheroma samples, even though these
bacteria are usually present in periodontal samples. The authors
concluded that the presence of A. actinomycetemcomitans in
both the atheromatous plaque and the periodontal pockets of
the same patients could indicate a role for periodontal pathogenic bacteria in the atherosclerosis disease process (Padilla, et.
al. 2006). Similarly another investigation was aimed at testing the
validity of the translocation hypothesi and its role in promoting plaque development. The authors used 16s cloning and sequencing, to determine the microbial diversity of the subgingival
environment and atheroma plaques of patients concomitantly
suffering from periodontitis and obstructive coronary artery
atherosclerosis (OCAA). Subgingival biofilm and coronary balloons used in percutaneous transluminal coronary angioplasty
were collected from 18 subjects presenting with generalized
moderate to severe periodontitis and OCAA. DNA was extracted and the gene 16S was amplified, cloned and sequenced.
The authors results were similar to those obtained by Padilla,
et al.. They observed significant differences in microbial diversity between the two environments. While subgingival samples
mostly contained the phylum Firmicutes, in coronary balloons,
Proteobacteria was predominant. Additionally, the most commonly detected genera in coronary balloons were Acinetobacter,
Alloprevotella, Pseudomonas, Enterobacter, Sphingomonas and
Moraxella, while in subgingival samples Porphyromonas, Filifactor,
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and aortic atherosclerotic lesions than those that were not
Veillonella, Aggregatibacter and Treponema were found. Despite
challenged. The average coronary and aortic intimal areas were
such diversity, 17 identical phylotypes were found in atheroma
between≈3 times and ≈5.9 times larger than controls, a signifiand subgingival samples, indicating possible bacterial translocacant difference.These lesions were predominantly composed of
tion between periodontal pockets and coronary arteries (Serra
smooth muscle cells. In addition, hypercholesterolemic pigs likee Silva Filho, et. al. 2014). Again, these findings are seemingly
wise challenged with recurrent P gingivalis bacteremia develop
small pieces of data regarding the overwhelming question of
larger coronary and aortic atherosclerotic lesions, both having
a periodontal-atheroscleric connection. Nevertheless, sevan intimal area that was ≈2.2 times larger than controls. Brodala,
eral studies do indicate a strong correlation with respect to
N et al. summarized their results in Table 1 and Table 2.
Porphyromonas gingivalis (P gingivalis). Porphyromonas gingivaAdditional significant information was reported by the aulis has been strongly associated with adult periodontitis. This
thors. We mentioned previously the lack of evidence showing
bacterium is a Gram-negative, nonmotile, obligate anaerobe
that can invade and infect
Aorta
Coronary Arteries
epithelium,
endothelium, Low-Fat Diet
and vascular smooth muscle
Intimal Area, μm2
Intimal Area as %
Intimal Area, μm2
% Luminal
Intimal Area as %
Medial Area
Narrowing by
Medial Area
cells. Another group used
Intima
ApolipoprotienE knockout
982.7±217.5
8.06±2.5
192.09±93.92
5.25±0.89
5.45±2.19
(apoE−/−) mice which were Group 1.
gingivalis
orally administered the peri- PA7436–challenged
odontal disease pathogen
768.5±318.3
5.08±1.10
158.19±33.45
4.56±0.85
3.83±0.83
Group 2. P
Porphyromonas gingivalis. gingivalis FDC381–
The P. gingivalis was detect- challenged
364.3±184.5
1.1±0.5
11.2±7.4
0.4±0.22
0.38±0.24
ed in the blood and aortic Group 3. P gingivalis A7436–sensitissue of the mice. The mice tized controls
challenged with P. gingivalis
203.6±247.1
1.15±1.46
48.9±29.1
1.3±1.0
1.7±1.3
presented with an increase Group 4.
Unsensitized
in atherosclerotic plaque, controls
as well as expression of the TABLE 1. Aortic and Coronary Artery Atherosclerosis Morphometry in Pigs Fed a Low-Fat Diet
innate immune response
markers Toll-like receptors High-Fat Diet
Aorta
Coronary Arteries
(TLR)-2 and TLR-4 in the
Intimal Area, μm2
Intimal Area as
Intimal Area, μm2
% Luminal
Intimal Area as %
aortic tissue (Gibson, 2004).
% Medial Area
Narrowing by
Medial Area
Intima
In order to determine
4584±3371
17.7±11.5
1536±1917
34.9±21.5
26.9±18.7
whether recurrent intrave- Group 5.
P gingivalis
nous injections of P. gingivalis, A7436–challenged
mimicking periodontitis-as- Group 6.
1976.6±1014.7
7.9±4.0
695.1±804.5
16.3±15.7
11.8±10.4
sociated bacteremia, pro- Unsensitized
motes coronary artery and controls
aortic atherosclerosis the TABLE 2. Aortic and Coronary Artery Atherosclerosis Morphometry in Pigs Fed a High-Fat Diet
periodontal bacteria within the atheromatous legions. Previous
researchers chose pigs for this experiment since they develop
studies only showed a correlation between the two diseases.
coronary lesions that closely simulate human disease. Showed
Brodala, et al. discovered the following. P gingivalis ribosomal
Thirty-six pigs were sensitized with 109 killed P gingivalis subDNA was detected in the carotids (5 of 5) and the aortas (4 of
cutaneously. Four weeks later all sensitized pigs in the group
5) from the 5 P gingivalis-treated pigs on the low-fat diet and
to be challenged started intravenous injections three times a
the aortas of all 7 P gingivalis–challenged pigs on the high-fat
week for 5 months with 106 to 107 units of P gingivalis while
diet. However, none of the aortas or carotids from saline-chalcontrols received saline. Pigs were euthanized 2 weeks after the
lenged control pigs, whether sensitized or not, had amplifiable
last injection, and coronary arteries and aortas were analyzed.
P gingivalis ribosomal DNA. The authors themselves note two
The results were significant. The authors found that the pigs
limitations in their study. Firstly, the pig model used does not
that received intravenous P gingivalis challenges demonstrated
entirely and accurately replicate the bacteremia of oral ora >100-fold increase in anti–P gingivalis antibody levels.This was
igin from inflamed human periodontal tissues. Nonetheless,
in conjunction with the result that pigs challenged with recuras seen previously in rodents, the P gingivalis–challenged pigs
rent P gingivalis bacteremia develop significantly larger coronary
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developed an anti–P gingivalisantibody response as a consequence of P gingivalis challenges in association with increased
atherosclerosis. Second, the number of pigs was not sufficient
to exclude an effect of gender in this study. Data that was not
available at the time of this study suggests that human males
have a greater prevalence of asymptomatic carotid disease
than females with comparable severity of periodontitis. This
study does not account for such differences (Brodala, et al.
2005).
Other systemic markers also present evidence that periodontitis can lead to a systemic inflammatory response. Loos,
(2006) outlines several systemic effects of periodontitis. He
writes that in severe periodontitis, characterized by extensive plaque buildup, bacteremia occurs frequently, leading to
leakage of lipopolysaccharides, a major component of periodontopathogens. Additionally, Loos was involved in several
studies which investigated the presence of systemic markers
of cardiovascular disease in patients with periodontitis. The
author took peripheral blood from patients and analyzed the
presence and levels of white blood cells, red blood cells and
thrombocytes. He also analyzed the presence of important
marker molecules such as acute phase proteins, proinflammatory cytokines, and markers of procoagulant state. The suggestion is that increased numbers of white blood cells may
make the blood more viscous and increase blood rheology.
Additionally, white blood cells tend to stick to the inside of
blood vessels, particularly where there is inflammation. This
may contribute to reduced blood flow which in turn increases
the risk of microthrombus formation. The author writes that
he found that the highest number of white blood cells were
present in patients with severe periodontitis, the lowest numbers were found in control groups, and subjects with moderate
periodontitis presented levels in between. Thus, the presence
of elevated WBC’s in the blood stream due to periodontitis is
evident. We can then postulate that such inflammatory markers can exacerbate an atherosclerotic lesion.
The presence of other systemic markers of inflammation in
periodontitis is also evident. One of the important markers of
CVD is proinflammatory cytokines. In particular, interleukin-6
(IL-6) is produced by monocytes, neutrophils, endothelial cells,
and B cells, and stimulates the hepatocytes to produce acute
phase reactants. The author found that in general, patients
with severe periodontitis had much higher levels of IL-6 than
the controls. In many controls the levels of IL-6 could not
be detected at all. Additionally, when patients with aggressive
periodontitis were treated, IL-6 levels decreased, highlighting
the correlation between periodontitis and IL-6 levels.
C-reactive protein (CRP) is another systemic marker of periodontitis. CRP is one of several acute phase proteins produced
in the liver. The liver produces these acute phase proteins in
response to infection or an inflammatory process, mainly due

to elevated IL-6. CRP acts as a substance that binds to foreign
microorganisms or cells, making them more susceptible to
phagocytosis, also known as an opsonization. What is especially
important is that CRP is associated with CVD. The relative risk
of CVD is increased 90% when CRP levels are equal to or more
than 2 mg. Thus, a possible mechanism would also be associated
with these findings (Loos, 2006).

Evidence of the Role of Inflammation in CVD
Until recently, most believed that atherosclerosis was an arterial
collection of cholesterol, complicated by smooth muscle cell
accumulation. According to that theory, endothelial denuding
injury led to platelet aggregation and release of platelet factors
which would trigger the proliferation of smooth muscle cells
within the arterial wall. It is now widely accepted that a major
component of CVD in general, and atherosclerosis in particular, involves numerous components of the adaptive and innate
immune systems leading to an inflammatory response within
atheromatous lesion. A brief synopsis of these findings follows.
The innate immune system plays a major role in the inflammatory response in atherosclerosis. Considerable evidence
supports the notion of early involvement of the monocyte/
macrophage, the most prominent cellular component of the innate immune system, in atherosclerosis. Observations in human
arterial samplings have identified monocyte recruitment as an
early event in atherogenesis. Additionally, recent examinations
of monocyte recruitment in mouse atherosclerotic lesions have
shown that monocyte entry into the atherosclerotic lesion
continues throughout lesion maturation. High levels of proinflammatory monocytes in mice are recognized by the high levels
of a marker known as Ly6C, or Gr-1, and may correspond to a
human monocyte subset marked by the presence of P-selectin
glycoprotein ligand (PSGL) These proinflammatory monocytes
express high levels of proinflammatory cytokines and other
macrophage mediators. Recent studies have also highlighted
the possible participation of mast cells, which exhibit numerous functions implicated in atherogenesis. For example, mast
cells are known to release certain serine proteinases, histamine
and leukotrienes, and heparin, a cofactor in atherogenesis. An
additional area of evidence links thrombosis with inflammation.
Thrombin may induce the expression of proinflammatory cytokines (Libby Peter, 2009).
The adaptive immune system also contributes to the inflammatory response in atherosclerosis. T lymphocytes populate atherosclerotic plaques and can be stimulated by certain heat shock
proteins, components of plasma lipoproteins and other molecules.
These T cells, upon further stimulation, produce cytokines and trigger inflammation. Additionally, biomarkers, such as highly sensitive
C-reactive protein (CRP), apolipoprotein B (ApoB), and lipoprotein
(a) amongst others, have been identified in conjunction with atherosclerosis predictability (Libby Peter, 2009) (Wong , 2012).
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Proposed Mechanisms Linking Periodontitis to
Cardiovascular Disease
Based on this review regarding systemic effects of periodontitis
and inflammatory roles in CVD, we can begin to hypothesize
the different mechanisms that link the two diseases. The authors suggest that the host response to bacteremia may vary
between patients with periodontitis due to individual variation
in inflammatory pathway. It is also possible that inherited genetic
variations could enhance these mechanisms.
The authors maintain that a number of inflammatory mediators
and markers are present in higher concentrations in the systemic
circulation of periodontal patients than in those with healthy oral
cavities.There are theoretically two pathways by which this could
occur. There are ample data indicating that inflammatory cytokines and other mediators are produced in the periodontal lesion
(Siddeshappa, et al. 2016)( Loos, 2006). It has been hypothesized
that these mediators could enter into the circulation from the
oral cavity. If this occurs, and the mediators achieve adequate concentrations, they would then impact tissues and organs distant
from the oral cavity. In particular, these mediators from the periodontium could affect other organs, such as the liver, to initiate an
acute-phase response that would impact other organs.The result
is that the mediators themselves cause inflammation, as well as
stimulate other organs to produce a pro-inflammatory response.
This would lead to inflammatory changes in the endothelium
such as up-regulation of adhesion molecules and promotion of
cytokine production, which directly causes initiation and/or acceleration of atheroma development. It should be noted that there is
not strong evidence supporting this mechanism for inflammatory
cytokines and other mediators accessing the circulation (Teles,
Wang, 2010).
In addition, it has been shown patients with periodontitis have
frequent bacteremic incidents and that detectable concentrations
of lipopolysaccharides are frequently found in the circulation.
Thus, bacteria, or their pro-inflammatory components, may stimulate systemic inflammatory responses as well as local inflammatory responses in atheromatous lesions. This would follow their
association with, or modification of serum lipids, engagement of
receptors on inflammatory cells and endothelium, invasion of endothelial cells, or seeding of atheromatous lesions with bacteria
or bacterial components. Bacteria or their products could then
promote inflammatory changes that would contribute to the development or propagation of atheromatous lesions.
There are a number of antibodies that can also effect an
inflammatory response. Some of these anti-bodies have been
found to react as models of “molecular mimicry,” which is defined as the theoretical possibility that sequence similarities
between foreign and self-peptides are sufficient to result in the
cross-activation of autoreactive cells. This is the case in which
antibodies that have arisen due to infection by oral bacteria in
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the oral cavity make thier way into the systemic blood, engage
with the host antigens and regulate their operation. These are
cross-reactive antibodies. It is possible that sometimes these
antibodies promote cardiovascular disease by exacerbating the
endothelial reaction to their presence which causes further
endothelial inflammation, or increasing the absorption of lipids
into phagocytes.
Several studies indicate that serum concentrations of potentially inflammatory lipids, including LDLs, triglycerides, and very
low-density lipoproteins (vLDLs) are elevated in periodontitis
patients. These lipid subforms are thought to enter the blood
vessel wall more easily, may be more susceptible to modification
and therefore more likely to be incorporated in to the atherosclerotic lesion. This would accelerate and promote the development and maturation of the lesions (Schenkein, Loos, 2013).
It is thought that patients who present with periodontal disease are at risk for some or all of the activities outlined above.
These mechansims may separately, or in partnership with each
other, be implicated in arterial disease in periodontal patients. If
these mechanisms work together, their cumulative effects could
impact greatly on the severity of the cardiac and arterial disease
in the periodontal patient.

Conclusion
In conclusion, to date the research does not absolutely prove
that periodontitis causes cardiovascular disease. However, as
seen above there is strong evidence supporting this idea, and
many possible and logical mechanisms have been delineated
through which periodontitis with all of its ramifications could
effect cardiovascular disease. More recently, patients being admitted for surgeries with no seeming connection to periodontitis, for example hip replacement surgery, have been required
to receive authorization from their oral care providers that
they do not have any periodontal diseases. This is due to the
mounting evidence, over the last few years, that there is indeed
a correlation between PD and the rest of the body. Oral care
providers should be wary of these problems and should advise
their patients accordingly of the importance of oral care, not
only with regard to the oral cavity.
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Abstract
The Long QT Syndrome (LQTS) is a familial, potentially fatal cardiac arrhythmia. Traditionally, it has been diagnosed by ECG.
Molecular studies have provided evidence that LQTS can be caused by a range of underlying molecular abnormalities. Genetic
research has proven that different forms of LQTS have different genotypic bases. Therefore, it has become possible to diagnose
the specific type of disease genetically. This study examines the advancements made in the past thirty years in understanding
LQTS and research regarding the use of genetic testing, in order to determine the benefits of genetic testing for this disease. A
survey of original studies which produced the information is presented here, and provides the reader with an understanding of the
mechanics of the disease and how they differ in the several genetic variants. Research shows that the benefit of genetic testing
must be weighed against the personal implications in may have for a particular patient and his or her family.
Introduction

Methods

In the year 1856, the German scientist Freidrich Ludwig
Meissner described what may have been the first recorded
case of the Long QT syndrome (LQTS). He recorded a case in
which a deaf female student died suddenly during a moment of
emotional stress.There had been two other children in her family who had died previously under similar circumstances. Since
a diagnosis of LQTS requires an electrocardiogram, and at that
time the ECG had not yet been invented, (Rivera-Ruiz, 1927)
it is not known for certain that these cases were an example
of LQTS (Vincent, 2002). Over a hundred years later, a study
was performed on a family of 10 children. Four of the children
had profound deafness and would often faint during moments
of emotional or physical stress (Jervell, Lange-Neilson, 1957).
Later, a similar familial tendency to faint during stress was observed in case studies (Ward, 1964). A prolonged QT interval
was observed in the ECGs of subjects. At that time, two familial
heart diseases known collectively as Long QT Syndrome were
fully discovered and defined.
The advent of molecular and genetic science has revolutionized the medical world’s approach to this disease, as it has
done for that of many others. Molecular studies have divided
the cases of LQTS, which seemed in the past like one basic
condition, into larger categories differentiated based upon molecular mechanism. Genetic differences were discovered between these types in the lab, and since genetic testing became
available to the public in 2004, 15 categories including over
1500 different mutations have been found to be the underlying
cause of a prolongation of the QT interval. This study focuses on the three categories which make up the overwhelming
majority of cases. In some cases, certain genetic origins and
molecular mechanisms have been linked to certain phenotypic
characteristics, and some believe that genetic diagnosis may
aid in recommendations and treatment for LQTS patients.
This study aims to give a full description of the physiological
and molecular mechanisms of LQTS based upon the latest research, and analyze the contribution of genetic research to the
understanding and treatment of the disease. Most importantly,
the primary objective of this study is to answer the question:
Should genetic testing be universally recommended to LQTS
patients and their relatives?

The Touro library system was an invaluable source of recent,
high-quality academic papers. In addition, the National Institutes
of Health and NCBI provided excellent references to PubMed
articles which provided useful information. The author sought
out independent studies and other primary sources to provide up-to-date reports of developments in the molecular and
genetic understanding of the disease. Studies regarding recent
attempts at gene-specific treatments and current academic
medical surveys are considered in determining when genetic
testing is indicated.
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Discussion
Physiology of LQTS
The QT interval indicates the length of time from the beginning of the depolarization of the ventricles to the end of their
repolarization. A prolonged QT interval will mean that the
ventricles are taking too long to repolarize. This usually does
not interfere with cardiac function, but occasionally can cause
life-threatening ventricular fibrillation. The major mechanism
of ventricular fibrillation which is brought about by a prolonged QT interval is the result of Early Afterdepolarizations
(EADs). The plateau curve caused by the delay in repolarization can cause some of the heart’s cells to begin depolarizing
while others are in the process of repolarizing. This can cause
heterogeneous activity in the heart tissue, especially the ventricles, with some regions contracting and others relaxing. The
result is a quivering or fibrillating heart, which cannot produce
sufficient blood output and quickly leads to syncope and death
(January, et. al. 2000).

Clinical Manifestation
Normally, depolarization and excitation of the cells of the heart
are caused by a quick flow inwards of positively charged ions.
These are usually Sodium and Calcium ions. However, the repolarization of the cells is not the result of those same ions flowing
back out; it is an outward current of positively charged Potassium
ions which causes repolarization. As the Potassium outflow increases, it overtakes the Sodium inflow, and the cell begins to
repolarize. In all forms of LQTS, the symptoms are caused by
a surplus of positive charges remaining within the cell. When
some channels malfunction, the extra positive charge is caused
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by reduced outward Potassium current. When other channels
malfunction, the extra positive charge is caused by increased or
unchecked inward Sodium current. In either case early afterdepolarizations can result, meaning that depolarization may still be
going on after the effects of repolarization have subsided.This can
cause what is called a U wave (Roden, et. al. 1996). This U wave,
however, is not a homogenous contraction of the heart. Some of
the cells will show this depolarization, and others will not. If this
EAD is still going on when the next beat occurs, it can cause the
heart to contract in an uneven way (Antzelevitch, Sicouri, 1994).
This leads to a characteristic ECG graph known as Torsades de
Pointes. This is French for “Twisting of the Points,” and is named
for the peculiar way the wave form seems to twist around the
isoelectric line (El-Sherif, et. al. 1996).
Torsades de Pointes is not able to sustain a sufficient stroke
volume of blood to support brain function. After some time
with this abnormal ECG morphology, the patient will faint. Most
of the time, the heart will overcome the Torsades and regain a
normal heartbeat. At other times, the heart will not be able to
“snap out of it” and the rhythm will deteriorate to ventricular
fibrillation, without providing any meaningful output of blood.
Unfortunately, this situation leads to death within minutes.
A patient who presents with Torsades is considered a medical
emergency due to the risk of ventricular fibrillation which may
result. However, the situation rights itself in the vast majority of
cases. Therefore, DC shock defibrillation is not used as a primary course of action since it can cause recurrent arrhythmias.
One of the major aspects of treatment is preventing the patient
from returning to a state of Torsades; whatever caused it the
first time might cause it again. Therefore, it is urgent to remove
or mitigate the effects of any drugs which may have caused the
Torsades. It is also advisable to take measures to suppress EADs,
among other things. Magnesium is effective at suppressing EADs
(Viskin, 1999).
Since the danger resulting from a prolonged QT interval depends not only on the actual length of the interval but also the
way it interacts with the surrounding segments of the ECG wave,
it is important to have a method with which to accurately measure the clinical significance of any particular QT prolongation.
To this end, the concept of QTc was developed, in which the
actual length of the QT interval is mathematically corrected to
take heart rate into account (Bazett, 1920). Since that time, many
other methods have been proposed, and the medical community
is currently in debate over which is most useful and accurate.

Molecular Mechanisms
To understand the cellular and molecular mechanics of Long
QT Syndrome, we must understand the process of the action potential itself. At rest, nerve cells have a higher level of
positive charge outside the cell than they do inside. When a
nerve cell is stimulated, the chemical or electrical impulse it

receives activates voltage- or ligand-gated Sodium channels.
This creates an influx of positive current (depolarization). After
a certain amount of positive flow is admitted to the cell, voltage-gated Potassium channels are activated, creating an outflow
of Potassium ions and returning the cell to its resting state with
more positive charge on the outside. Many different types of
channels are involved in these processes. Cardiac muscle cells
are unusual in the sense that they act to carry an action potential as efficiently as nervous tissue can, and therefore depend
upon a similar set of ion channels (Sanguinetti, Jurkiewicz, 1990).
We will delve deeper into this process shortly.
Some years ago, a groundbreaking study uncovered information about the process of repolarization in cardiac tissue.
The goal was to understand electrophysiological differences
between different areas of the heart. Microelectrodes were
used to measure delays in repolarization found in certain canine
heart cells, known as M cells. These cells, which had been previously found to show markedly longer repolarization times, are
found in the deep sub-pericardial and mid-myocardial regions.
The researchers measured the durations of their action potentials to have a mean of 358 ms, as opposed to 282 ms or 287 ms
found in other regions of cardiac muscle. Upon further examination of the M cells, it was shown that they show differences
in IK when compared to other cells. IK means Potassium ion
current, which is the current responsible for the repolarization
that ends every action potential.There are two distinct currents
found in cardiac cells, the IKr, or rapid-activating current, and
the IKs, or slow-activating current. These currents are mediated
by two separate transmembrane voltage-gated protein channels.
The M cells have smaller IKs (Slow-acting Potassium current)
than the other cells, while IKr (Rapid-acting Potassium current)
is generally the same. (Of course, the mechanism for the rate
of an action potential has many factors, and depends upon the
inward rectifier (IK1), Calcium ion inward current, SodiumPotassium pump inward current, Sodium-Calcium inward current, and others.) (Sanguinetti, Jurkiewicz, 1990). The IKs in the
M cells was measured using a selective IKr blocker, E-4031. The
Potassium current was measured in the cells with E-4031 and
in the cells without E-4031. The difference between the two
measurements was the IK due to IKr, and the common portion
was the IK due to IKs. It was found that the IKr in different cell
types was essentially the same, and reduced IKs current was
responsible for the delayed repolarization in the M cells. It was
discovered in this study that IKr differs from IKs in its kinetics of
activation, more negative threshold for activation, and different
protein structure suggested by its selective blockage by methane sulfonamide class III agents like E-4031. However, studies of
M cells demonstrated that delayed IKs can play a principle role
in delayed repolarization. The researchers predicted that the M
cells may be found to be the culprits of diseases such as LQTS
(Liu, Antzelevitch, 1995).
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Later the same year, it was shown that the plateau portion of
repolarization is accomplished principally by the IKs protein. It
was also discovered that in the heart in general, blocking either
IKr or IKs can prolong duration of the action potential by the
same degree. This means that either protein can be a target for
antiarrhythmic drugs for tachycardia. By the same token, either
protein could also be the culprit of an arrhythmia with extended action potentials, such as LQTS (Zeng, et. al. 1995.) As we
will see soon, genetic studies have confirmed that LQTS can
result from mutations in the genes which code for either of the
proteins, and others as well.

Genetic Variation
It has been known for many years that not all cases of LQTS
have the same symptoms. For example, some cases of LQTS
are dangerous specifically under situations of emotional stress.
Other cases are set off especially by exercise, whereas some
cases seem to cause syncope specifically during swimming. It
was established that in these cases it was not the stress or
exercise of swimming which caused the ill effects, but rather the
actual immersion of the face in cold water (Mayumi, et.al. 1995).
Genetic research has since shown that mutations in several
genes, coding for several proteins, can cause LQTS. Different
types of the disease have been linked to different genes, and
over 1500 different novel mutations have thus far been discovered on 15 different genes which code for 15 different proteins.
One such gene is the KCNQ1 gene. This gene on chromosome
11 codes for the alpha subunit of the voltage-gated Potassium
channel. It has six transmembrane domains. Even though there
is ion pore function for this protein alone, some of the functioning of the channel requires it to be co-assembled with the
beta subunit. This subunit is called KCNE1. The two subunits
together account for the cardiac IKs. Mutations in different segments of this protein channel cause varying degrees and kinds
of diseases. The S4 domain contains a voltage sensor, and lossof function mutations in this area can cause LQTS. In addition,
there is a pore helix selectivity filter segment which can, when
its shape is altered, severely affect the functioning of the IKs
current. In this segment, certain mutations cause more loss of
function than others. For example, an I313K mutation in the selectivity filter segment can cause all of the symptoms of LQTS,
including syncope and risk of death, whereas an I313M mutation
will prolong the QT interval, but the patient will be otherwise
asymptomatic. All KCNQ1 and KCNE1 mutations are included
in the category LQT1 (Ikrar, et. al. 2008).
LQT2 is a result of a loss of function in the HERG channel.
HERG stands for Human Ether a go go related gene, so named
for the fact that a mutation in its homolog in fruit flies causes
them to “dance” when exposed to ether. More than 80 mutations
were known in this gene in 2000, and many more are known
today. HERG is a gene located on chromosome 7 that codes for
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the pore-forming subunit for the IKr channel. There are several
mechanisms by which HERG mutations cause reduced IKr. One
of them is that a certain degree of codominance exists in heterozygous individuals with certain mutations. The protein which
comprises the HERG channel is actually a tetrameric structure
formed by the co-assembly of four copies of the HERG gene
product. Depending on how the subunits combine, the mutant
gene products might be excluded from the ion pores, causing
a 50% reduction in pore function. On the other hand, the mutants might be included in some of the complete proteins, causing
more than 50% to be defective. Other mutations in the HERG
gene are truly dominant, and produce channels which activate
at voltages which are more negative than usual. One mutation,
N629D, was found to make the pore channel nonselective and
allow ions other than K+ to pass through. Interestingly, many
mutations in the HERG protein affect not the actual functioning
of the ion pore, but its “trafficking,” i.e. its ability to be properly
packaged and transported to the plasma membrane. In these
cases, the mutant proteins are marked as abnormal by the cell’s
quality control systems and are kept in the endoplasmic reticulum and degraded. In these scenarios, applying E-4031 to affected
cells was shown to allow trafficking of the proteins to the plasma
membrane, and the drug could later be washed off. Applying this
method in vivo is still an area of study for these particular mutant
forms. This is a form of gene-specific therapy for LQT2. Another
form may be increasing serum K+ concentration, since HERG
current is highly sensitive to extracellular K+ concentration.
(January, et. al. 2000)
More work was done recently on attacking the gene-specific
therapy problem from the trafficking angle. It has been shown
that certain mutations cause misfolding of the protein, and this
is what prevents it from leaving the endoplasmic reticulum. This
was discovered by causing chemical unfolding of several different mutant forms and measuring the difference between the
stabilities of each mutant’s folding. It was found that there was
a direct correlation between the conformational stability of the
protein and its degree of trafficking deficiency (Harley, et. al.
2012).
LQT3 is has a very different molecular basis from that of both
LQT1 and LQT2. The first two forms of Long QT syndrome
are caused by malfunction of Potassium channels. These channels function to create an outflow of positive current during
repolarization of the heart’s muscle cells. These mutations are
examples of what is known as “loss of function” mutations. In
other words, the protein coded for by the gene does not work
as well with the mutation as it does in the wild type. LQT3,
however, is a “gain of function” mutation. It causes the Sodium
channel pores to become more effective than in the wild type.
This means that the depolarization process lasts longer, thereby
slowing repolarization and extending the QT interval (Mazzanti,
et. al. 2016).
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Gene-Specific Recommendations and Therapies
Phenotypic differences have been found between LQT1 and
LQT2. Heterogeneity has been noticed among LQTS patients
regarding the effect that exercise has in precipitating Torsades
de Pointes and ventricular fibrillation. It was discovered that
patients matched for age and gender showed differing QT adaptation patterns during exercise. Patients with LQT1 showed
a steady QTc prolongation, even at higher heart rates. Since
each heart beat occurs at a faster rate, and the QT prolongation remains the same, it is more likely that the repolarization
process will interfere with the following QRS complex, bringing
about Torsades de Pointes and ventricular fibrillation, causing
syncope or death. In LQT2, however, the QT interval prolongation is actually reduced as the heart rate increases, meaning
that the QT interval occupies the same proportion of the total
ECG sequence that it does at lower heart rates, such as during
rest. Therefore there is no greater risk of syncope in LQT2
during exercise than at any other time. This is consistent with
the molecular and genotypic understanding of the differences
between these two disease types. Exercise creates an increase
in sympathetic activity, i.e. the heart is being driven not only
by its internal pacemaker, but also by hormonal and systemic
nervous impulses and stimulants, such as epinephrine and other
adrenergic agents. In this situation, the predominant current for
the increase in the rate of repolarization has been proven to be
the IKs current, precisely that one which is affected by LQT1.
Therefore, it is understandable that LQT1 patients will be more
susceptible to syncope brought on by exercise-related stress.
These differences are generalizations; actual recommendations
to patients still must be based upon observation and testing
under different types of stress (Sy, et. al. 2010).
In addition, many symptoms have been found to be associated with different forms of LQTS. As stated, LQT1 is associated
with syncope brought on by exercise, with swimming being a
particular stimulus in certain cases. LQT2 is associated with
cardiac events connected with mental stress such as fear or
anger. LQT2 patients also faint when they hear sudden noises
such as alarm clocks and phones. LQT3 seems to be associated
with attacks which come while a person is resting or sleeping.
Knowledge of the genetic basis of the disease can thus be helpful
in advising the patient which activities to avoid. However, even
though statistically there is a significant association of these
properties with these forms of the disease, a genetic diagnosis
is by no means conclusive of a specific expression. Among the
1500 variations discovered thus far, most do not exactly fit the
general trend. Therefore, although genetic testing can be helpful
in planning an avoidance or treatment plan, clinical manifestation
is the ultimate deciding factor (Mangset, Hoffman, 2014).
Several gene-specific therapies have been proposed for
LQTS. Beta Blockers are effective for LQT1 and LQT2, whereas
they can have negative effects in the case of LQT3. Potassium

supplements also are suggested for LQT2, since an elevated
blood potassium level has been shown to enhance the activity of
the HERG channels. Mexiletine, a methane sulfonamide Sodium
channel blocker, may be effective for LQT3, as described before.
Although some of these have shown promise, comprehensive
and clear proof of their efficacy and safety has not yet been established (Viskin, 1999.) Recent studies have shown Mexiletine
to be effective at reducing the QTc of more than two thirds of
patients with LQT3. These studies had certain limitations, however, and were not sufficient basis for widespread use of this
gene-specific therapy (Mazzanti, et. al. 2016).

Implications of Genetic Testing
Since 2004, genetic testing has been made available on symptomatic people to discover what the genetic source of their
syncopal episodes may be. However, in many cases there is a
dilemma for the patient. Most cases of LQTS do not require
genetic testing for diagnoses, and if pathology is suspected in a
newborn based on heredity, risk of serious effects can usually be
effectively determined by ECG. In addition, even if the genetic
testing comes up clear, preventive measures will still be taken
for anyone whose QTc is over the limit of .45 ms. Therefore,
the primary justification for genetic testing is not identification, but rather the possibility that gene-specific therapy will
be available. As explained, most gene-specific therapies which
require a genotypic diagnosis are still not available to the public.
Those therapies and recommendations which are available can
be safely used without genetic testing. This creates a dilemma
for many patients and their relatives. On the one hand, there
is the patient’s right to know. A clear, empirical knowledge of
the source of their disease helps some patients adjust and cope
psychologically. On the other hand, who would want to know
for certain that they carry a gene which may or may not have
deleterious effects on their children? Since there are effective
screening methods, and this knowledge can be a significant
source of fear and anxiety as well as causing moral dilemmas,
many people are uncomfortable going for testing. Sensitivity to
this discomfort has been termed by some as “the patient’s right
not to know.” This consideration is rarely addressed by health
care providers, and the National Society of Genetic Counselors
is making an effort to educate providers about the psychological
impact of genetic testing (Mangsett, Hoffman, 2014).
A longitudinal study was done to observe the long-term effects of congenital LQTS. Individuals from 328 families with multiple cases of LQTS were observed over the course of several
years. The probands had usually fainted at some time during
their childhood years, with an episode of fainting or death occurring in 50% of them by age 12. The majority were women,
showing that the effects of the gene are more serious in females.
The yearly rate of fainting spells till age 50 was 5.0% per year for
those enrolled in the study, and the rate of death was .9%. This
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was higher not only than the rates in unaffected family members,
but also higher than the rates in affected family members. This
shows that LQTS genes can have a variable level of expression
even among affected people (Moss, et. al. 1996). Since the disease can have varying levels of effect even among those who are
stricken by it, it may be true that testing of all family members
can help in discovering mildly affected people.
More recently, however, a survey was taken to determine the
effects of genetic abnormalities on people who were otherwise
clinically normal in terms of ECG and symptoms. Interestingly,
no ill effects were found to be associated with genetic defects
alone, even in situations where those same genetic defects produced significant disease in other patients. Some suggest that
this might be affected by the fact that genetically positive patients tend to take care to avoid activities which bring on syncopal episodes.This information was not part of the study however, and it is therefore unclear whether clinically normal but
genetically abnormal individuals need to take any action at all
to protect themselves from syncope or death (Lampert, 2015).
One other argument has been made in favor of genetic testing
of family members of affected individuals. Some drugs which are
administered by psychiatrists to relieve psychological symptoms
either function directly through changing the electrophysiological workings of the heart, or have side effects which can affect
or alter the action potential of the heart cells. It is suspected
that an increased rate of sudden death among psychiatric patients may be caused by underlying QT interval abnormalities
which may, when augmented by the effects of the drugs, come to
have deadly effects upon the heart’s rhythm (Sayako, et.al. 2014.)
However, the effects were only observed in a small percentage
of the psychiatric population.
Certain specific mutations have been identified as conclusively pathogenic. Individuals who carry these variants are advised
to take beta blockers as a prophylactic measure. Although these
are official recommendations due to an abundance of caution,
there is still no evidence that these mutations pose a significant
risk in unaffected people, and the testing of relatives is not universally required (Vincent, 2001).

Conclusions
The Long QT Syndrome is a great example of how a little information can be a dangerous thing. This is an area in which there
has been a recent surge in pure information: exact mutation types,
statistics, symptoms, etc. However, the tying together and understanding of this information is lagging far behind its production,
and that which exists is ambivalent and confusing. Since people
rely on their healthcare providers not only for information, but
also for confidence and reassurance, it can be difficult for the provider to respond appropriately to questions about this disease.
One patient commented that he gets different recommendations
from the same doctor on different occasions. In these situations
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the doctor must try to convey confidence to the patient while
honestly admitting that he or she does not know the full significance of genetic results, and possibly nobody in the world knows
(Mangsett, Hoffman, 2014).
Genetic testing is definitely a powerful tool in the understanding of LQTS. However, both methods of interpreting the genetic
data and the treatments that might be tailored to the specific
types have not yet been developed in a way which provides institutionally recognized necessary medical benefit. In addition, in
most cases, only minor benefits have been shown to come from
testing unaffected relatives for identification purposes.This makes
it difficult to argue that all patients and relatives should universally
submit to genetic testing, since research has observed emotional and ethical difficulties which can arise from the testing itself.
However, a specific genetic diagnosis can influence the recommendations and, to some degree, the treatment that a patient will
be provided with. In addition, since treatment is recommended
for some variants even in the absence of ECG symptoms, relatives
of individuals with those variants have more reason to submit
for genetic testing. A physician and genetic counselor should
therefore discuss the benefits as well as the pitfalls of testing with
the patient or relative, and the patient or relative should decide
whether or not to submit to testing. In the coming years, the approval of developing gene-specific treatments may make genetic
testing more important for affected individuals.
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Abstract
Stress is a huge part of life. Our body responds to stress in different ways and most of the times the body overcomes the stress.
There are a few incidents when the body is not capable of dealing with the stress and the toll it takes on the brain is undeniable.
One result of intolerable stress is Dissociative Identity Disorder (DID) in which biopsychology comes to life, as we see how the
body is affected by psychology, and vice versa. The mediators that help the body adapt to stressors become detrimental when a
person faces trauma or chronic stress. Glucocorticoids, cortisol, and glutamate are all involved in either helping the body endure
stress or causing plasticity in parts of the brain that are essential to being mentally healthy. This paper delves into the nature of
DID, and how stress creates changes in the hippocampus and amygdala, the two parts of the limbic system that are smaller in
patients with DID..
Introduction
In 1957 the world was exposed to what was then known as
Multiple Personality Disorder (MPD) through the storyline
of the movie, Three Faces of Eve. A classic example of MPD, a
woman named Eve White was having symptoms of headaches
and blackouts while being unaware of her disorder. One of the
three identities, known as Black, is the reason her husband abandons her and is also why she tries to kill her own daughter. Black
knows about White, but White does not know about Black.
Through therapy the third identity emerges, known as Jane. Jane
knows about all three identities and eventually all three identities merge (Lehman, 2014). This story of the Three Faces of Eve
is a glimpse into the world of MPD. As time progressed new
research has been developed and continues to develop regarding MPD, currently referred to as Dissociative Identity Disorder
(DID), broadening the subject in all areas.
DID is a psychophysiological disorder that affects about
1-3% of the world’s population (Vermetten et.al.,2006). DID
diagnosis requires a minimum of two identities residing in one
body. Each of these identities have their own biology, memories, perceptions and preferences. Common symptoms of DID
include hallucinations and amnesic periods. An average of 8-13
identities develop and Daniel Goleman (1923) states that it is
possible for one to be living with up to 60 different identities
within oneself. The different identity types include the childlike
personality type, the protector, and the persecutor. A misconception that the host personality is in fact the patient’s original
identity since it is the identity or alter ego will commonly seek
treatment. The split in identities originates from the childhood
of the patient. People with DID have a history of either sexual or physical abuse typically between the ages 3-8. Coherent
with the common identity types, the childlike personality is
the age in which the abuse took place. The persecutor is the
identity that mirrors the abuser. The protector is the identity
that feels responsible to protect the rest of the personalities
from any abuse or trauma (Goleman, 1985). Each identity can
be categorized as either an emotional personality or a normal
personality. The emotional personalities are the ones that react
and respond to the trauma they experienced. The normal personalities are the ones that deal with normal and daily functions
(Nijenhuis, Steele, 2010) . DID is often misdiagnosed as other
personality disorders due to the complexity of the various
identities. An identity in itself may have a personality disorder
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such as Obsessive Compulsive Disorder and be treated for that.
From an outsider’s perspective what might seem like a suicide
attempt may actually be one identity trying to kill another and
thus must be dealt with appropriately. Additionally, DID is very
similar to Post Traumatic Stress Disorder (PTSD) except that in
a patient with DID the trauma happens in early childhood and in
PTSD it occurs in adulthood (Gillig, 2009).In addition, 80-100%
of patients diagnosed with DID are diagnosed with PTSD as
well (Vermetten et.al., 2006).
There are cases in which one alter ego can be deathly allergic
to bee stings, or may need glasses to see, while another alter
ego in the same body may not have any reaction to bee stings
or may not need glasses to see. There is a case study involving
a 33-year-old female diagnosed with DID who suffered from
blindness after a car accident. She was confirmed to be visually
impaired after going through tests such as ocular fundus inspection, Humphrey refractometry, and intraocular tension measurement, which are all ways to test for vision or lack thereof.
She even failed to show signs of involuntary refluxes such as eye
watering and winking. After years of treating the patient with
therapy for DID, one of the identities became visually active
and soon many of the identities followed and retrieved vision.
Because only some identities were blind, just like any identities can fluctuate, the patient was fluctuating between sight
and blindness within seconds. Proof of complete blindness in
one identity and complete sight in another was seen by visual
evoked potential (VEP) recording system. In a blind identity the
pattern evoked potentials showed a disorganized blind pattern.
When the VEP was run on a sighted identity, there were organized patterns cohesive to a visually active person. The VEP
results for the blind identity shows lack of vision, yet insufficient
for complete blindness. The blindness that was relayed by the
tests can be explained as psychogenic blindness that was activated by a temporary loss of vision caused by the accident. The
psychogenic blindness is proof that in DID psychology takes a
toll on the biology of a person (Strasburger, Waldvogel, (2015).
Dissociative identity disorder creates questions within the
realms of sense of self; how can it be that two completely different identities are being controlled by one brain? Experiments
using Positron Emission Tomography (PET) were performed to
see how the brain creates these two different senses of self.
To help explain this phenomena Damasio and coworkers created a theory that there is a core self, constantly synchronized
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with the body and controlled by the body’s biology, and the
autobiographical self that are memories and is influenced by
environmental factors. According to this theory only the autobiographical self is capable of change, yet the core self remains
intact because it comes from the same biological makeup. Since
the autobiographical manner of processing memory can be
disrupted, the neutral personality state processes trauma in a
non-autobiographical way, causing different senses of self in the
brain. A study consisting of 11 females with DID in four different
conditions was done. These four conditions included a neutral
memory exposed to both the neutral and traumatic personality
state, as well as a traumatic memory exposed to both a neutral
and traumatic personality state. There were decreased amounts
of regional cerebral blood flow (rCBF) perfusions when a traumatic memory was exposed to the traumatic personality state.
The rCBF perfusions were unchanged when a traumatic memory was exposed to the neutral personality state, and when a
neutral memory was exposed to both traumatic and neutral
personality state. The areas that showed a decrease in rCBF
perfusion correlated with the areas associated with the autobiographical senses-of-self. Decreased perfusion in the visual association area and the middle occipital gyrus causes the lack of
integration of information and blocks emotional processing; this
is the defense system manifested by patients with DID. Another
symptom of DID is depersonalization, which is caused by decreased perfusion in parietal and occipital areas of the brain.
Additionally, there is decreased perfusion in the medial prefrontal cortex that plays a big part in a person’s sense of self. The
only part of the brain that shows increased perfusion of rCBF
is the parietal operculum regulating emotions in response to
pain.This comes forth as emotional dissociation in the traumatic
personality state of a DID patient (Reinders et.al., 2003).
Testing the autonomic nervous system through heart rate
and skin conductance is an additional test that proves the authenticity of the various alter egos. Nine patients diagnosed
with DID were brought in each day for testing. Each patient
had three identities involved in the study: the host personality
and two other identities. As the researchers hypothesized, each
identity showed differing results of heart rate and skin conductance when exposed to specific stimuli. Since the autonomic
nervous system is completely voluntary it is safe to assume that
the identities are genuinely distinct (Putman et.al., 1990).

Amnesia and Memory Transfer
According to the DMV, DID should be a possible diagnosis when
there is an “inability to recall important personal information that is
too extensive to be explained by ordinary forgetfulness.” Amnesia
is the most dominant symptom in a patient with DID and according to the Journal of Abnormal Psychology is said to be a psychological disorder as a response to stress or trauma. Furthermore,
it’s questionable whether inter-identity memory transfers exist. A

study was conducted proving that DID patients only show memory transfer of implicit memories/words, but when there was an
emotional or explicit word the patient regressed into an amnesic
state. When these memories are restored it’s possible to develop
dissociative memories in which at times the trauma is remembered
and at times the patient has amnesia.
The amnesic periods are only found between different identities and not within one identity. Therefore, in order to get
to that amnesic state the identity fluctuates. Accordingly, the
psychological perspective to DID is believed to be that DID
patients are capable of switching identities in order to forget,
and to avoid re-experiencing the trauma (Elzinga et.al., 2003).

Trauma During Childhood
Vermetten et. al. (2006) describe DID as a childhood-onset
posttraumatic developmental disorder. The post traumatic
model of DID states that when a child goes through the traumatic experience of physical or sexual abuse it is natural that
the child will dissociate, mentally compartmentalize, and have
amnesic periods as a response. This coping mechanism removes
unbearable memories that the child cannot deal with. As the
child grows up, each painful experience gets compartmentalized
and is expressed as a different identity (Piper, Mersky, 2004).
Studies show that childhood trauma is imperative to the development of DID. Traumatic is a relative word and is not referring
to a one-time beating. The trauma endured is unusually sadistic
abuse and it happens about twice a week for 50 weeks out of
the year for 10 years. Statistically the type of abuse that will
cause DID is 60-75% physical abuse, and 68-83% sexual abuse
(Piper et.al., 2004).
DID specifically only develops when the trauma occurs in
childhood because children are not yet equipped with the resources to react. Furthermore, children are more prone to peritraumatic dissociation, and do not personalize the trauma that
they are experiencing. DID can be classified as a developmental
disorder due to the child not being able to handle dealing with
the trauma and it takes a toll in later years. When a normal person deals with stress their mental health is improving. However,
when the stress is overbearing it reduces the mental health of a
person (Goleman, 1985). Stress in early development biologically embeds itself in a person and has long lasting effects. When a
child experiences abuse versus being cared for it will affect his
social experiences in later life (Mcewen et.al., 2015).

Hippocampus and Amygdala
Stress related trauma plays a role psychologically and biologically in patients with DID.
Changes in the limbic system have been linked to stress factors (Gulyaeva, 2014). Parts of the limbic system such as the
hippocampus and amygdala are two major parts of the brain
that are involved in the formation of DID. Patients with DID
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have a significantly reduced sized hippocampus and amygdala.
The hippocampus and amygdala are located in the medial temporal lobe (Figure 1) and although they have different functions
they ultimately influence each other (Phelps, 2004).

amygdala), symptoms normally seen in patients with DID, such
as amnesia and hypermetamorphosis were present. (Cristinzio
et.al., 2007).

Amygdala and Hippocampal Size Difference

Figure 1: illustration of the hippocampus and amygdala. Notice how
the hippocampus and amygdala are neighboring each other. Source:
Mechanism of stress in the brain. Mcewen, et. al.. (2015)
The hippocampus is the part of the brain that is involved in
episodic memory and the primary memory system of the brain.
Learning and stress regulation are also part of hippocampal
function.The amygdala controls fear conditioning and processes
emotion. Although the hippocampus and amygdala reside adjacent to each other, studies introducing a blue box that gives a
shock proved that the hippocampus and amygdala have independent functions. The study was performed by introducing a
blue box that gives a shock.. People with focal lesions on the
amygdala understood that the blue box causes a shock but
failed to show any sign of fear. Focal lesions to the hippocampus
caused one to fear the shock but fail to register that the shock
comes from the blue box (Phelps, 2004).
The hippocampus and amygdala are dependent on each other
when it comes to emotional memories. The amygdaloid complex consists of the subunits of the amygdala that are difficult to
distinguish in MRIs. The amygdaloid complex is divided by function, receives, and relays information involved in fear conditioning and response.The forebrain receives input from the amygdala to stimulate attention, and the brainstem stimulates fear. The
hypothalamus receives input from the amygdala for hormone
release during stress that eventually affects the hippocampus.
Through animal studies researchers were able to see that
stress hormones were attacking androgenic receptors on the
basolateral amygdala that were affecting hormones in the hippocampus. Further research revealed through fMRI scans that
activity of the hippocampus causes less activity of the amygdala
and vice versa(Phelps, 2004). When studies were done removing the temporal lobe (which includes both hippocampus and
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The difference in hippocampal volume between a patient with
DID and a healthy person is significant. The hippocampus in a
patient with DID is 19.2% smaller and the amygdala is 31.6%
smaller than that of an average person. In addition to stress
causing smaller hippocampal volumes in patients with DID,
other disorders such as PTSD that are associated with abuse
in childhood show smaller hippocampal volumes, which can
be seen on MRI readings. On the contrary, people who experienced childhood abuse and did not develop PTSD or DID,
showed a normal sized hippocampus. There is no proven decrease in the size and volume of the amygdala in PTSD patients
with no childhood trauma. In contrast, a PTSD patient with record of childhood abuse revealed a 15% decrease in amygdala
size (Vermetten et.al., 2006).

Methods
To research the different mechanisms and causes that stress has
on DID, search engines such as Touro College Library, Proquest,
and Google Scholar were used. Keywords such as “dissociative identity disorder”, “glucocorticoids”, and “hippocampus
and amygdala” were used to retrieve appropriate information.
Multiple articles and medical journals were found presenting
the different perspectives to answer the question above.

Discussion
Not much is known regarding the neurobiology of DID, but the
way that stress affects parts of the brain associated with DID is
discussed. The parts of the brain affected may be the underlying
cause of the symptoms of DID.
The homeostasis of the body is disrupted as a result of stress
(Krugers et.al., 2010). Allostasis is the body adapting to stressors through mediators. Mediators can be steroid hormones
such as glucocorticoids. Through glucocorticoids the body is
able to adjust and adapt to the stress that it is handling. These
effects of glucocorticoids can either be helpful for the person’s
survival or detrimental to the brain. The brain can be altered
through the expansion or retraction of the dendrites or change
in synaptic density. Receptors in the brain are important factors
in brain alterations (Mcewen et.al., 2015),

Glucocorticoids
Glucocorticoids are adrenal steroid hormones that are produced in the zona fasciculata of the adrenal cortex in response
to stress. One major class of glucocorticoids is cortisol.
Glucocorticoid or cortisol secretion from acute stress is crucial for the survival of a person. Stored energy is retrieved to
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enable the body to react appropriately to stressors.The harmful
effect of glucocorticoids appear in the hippocampus and can
take a toll on a person’s memory, specifically explicit memory
(Sapolsky, 2003).

help cause the hyperactivity of the HPA axis (Zhu et.al., 2014).
A study using metyrapone was conducted on rats to determine the correlation between glucocorticoids and HPA axis
hyperactivity that causes depressive behaviors. Enzyme 11-b-hydroxylase, found in the adrenal cortex, is responsible to convert

HPA Axis
A major gland involved in stress regulation is the adrenal gland.
Located superior to the kidney, the adrenal gland either reacts
to stress in a fight or flight response or supplies energy for the
body’s response via the HPA axis. The adrenal gland is made up
of the adrenal cortex and the adrenal medulla. The stimulation
of stress causes the adrenal medulla to secrete epinephrine
(adrenaline) and norepinephrine (noradrenaline) so the body
can respond in a fight or flight manner. When the stress is continuous the adrenal cortex secretes glucocorticoids or cortisol
which mostly bind to proteins. The cortisol that does not bind
to proteins exists as free cortisol and supplies the body with
the energy it needs to react to the stress. Cortisol acts in different reactions to produce glucose through gluconeogenesis,
fatty acids from triglycerides, and amino acids from proteins to
create new energy or to repair cells that were damaged by the
stress (Hannibal, Bishop 2014).
Hypothalamic pituitary adrenal axis (HPA axis) is a negative
feedback mechanism that helps regulate glucocorticoid production in times of stress (figure 2). The reaction begins in the
hypothalamus, the link between the nervous and endocrine system. The paraventricular nucleus in the hypothalamus responds
to a relative amount of stress and causes the release of corticotropin releasing hormone (CRH). The CRH thus stimulates
the anterior pituitary to release adrenocorticotropic hormone
(ACTH) that travels through the blood to the adrenal cortex.
Glucocorticoids are released and supply energy to the body.
When there is an excess of glucocorticoids the hypothalamus
and anterior pituitary receive signals to stop the production of
CRH and ACTH in order to inhibit the overproduction of glucocorticoids (Zhu et.al., 2014). However, this negative feedback
mechanism may be disrupted. Only a small amount of stress is
required to activate the HPA axis, but when there is too much
stress it is possible for the HPA axis to become hyperactive.

HPA Axis Hyperactivity
Hyperactivity of the HPA axis can be caused by many factors,
including excess glucocorticoids. Excess glucocorticoids in the
brain can be attributed to receptor changes. Two different glucocorticoid receptors in the brain are: glucocorticoid receptors
(GR) and mineralocorticoid receptors(MR). GR and MR are
found on both the hippocampus and the hypothalamus. MR are
more likely to attract glucocorticoids even when glucocorticoid
levels are low. GR only receive glucocorticoids when there is an
excess amount of glucocorticoids from stress (Krugers et.al.,
2010). If there is a decrease in GR in the hippocampus it can

Figure 2: A clear chart of the HPA axis.The arrows with a positive
depicts stimulation of hormone release.The arrows with a negative
sign depicts the inhibition of hormone release. Source:https://www.
integrativepro.com/Resources/Integrative-Blog/2016/The-HPA-Axis
deoxycorticosterone to glucocorticoids. Metyrapone, is used to
block the function of 11-b-hydroxylase therefore terminating
the process which would result in hyperactivity and depressive
behaviors (Zhu et.al., 2014).

MR-NNOS Pathway-Hyperactivity of HPA Axis
An additional pathway that decreases the activity of GR in the
hippocampus is the MR-nNOS pathway. Glucocorticoids react
with neuronal nitric oxide synthesis enzyme (nNos), causing the
overproduction of nitric oxide (NO) in the hippocampus.The GR
in the hippocampus, which is crucial for the HPA axis to maintain
homeostasis, interacts with the NO causing the negative feedback
mechanism to be disrupted. The relatively decreased amount of
GR in the hippocampus explains why excess glucocorticoid exposure would generate hyperactivity of the HPA axis.
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The reason that the hypothalamus is not involved with the
hyperactivity of the HPA axis is because of the low amount of
MR in the hypothalamus. Thus, the MR-nNOS-NO pathway is
non-existent in the hypothalamus and the hypothalamus is only
capable of activating the negative feedback of the HPA axis (Zhu
et.al., 2014).

Different Pathways of Glucocorticoids
There are two effects that glucocorticoids can have: genomic or
nongenomic. A non-genomic effect is a transcription independent
mechanism that can interact with a cell membrane specifically
or nonspecifically. The genomic effect works through interaction
with Glucocorticoid Response Element directly or indirectly.
Direct interaction is through receptors themselves and indirect
interaction is through other transcription factors. Direct interaction of glucocorticoids is responsible for glutamate secretion.
Indirect interaction of glucocorticoids uses endocannabinoids to
control glutamate and GABA (Mcewen et.al., 2015).

NMDA and AMPA Receptors
One type of glutamate receptor is N-methyl-d-aspartic acid
(NMDA) receptor found on the hippocampus. NMDAR is activated by glutamate with glycine and when activated permits
charged ions to travel through the cell membrane (Mcewen
et.al., 2015). Studies show that ketamine, an NMDA antagonist,
causes the same symptoms seen in DID: amnesia, out of body
experiences, and time standing still (Vermetten et.al., 2006).
Alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor(AMPAR) or quisqualate receptor is a transmembrane receptor. AMPAR only requires glutamate to activate the ion channel.
Recent research show that activated glucocorticoids regulate
AMPAR and effect learning and memory in the hippocampus.
Learning and memory are disrupted by the synaptic connectivity
in the hippocampus. Plasticity of the brain is in the control of
the pre- and postsynaptic sites, and can be controlled by either
limiting the neurotransmitters or the neurotransmitter receptors
at the pre and postsynaptic sites, respectively. Further research
proves that AMPAR also causes changes in synaptic function and
plasticity of the brain. Miniature excitatory postsynaptic currents
(mEPSC) are used to measure the strength of a synapse. When
the nongenomic effect (fast) on AMPARs was measured the increase in the mEPSC of the hippocampus and amygdala were
similar to those experienced upon glucocorticoid exposure. The
genomic effect (slower) of AMPARs is detrimental to the function
of neurons (Krugers et.al., 2010).

Brain Plasticity
Brain plasticity is caused by the conjunction of glucocorticoids
and amino acids.
Dendrites are altered in the way of expansion or retraction,
and increase or decrease of dendritic synapses. For example,
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CRH, released in the hippocampus, down regulates thin spines.
Parts of brain affected by hormones and intra and extracellular
mediators are the hippocampus, amygdala and prefrontal cortex
(Mcewen et.al., 2015).
Studies show that chronic stress leads to permanent alterations to the brain. Regardless if the chronic stress subsides,
the brain creates a new way to handle stress and hippocampal
changes remain. Additionally, experiments with rats prove gene
alterations due to stress, including delayed alterations.The delay
in gene response comes from epigenetic regulators. Even though
the dendrites can regrow they are different in that the dendrites
grow more proximal to the cell body (Mcewen et.al., 2016).
The neuroendocrine model was postulated regarding the effects that stress has on the hippocampus and the role of the
amygdala in hippocampal plasticity. It was proven that hippocampal plasticity can be achieved through limiting input from
the amygdala.
A part of the hippocampus, the dentate gyrus, is known for
its constant rearrangement and its reproduction of its cells to
replace lost cells. Reproduction of the new cells is inhibited by
the amount of adrenal hormones in the brain through a mechanism involving NMDA receptors. Stress exposure results in glucocorticoid production and the release of glutamate from the
hippocampus which blocks the reproduction of neurons in the
dentate gyrus. Only chronic stress has effect on proliferation in
the dentate gyrus, because small amounts of stress were seen to
have no effect on neurogenesis in the dentate gyrus.
In acute stress the new cells that are produced take part in
stress response. When there is an excess amount of glucocorticoids caused by chronic stress the dendrites in the hippocampus
retract and do not partake in stress response (Gulyaeva, 2014).

Hippocampal and Amygdalar Role in Memory
Both the hippocampus and the amygdala contain GR and MR. As
a result of stress, the role of the amygdala in fear conditioning
is altered. According to Sapolsky (2016) when the hippocampus is affected by stress the amygdala will start to process the
memories. For example, amygdala long term potentiation will
substitute the hippocampal long-term processing. Studies show
that when hippocampal dendritic processes go through atrophy
it causes the extension of the amygdalar processes’. The mechanism as to why this happens is currently unknown. Despite the
fact that the hippocampus is irrelevant in memory processing,
the hippocampus is said to process explicit memories. The reason is that the hippocampus and the amygdala work together to
process the memories. Since the hippocampus cannot process
the memories normally and neutral it acts like the amygdala
and processes the memories inaccurately, causing flashbulb-like
memories. The mechanism is controlled by the sympathetic
nervous system and is activated by stress. Stress causes catecholamines to be released by the adrenal medulla and stimulates
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the vagus nerve. Thus, the vagus nerve stimulates the nucleus of
the tractus solitarius (NTS) to have an effect on the amygdala.
The amygdala begins to play a part in memory processing from
the glucocorticoids in the hippocampus, amygdala and the NTS
(Phelps, 2004).
Animal studies show that by exposing glucocorticoids to
the hippocampus it causes a decrease of pyramidal neurons
and dendritic branching that are used to integrate memories
(Nijenhuis, Steele, 2010).

Genetic Factors
Genetics are very influential in the development of any disorder.
People that are born with a smaller hippocampal or amygdalar
volumes have been seen to be more prone to developing DID
(Vermetten et.al., 2006). When one is born with an overabundance of glucocorticoid receptors, there is an increased probability to develop mood disorders and are more responsive to
antidepressant drugs. The opposite effect is on those who are
born with less GR than an average person (Mcewen et.al., 2016).
It is more common for a male to develop DID than a female.
The hippocampus in a male naturally becomes reduced 1-1.5%
per year while the amygdala is unchanged. Female resistance to
this reduction is attributed to the production of estrogen which
somehow acts as a prevention (Vermetten et.al., 2006).

Conclusion
It is clear how much damage stress can do in terms of brain
plasticity. Through mechanisms of how stress affects the brain
it can be understood how DID can possibly develop. Treatment
regarding DID is not proven to be 100% efficient or effective,
but it may improve and make the disorder livable. Therapists
dealing with DID patients will try to bring forth all their identities and help the patient deal with the trauma they experienced
that sparked this disorder. As seen in the Three Faces of Eve,
therapists may attempt for years to merge all the personalities together in order to diminish symptoms of dissociation.
Cognitive behavior therapists introduce the patient to various
coping mechanisms as an alternative to switching identities. One
form of treatment that is not effective is to diminish personality states that are not positive or that may be detrimental
to the environment. Since those identities exist to protect the
patient from abuse it should be incorporated appropriately into
their comprehensive personality (Gillig, 2009). Antidepressants
may be another form of treatment for DID because in rodents
neurogenesis of hippocampus was induced by them (Vermetten
et.al., 2006). Recent studies show that the drug paroxetine may
be useful in treating DID. Paroxetine has proven to regenerate hippocampal growth by 4.6% and to limit the symptoms of
DID and PTSD . The correlation between DID and PTSD has
shown to be very similar in neurobiology and causation of the

disorders (Nijenhuis et.al., 2010). So many factors are involved
in the development of DID, thus making the disorder very rare.
The treatments noted are just a step in the direction to help
understand the disorder and to further the subjects of research
on DID. Even though it is understood how stress causes plasticity to the hippocampus and amygdala creating symptoms involved in DID, there is still so much about DID that is unknown
to the world and is a mystery till today.
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Abstract
The use of gene therapy as a medical treatment option was first introduced to the world in 1990, when a four-year-old girl
became its first patient. Since then gene therapy has met great success but also severe drawback. Incidences with severely
negative outcomes on patients gave gene therapy a bad name and many began skeptical towards its use, but the constant work
and progress on the safety and effectiveness of gene therapy is making it a more viable route of treatment. This paper focuses
on gene therapy as a form of cancer treatment. Viral insertion of the modified genetic material is the most effective method of
insertion, targeting a large number of cells, although physical insertion may be safer and more economical. The mechanism by
which many gene therapies work is suicide genes, genes that cause the cell they enter to lyse. The paper goes on to discuss the
H-19 locus on the genome, which plays a significant role in cancer development and conversely, treatment. BC-819 is a plasmid
that is synthetically produced to treat cancer based on targeting the H19 locus. Research and test models of the BC-819 show
promising results for many cancer patients.
Introduction
Cancer is the second leading cause of death worldwide, taking
the lives of over 8.2 million people every year.The standard cancer treatments, such as chemotherapy and radiation therapy, are
often inadequate and debilitating, destroying healthy fast-growing cells in the process of treatment. Over the past decade,
gene therapy has become a more prevalent option for treating
cancers. Gene therapy avoids targeting healthy cells, selecting
only cancerous cells for treatment. There are three approaches
to gene therapy immunotherapy: stimulating a patient’s immune
system to recognize and attack cancer cells, oncolytic virotherapy, which generally uses viruses to infect and kill cancer cells,
and gene transfer, which is the insertion of genetic material into
the cancerous cells. This paper aims to consider the viability of
gene transfer therapy. Gene transfer therapy is an exciting new
technology that is shifting the paradigm of cancer treatment.
It involves inserting a foreign gene directly into the cancerous
cells or surrounding tissue’s genome (Cross, Brumester 2006).
With all the strides and progress made in gene transfer there
are still problems that need to be rectified. In early safety test
cases, gene transfer scared many by causing the death of a patient (Raper, et. al. 2003). Also, in some cases, gene transfer
methods have promoted leukemia in their attempt to cure the
patient of his disease (Thomas, et. al. 2003). Additionally, there
is still plenty of research yet to be done in this area due to its
relative newness. This paper will assess how much of an option
gene therapy is for cancer patients, taking into account its numerous benefits and sometimes severe drawbacks.

Methods
Research literature for this paper was obtained through the
Touro College Online library. Searches done on the Touro
College Online library led the student to Proquest and Pubmed,
where majority of the articles were obtained. Articles found on
other scholarly sites were also used. The articles discussed experimental studies done and the thorough analysis of these articles allowed for the assessment of gene therapy’s practicability.
Review articles also assisted in composing the formal analysis.

Discussion
The standard treatment method for cancer today is chemotherapy. Chemotherapy can cause an array of both short term and

long term side effects. Short term side effects are side effects
that are present during the time of treatment and are often
reversible, while long term side effects cause more severe and
permanent damage. Short term side effects include hair loss,
nausea, and vomiting, which can sometimes hinder patient compliance. Long term side effects such as arthritis, appendicitis,
and thyroid damage have less of a probability of occurring, but
do occur in some patients (Ramirez, et. al. 2009). The above
mentioned are general side effects, but each patients’ individual
circumstance can pose other possible risks. If patients could be
assured that chemotherapy would remove the cancer in totality,
undergoing chemotherapy would be more tolerable, yet in many
cases the chemotherapy fails to rid the body from the cancer
and therefore, is often not a preferable option.
In this paper, gene therapy will be analyzed to assess whether
it is a better option of treatment for cancer patients or whether
it is yet another treatment method that provides partial results
and causes severe side effects. How efficient gene therapy is in
treating cancer, what side effects it includes and what the severity of the side effects are all questions that need to be addressed.

Insertion Approaches
There are two approaches to gene insertion; it can be done
by means of either a viral or a non-viral vector (Amer, 2014).
A viral insertion uses a virus as a vector to harbor the drug. A
non-viral vector, which generally uses naked DNA or toxic material for the cell as a vector, can be inserted either chemically
or physically. Physical insertion can be done by a gene gun or
ultra sound. Another physical approach is that of electroporation, which uses high voltages of electricity to disrupt the cell’s
membrane, allowing the drug to enter the cell (Baranyi, et. al.
2013).

Viral Insertion
Viruses have long been a choice for a vector because of some
important properties they contain. Viruses are small pathogenic
particles that contain either DNA or RNA encoded in a protein
coat. Some viruses also contain a lipid bilayer surrounding the
protein coat. The mechanism in which a virus infects a cell is
by implanting itself on the host cell’s membrane and inserting
its viral DNA into the host cell. The host cell then transcribes
and translates the viral DNA, which codes for the creation and
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assembly of more viral particles. These new viruses cause the
cell to burst and proceed to infect more cells. The mechanism
by which the virus operates is useful, for genetic material that
will lead to cancer cell death or degeneration can be placed
in a virus vector, which is essentially the outer protein coat of
the virus deprived of its viral genome, and then infect the target tissue area. Before using it as a vector, the virus has to be
rendered non replicative so it no longer behaves as a pathogen.
Viral vectors are advantageous since they can be produced in
high concentrations and have minimal side effects (Amer, 2003).
The most popularly used viral vector is the adenovirus. The
adenovirus is favored since it can be made in high titers and can
infect both dividing and non-dividing cells. When using a viral
vector such as the adenovirus, steps must be taken to ensure
that the virus will not reproduce in the host’s body like it naturally would. Prevention of the adenovirus replication can be
achieved by removing early regions of the adenovirus vector’s
genome (Pulkkanen, et. al. 2005).

Comparing Adenovirus to Retrovirus
A comparison of the efficiency of the adenovirus and the retrovirus as vectors for gene transfer was done. Ten patients with
malignant glioma, a spreading brain tumor, were treated with a
beta galactosidase gene via retrovirus and adenovirus vectors.
This was done by inserting a catheter into the tumor and injecting the patient with retroviruses and adenoviruses for three
consecutive days. This was followed by resection of the tumor
one to two days later. X-gal staining was then used to highlight
the beta galactosidase gene and to evaluate its efficacy in gene
transfer. Findings showed that beta galactosidase was well tolerated with both vectors. In all but two patients, no systemic
or tissue complications were apparent. The gene transfer was
successful, with an efficacy between <.01- 4% for the retrovirus
and an efficacy <.01-11% for the adenovirus. The adenovirus
was thus more efficient then the retrovirus as a gene transfer
vector (Puumalainen, et. al. 1998).

Malignant Glioma Adenoviral Gene Therapy
Although adenoviral vectors have some of the highest efficacies
of gene transfer amongst other viral vectors, they still fall short of
producing significant effects on the treatment of tumors. A study of
the treatments of malignant glioma was conducted with the aim of
evaluating the safety of the adenoviral vector as well as determining
the maximum possible dose that would be tolerated. Fourteen patients with relapsed malignant glioma were treated with adenoviral
vector containing the Herpes simplex virus thymidine kinase (HSVtk) and its promoter (IG.Ad.MLPI.TK), and were then treated with
ganciclovir, an antiviral drug. Prior to this the retrovirus had been
used as a vector for HSV-tk gene therapy treatment. However, the
adenovirus was used in this study because of its advantages of high
titer production and efficacy of gene transfer.
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The patients underwent as much debulking of the tumor as
was considered safe. The wound bed was then infiltrated with
around 50 evenly spaced injections of the HSV-tk gene. The
patients were treated with different dose levels and then monitored for any adverse events. The patients reported either
adverse events or serious adverse events. From surgery until
completion of the ganciclovir treatment, 27 adverse events and
5 serious adverse events were reported. However none of the
adverse events or serious adverse events were from the adenoviral vector.
After surgery, the patients were kept in strict isolation in the
ICU, and viral cultures were taken until there were two consecutive days of negative culture results. None the cultures taken
were found to be positive, indicating that the viral vector did
not shed during its administration and did not pose a hazard to
the environment.
The adenovirus was thus considered to be a safe vector internally and externally. However, in regard to the results of the
patients’ tumor responses, the adenovirus does not appear as
promising. Unfortunately, none of the tumors responded to the
successful gene transfer. Overall the patients did not fare well.
The median survival time was four months, with four patients
surviving for over a year. The median survival time attained in this
study with the injection of the adenoviral vector was no better
than the survival time in respective studies of malignant glioma
with no gene therapy treatment. According to the study, even the
survival of patients with the favorable prognosis was most likely
due to the nature of the tumor and not the gene transfer.
It is clear that the adenoviral vector used in this study is a
safe method of choice but not significantly effective in diminishing the tumor growth. It is not definitive from this study if
the adenoviral gene transfer had even any effect on the tumor.
(Smitt, et. al. 2003).
In contrast to viral vectors, non-viral vectors are generally
more economical and easier to produce in large quantities.They
also have limited immunogenicity which allows for re-dosing.
There is no concern of a gene recombination causing the virus
to become competent and pose a danger to the body (Amer,
et. al. 2014).

Physical Insertion
Physical insertion involves injecting naked DNA or liposomes
directly into the target cell through a breach in the membrane
made by rapid needle or jet injections, particle impact, electric
pulse, laser radiation, or ultrasound. A novel method of physical
insertion is the Jet injection, which was first introduced in 1947
as an alternate to needle injections. Jet injection uses a pressurized gas, like carbon dioxide, to drive an ultrafine high speed
stream of DNA into the target tissue in the form of plasmids.
Comparisons done between jet and needle injections demonstrated that gene expression was fifty times greater when

Is Gene Therapy a Viable Option for Cancer Treatment?

done by jet injection than it was done by the standard needle
injection.
A phase 1 study was conducted to determine the safety and
feasibility of jet injection on patients with skin metastases from
melanoma and breast cancer. Seventeen patients received five jet
injections of B-galactosidase, a LacZ- expressing DNA plasmid,
into a single cutaneous lesion. To monitor the clearance of the
plasmid in the blood stream, real time quantitative PCR of blood
samples was done throughout the study. After two to six days,
the lesions were resected and a series of tests were performed
to determine the efficiency of the plasmid uptake, as well as the
transcription of DNA to mRNA and translation to a protein.
All the patients responded well to the jet injections. Four
weeks after jet injection, all the patients were alive and none
showed any adverse effects from the jet injection. Within
forty-eight hours any small bleeding and jet penetration at
the injection site disappeared. Additionally, the LacZ plasmids
were successfully taken up by all the tumors, with variation in
amounts detected in each tumor (Wolfgang, et. al. 2008).
Because this was a phase 1 study, research was taken to determine the safety of the jet injection and did not cover the
efficacy of jet injection in reducing cancerous growth. The LacZ
gene did not have any association to reduction of cancerous
growth, but rather served as a marker to determine if jet injection was a viable method of gene transfer. Research on humans
using jet-injection-based gene transfer as antitumor therapy is
limited and quite recent.There have been studies done on mice,
though, with encouraging results.
A study was conducted on mice containing human colon carcinoma to test the effectiveness of gene transfer jet injection in its ability
to inhibit tumor growth. The mice were injected four times with
a suicide gene, Escherichia coli cytosine deaminase, and then after
forty-eight hours treated with 5-flurocytocine, an antifungal drug.
Tumor volumes were monitored, and starting on day five, there was
a significant decrease in the size of the tumors treated with the jet
injected suicide gene in comparison to the control groups’ tumors.
Additionally, protein and mRNA levels revealed that the suicide
gene was sufficiently expressed (Walther, et. al. 2005).
Although this study was not conducted on humans, it still has
significant findings, chiefly that non-viral jet injection of suicide
genes is an alternate method to injection via viral vectors, with
comparable therapeutic response. Though there are studies, as
mentioned above, of successful adenoviral vector gene transfers,
the adenoviral vector does have limitations that the jet injection
does not. When using the adenovirus as a vector, there is always
the concern that it may have a pathogenic effect on the patient,
or that the patient’s immune system will respond to the viral
proteins and inhibit the vector in completing its task. Jet injection looks promising for cancer treatment, but it is only useful
for subcutaneous cancerous growths, like that of melanoma and
breast cancer, since it cannot penetrate very deep.

Suicide Genes
Once the genetic material is successfully transferred into the
host cancer cells and incorporated into the nuclear genetic
DNA, there are a few methods by which it represses tumor
growth. A key method being the injection of suicide genes,
which are genes that cause apoptosis, or cellular death, when
expressed. These genes are usually transcribed by various promoters found within the host cell. The H19 RNA gene is an
example of one such promoter. The H19 gene locus was the
first imprinted non-coding RNA identified. Recently, extensive
study has been done on the role of the H19 gene and tumorigenesis. It is found that there is an abnormal expression
of the H19 RNA gene in many cancerous cells, causing cancer
cell proliferation, genetic instability, vascular angiogenesis, and
tumor metastases. In a number of studies, blocking the H19
gene led to tumor regression and necrosis (Amer, et. al. 2014).

H19 Locus and tumorigenesis
The H19 RNA gene is greatly expressed in fetal organs but
is rapidly turned off at birth. In tumor cells, the H19 gene
becomes highly expressed or shows an abnormal expression
pattern when compared to normal non-cancer cells. In cancer
cells, the H19 gene expression can be activated by a combination of various transcriptional modulators and regulators that
have malfunctioned. The interplay of the H19 gene locus and
the modulators in tumorigenesis is highly complex, involving
many regulatory factors that rely on many other regulatory
factors (Matouk, et. al. 2013).

Hypoxia and H19
One such approach to the H19 gene’s upregulation in cancerous cells is through hypoxia. Hypoxia is the loss of oxygen to areas of cancerous growth, and is considered a major
trigger for metastasis, tumor angiogenesis, and chemotherapy
resistance. Hypoxia is also considered to increase H19 expression in tumor cells. A study was done to investigate the
relation between hypoxia and H19 upregulation in tumor cells.
Carcinoma and Hepatocellular carcinoma cell lines were placed
in an Aneropack rectangular jar and supplemented with Gaspak
to create a hypoxic environment. Some cells where left with
normal oxygen conditions as a control. The cells were then
monitored by a hypoxic indicator. After twenty-four hours, the
cells were examined and RNA from each cell was extracted and
amplified through PCR. Viewed on the gel, the cells under anaerobic conditions expressed the H19 RNA significantly more
than the cells under normal oxygen conditions.
In a similar study, mice were injected with Hep3B, cells containing hepatitis B, which caused the proliferation of Hepatocellular
carcinoma on their dorsal side. A group of those mice were
then injected with siRNA, a H19 gene knockout. The results
showed that the mice that were treated with the siRNA showed
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a significant retardation of tumor growth of 82%.Thus, from this
study it is clear that H19 plays a large role in tumor growth, and
is activated by hypoxia, which is common in cancerous growths
(Matouk, et. al. 2007, Matouk, et. al. 2005).

c-Myc and H19
Another factor that induces H19 transcription is the c-Myc
transcription factor. C-Myc is a transcription factor that, together with its obligate partner, protein Max, another transcription factor, binds to E-boxes, which are enhancer sequences on
the DNA that initiate transcription. C-Myc then promotes gene
transcription by initiating chromatin remodeling on the DNA
or RNA polymerase clearance. To assess the role of c-Myc in
tumor cells with increased H19 expression, a study was designed in which c-Myc was inserted into breast and glioblastoma
cell lines. Cells inserted with c-Myc showed a seven-fold to
ten-fold increase of H-19 expression based on Real-time PCR
readings. Breast and lung cancer cell lines were also used to
determine the correlation between elevated levels of c-Myc
and H19 and tumor growth. The cell lines containing elevated
levels of H19 and c-Myc were treated with siRNA to knock
down H19 expression. The cells with knockdown H19 exhibited significant retardation of tumorigenesis. Thus, c-Myc was
established as another factor that induces H19 upregulation and
thereby increases tumor growth (Barsyte, et. al. 2006).

contains bioluminescence. Results showed that serum-starved
cells had very little H19 expression, while cells in S phase had
remarkably increased levels of H19. The cells transfected with
the mutated promoter site had low H19 expression compared
to the wild type cells that had overall increased H19 expression,
especially at S phase (Fig. 1).
The correlation between H19 and E2F1 binding to its promoter is demonstrated when the comparison between the wild
type and mutated transfected cells are noted.The cells with wild
type H19 promoter sites showed a higher concentration of luciferase activities, since E2F1 was able to bind to the promoter
site and activate transcription, while the cells with the mutated
promoter sites exhibited a lower concentration of luciferase
activities since E2F1 was not able to bind to the mutated promoter site. Additionally, H19’s and E2F1’s definite role in G1/S
phase is observed by the fact that the greatest percentage of
cells were recorded during the S phase of the cell cycle.

E2F1 and H19
Another basis for increased H19 expression in cancer cells is
the E2F1 regulatory factor. E2F1 belongs to the E2F protein
family that regulates DNA by binding to promoters. E2F1 binds
to the H19 promoter and initiates its transcription. E2F regulation is based on the stages of the cell cycle. E2F1 is considered
a key factor in the transition from G1 to S in the cell cycle, as
it promotes the transcription of genes whose protein products
are necessary for the progression of the cell cycle and for imitating DNA duplication. Thus, increased E2F1 expression when
it is not the appropriate cell stage or time for cell replication
can lead to cancerous growths.
A study conducted assayed the correlation between increased
E2F1 and H19 gene expression in the S phase, as well as E2F1’s
impact on tumor growth. First, epithelial breast cells were
transfected with a luciferase reporter gene, a selectable marker
gene that, when expressed, causes the cells to emit a bioluminescence. Half of the cells were transfected with a luciferase reporter gene carrying the wild type H19 gene and the other half
with a mutated promoter site of an H19 gene, so E2F1 binding
is inhibited. The breast cells were then serum starved, and after
twenty-four hours, some cells were placed in a fresh medium to
stimulate their entry into cell cycle. After a set time, the cells
were then compared using FACS analysis, a fluorescent strength
intensity test, because the luciferase reporter that was used
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Figure 1: A. Cells were treated with luciferase reporter gene with
either wild type (WT) H19 promoter sites or H19 promoter
mutated in two E2F sites (DMut).The cells with the wild type
promoter exhibited the higher concentration of luciferase activities
than the mutated cells.
B. Shows the percentage of cells distributed throughout the cell
cycle. Note the elevated S phase line. (Berteaux, et. al. 2005)
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The second step of the study was to examine the roles of
H19 and E2F1 in cancer proliferation. Breast cancer cell lines
were obtained and the levels of E2F1 mRNa and H19 RNA were
calculated. Normal breast cells were used as a control.The data
showed that the expression of E2F1 and H19 were generally
corresponding. In the healthy breast cells there were low levels
of both E2F1 and H19 expression, while most of the cancer
cells showed notable activation of E2F1 and H19 gene. In one
line of cancer cells however, the E2F1 expression was high but
the H19 expression was comparatively low. This discrepancy
was attributed to heterogeneity of breast tumors. In general,
there is a correlation between E2F1 and H19 upregulated gene
expression in cancerous tissue (Berteaux, et. al. 2005).
Based on the studies discussed above, increased H19 expression is regulated by a number of regulatory factors, such as
c-Myc and E2F1. Their upregulation is also triggered by environmental stress conditions such as hypoxia and S phase induced
cells after serum starvation. However, cells under normal conditions do not demonstrate significant H19 expression (Ayesh,
et. al. 2002). These findings reinforce the evidence that H19 is
upregulated in many cancer cells, for hypoxia and serum starvation are considered normal stages in tumor growth. Thus, the
tumor’s growth causes its further proliferation. As it outgrows
its blood supply, some portions of the tumor lack sufficient oxygen and reside in hypoxic microenvironments, which in turn
triggers the increased expression of H19, further promoting
cancerous growth.
Some of the explanations of H19 gene upregulation in tumor
cells have been presented, and the therapeutic methods involving the H19 locus will now be discussed.

BC-819 Gene Therapy
In the past couple of years, BC-819, a plasmid involving a suicide
gene and the H19 promoter, has been developed and has successfully improved treatment of a number of cancers. BC-19 is
a double-stranded DNA vector that contains Diphtheria toxin
A sequence, which isused to destroy the cancer cell, and an H19
promoter sequence. It is mixed with Polyethylenimine transfectant (PEI), which allows for easier entry of the plasmid into the
rapidly dividing tumor cells. In some cases, PEI is not used and
BC-819 is injected intratumorally or by hepatic artery infusion
(Matouk, et. al. 2013).
Once BC-819 is in the cancer cell, the H19 promoter is activated and transcribed continuing with the Diphtheria toxin A
sequence, which causes cell death by disrupting protein synthesis. BC-819 can actively select tumor cells to destroy, since
only tumor cells have increased levels of H19 transcriptional
factors. BC-819 will enter healthy cells as well, but since they
lack the H19 regulatory factors, they will not transcribe the
plasmid and the cells will not be destroyed. BC-819 is an ingenious development that acts as a ‘search and destroy’ unit by

only killing cells that contain H19 transcriptional factors thereby
triggering their own demise (BioCanCell, 2017). BC-819 has
been semi-successful at treating bladder, pancreatic and ovarian
cancer patient (Fig. 2)s.

Figure 2 (BioCanCell, 20170

Bladder Cancer
In the United States, bladder cancer is the fourth most common cancer in men, with an estimated 74,000 annual incidents.
Around 70% of bladder cancer patients suffer recurrence within
five years. A chief goal of battling bladder cancer is in preventing
its recurrence. For decades, the standard care option was the
BCG vaccine but the vaccine included drawbacks such as recurrence, resistance to the treatment, and negative side effects
(Matouk, et. al. 2013).
A phase 2b study was conducted testing the efficacy of BC819 treatment of bladder cancer. Patients who had confirmed
recurrent bladder cancer and for whom BCG and chemotherapy had failed were recruited and BC-819 with PEI was administered to them. First, they were given six weekly treatments
of BC-819, and at week nine, safety and efficiency of transfer
were assessed. In cases of no toxicity or recurrence therapy
was discontinued in patients and follow up maintenance therapy
was given for the duration of the year. From the first cohort,
nine out of eighteen patients had complete resolution of the
target lesion within eight to ten weeks. Overall, 63% of patients had recurrence-free tumors for the first three months
after treatment and 48% had tumors for a year after treatment.
Additionally, the patients tolerated the treatment well with only
mild to moderate adverse effects.
Reports of Phase III trials have not yet been published but
trials are in progress as of the year 2016.

Pancreatic Cancer
The eighth leading cancer cause of death in the United States
is pancreatic cancer, with a poor prognosis of five year survival.
The standard treatment for pancreatic cancer is gemcitabine,
a chemotherapy drug. However, gemcitabine has limited effect
because of its poor intracellular metabolism. Other methods
have been tried in combination with gemcitabine in the hope
of a more effective treatment, but none proved worthwhile.
Recently, BC-819 and gemcitabine were tested together on pancreatic patients in a phase 2b study that showed more promising
results. Patients received four week treatments of gemcitabine
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and were then administered with BC-819 through endoscopic
ultrasound. Continued treatment with gemcitabine and BC-819
was done for as long as the cancerous growth did not progress.
After three months, nine out of eleven patients showed encouraging results. Two had partial recovery and seven reached
a point of stable disease. There were several adverse events
mostly relating to liver function, but it was concluded that the
adverse events were not related to the BC-819 , but were rather due to the advanced stage of the cancer that all the patients
had (Matouk, et.a. 2013).

Ovarian Cancer
For women, ovarian cancer has a high mortality rate and is the
fifth leading cause of cancer related death in the United States.
Ovarian cancer patients generally have a poor prognosis, because
the initial detection of the cancer is usually after it has reached an
advanced stage. The typical course of treatment includes surgical
removal of the tumor followed by chemotherapy. Unfortunately,
most patients with the advanced stage tumor experience relapse after treatment. In the hopes of finding a better alternative
treatment course, a phase ½ study testing the efficacy of BC-819
plasmid was conducted on fourteen ovarian cancer patients. All
fourteen women had been pretreated with extensive chemotherapy. Different doses of BC-819 were administered to different
groups of the patients. The first cohort of patients were treated
for three weeks with BC-819, rested for a week, and were then
treated for six more consecutive weeks. This was followed by a
four week rest period. The second and third cohort were treated with increased dosages for three weeks, with four weeks of
rest and then an attempt at repeat treatment when possible. Of
the fourteen subjects, only 3 completed the study, while the rest
withdrew prematurely due to overall clinical deterioration. There
were fifteen reported severe adverse events, yet none were from
the drug. There were, however, five adverse events that were
possibly related to BC-819 administration. The best outcome of
the treatment was a stable disease, with insufficient shrinkage or
growth to qualify as either a partial response or progressive disease. The patients in the study all had advanced tumor growth,
but the findings suggest that with less advanced stage ovarian
cancer, BC-819 treatment would yield a partial response (Lavie,
et. al. 2017).
BC-819 shows great promise for cancer patients. Although
not every patient treated in the studies mentioned above had
a positive outcome from the treatment, no one’s medical state
was worsened. The study of the BC-819 treatment is still in
progress. The studies mentioned above are phase one or two
studies, which means they are being done to determine the
maximum tolerable dose of the drug, its safety, and efficiency. A
phase three trial is generally the final test performed before the
drug can be open to the public. A phase three trial is presently
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ongoing for bladder cancer, and a phase one/two has been completed for ovarian and pancreatic cancer.
Based on the various studies presented, gene therapy appears
to be a viable option for cancer treatment. Although in each
study there were some patients who did not fare well with this
form of treatment, as an overall option, gene therapy looks like
a promising alternative for cancer patients for whom standard
treatment is insufficient.

Gene Therapy and Leukemia
However, there have been studies that have shown that in its
attempt to rid the patient of his illness, gene therapy can actually
promote one of the deadliest cancers, leukemia.
In 2002, a group of infants with severe combined immunodeficiency (SCID) were treated with gene therapy, but four out of
the nine patients developed leukemia within the next five years.
This alarmed many patients and researchers, and was a major
setback in the advancement of gene therapy.
SCID is caused by a genetic mutation, making a patient with
it lack the IL-2 receptor γ (IL2RG) gene. To restore the absent
gene, the infants in the study were treated with a therapeutic gene via a retroviral vector. However, the retroviral vector
works by inserting its genome near a transcription start site
in the host genome, allowing the virus’ long terminal repeats,
which are repeated identical sequences of DNA that enable
insertion into the host genome, to unintentionally turn on
transcription of other nearby sites. In these infants with SCID,
the LMO2 oncogene site was found near the insertion site and
was turned on, promoting leukemic growth (Hacein-Bay-Abina,
et.al. 2008).
The events of this gene therapy treatment were unfortunate,
and did remove some of the enthusiasm for gene therapy at the
time. However, the fact that this occurred on SCID patients and
not on cancer patients must be taken note of, thus gene therapy
might not be the right choice for SCID patient, but that does
not rule out cancer patients. Cancer patients may not have an
oncogene site near the insertion site for their therapeutic gene,
which completely removes the possibility of inducing leukemia.
In the research done, no reports have been made demonstrating that gene therapy for cancer patients further induced new
cancerous growths.

Conclusion
Although gene therapy as a treatment option for cancer has
had some setbacks and inconclusive results, it still provides
a large source of hope for cancer patients. The paradigm of
treating cancer is slowly shifting due to the ongoing progress
of gene therapy. Based on the studies presented above, overall
gene therapy, whether administered through a viral vector or
a non-viral vector, was successful in treating a portion of the
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patients. Additionally, even in the studies done in which small or
no substantial recovery was obtained, there were no considerable adverse effects on the patients treated with gene therapy.
This greatly contrasts standard treatments like chemotherapy
that cause an array of adverse effects on the patient without
necessarily providing complete removal of the cancer. Thus,
even though gene therapy may not provide a complete cure
against cancer, it is a promising alternative to standard cancer
treatment. With the constant hard work and progress of medical researchers and physicians that is presently taking place, it is
anticipative to say that gene therapy will provide great relief to
many cancer patients in the coming years.
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Abstract
Alzheimer’s disease is a common neurodegenerative disease that is the 6th leading cause of death in the United States. An
estimated 5 million Americans are afflicted nationwide and the cost to the economy is valued at 259 billion dollars. Additionally,
unlike other major causes of death in the United States, there is no treatment for Alzheimer’s Disease. Alzheimer’s is a progressive disease and it is strongly tied to aging. In most cases symptoms make their first appearance in the late 60’s and gradually
worsen, eventually leading to a loss of cognitive function and death. The two outstanding changes in the brain associated with
Alzheimer’s disease are neurofibrillary tangles and beta amyloid plaque. The presence of these is used to diagnose Alzheimer’s
disease after death. Certain hormonal changes that are associated with age, such as a rise in luteinizing hormone levels, are
strong contenders for the age-related causes of Alzheimer’s disease. Elevated gonadotropin levels have been shown in studies to
correlate with amyloid beta accumulation in human and animal brains. The precise mechanism of action and the causation are
not yet fully understood. Nevertheless, some studies have shown that lowering levels of Gonadotropin-releasing hormone (which
releases luteinizing hormone) through the treatment with Leuprolide acetate, a gonadotropin releasing hormone agonist, have led
to lowered risk of mortality by Alzheimer’s disease in both mice and humans.This paper will discuss the association between elevated luteinizing hormone levels and Alzheimer’s disease as well as the possibility of a Gonadotropin-releasing-hormone blocking
based treatment for Alzheimer’s.
Introduction
Alzheimer’s disease is named after Dr. Alois Alzheimer who first
discovered the disease in 1906. Dr. Alzheimer had a patient with
severe memory loss, aphasia, and unnatural behavior who died
of complications related to her disease. Upon her death, he
performed an autopsy and noticed two unusual features in the
brain, tangles of fibers and protuberances. We now know these
as neurofibrillary tangles and beta amyloid plaques. It is difficult
to accurately measure tangles and plaques during the lifetime
of a patient with the disease; therefore, Alzheimer’s disease is
diagnosed based on symptoms. The symptoms that are used to
diagnose Alzheimer’s disease today are much like those of Dr.
Alzheimer’s original patient. The common symptoms are memory related issues, trouble with organizational skills, getting lost,
confusion, and personality changes. Eventually the deterioration
escalates and the patient may hallucinate, become unable to
recognize others, and then become unable to talk or eat. Lastly,
the parts of the brain that directly control living processes are
affected and death occurs. (National Institute on Aging, 2012)
The progression of Alzheimer’s disease does not happen
quickly, in fact Alzheimer’s is a very slowly progressing disease,
and there is usually 5-10 years between the first appearance of
symptoms and death. This being the case, it is theorized that
even before symptoms occur, perhaps years prior, there is a
form of “pre-Alzheimer’s”. This can be defined as asymptomatic
changes in the brain which are the true first steps of Alzheimer’s
disease. The ability to detect these changes would greatly assist
in the struggle to find a cure and is currently being researched.
(National Institute on Aging, 2012)
Unfortunately, it is not possible with our current level of
technology to reliably detect the changes in the brain that are
present in Alzheimer’s, even advanced Alzheimer’s. Although we
have come a long way with neuroimaging methods, they are unable to determine Alzheimer’s disease directly. Instead, after the
onset of symptoms, brain imaging techniques such as MRIs and
PET scans are used to rule out other probable causes of brain

dysfunction; such as stroke or other forms of dementia. If these
are not indicated, a diagnosis of probable Alzheimer’s is given
until death and autopsy. Upon autopsy, if there are neurofibrillary tangles and amyloid plaques, the diagnosis is then confirmed
(National Institute on Aging, 2015).
Neurofibrillary tangles and beta amyloid plaque are the two
main physical phenomena that define Alzheimer’s disease, but
the mechanism that they use to influence Alzhiemer’s disease
and cause the deterioration of the brain is not yet understood.
Neurofibrillary tangles are also called tau tangles as they are
composed and caused by defective tau proteins. Tau proteins
are microtubule-associated proteins that are common in the
central nervous system. In a healthy person, these tau proteins
hold microtubules in place and keep them steady. However in
Alzheimer’s disease the tau proteins become hyperphosphorylated and they cease to support the microtubules. The microtubules unwind and collapse and the hyperphosphorylated tau
builds up. Together they form filamentous clumps which are the
neurofibrillary tangles of Alzheimer’s disease. It is not certain if
the tangles participate in the cause of Alzheimer’s disease or are
just an effect of it (C. Bancher, 1989). However, the density of
the tau tangles correlates with the extent of dementia and they
are located in the affected brain areas. A possible mechanism
by which the brain degenerated by neurofibrillary tangles is as
follows. When disrupted microtubules are abundant, the neuron is weakened and it becomes unable to transmit impulses
at a normal rate. The body’s immune system detects compromised neurons and triggers apoptosis of the cells (Wang, Xia,
Grundke-Iqbal, & Iqbal, 2013).
The more significant Alzheimer’s disease marker is beta amyloid plaque. In the healthy brain, tangles and plaques are present
in small quantities and pose no problem. It is when the beta
amyloid amounts build up that issues arise. It is understood that
this build up is the result of a difference between the amount
of beta amyloid plaque that is formed and the amount that is
removed. Beta amyloid plaque is formed by the breakdown of
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Figure 1: Nuerofibrillary tangles in the Hippocampus of an elderly man with Alzheimer’s related pathology.
(Above:The tangle is enlarged and is visible above the the dark stain) (Patho, 2015).
amyloid precursor protein (APP), which is present in the synapses of neurons.APP is present all over the brain and is thought
to perform a function relating to neuron growth (Thinamaran
& Koo, 2008). APP is broken down by several enzymes known
as alpha, beta, and gamma secretase. When amyloid precursor
protein is broken down by a combination of alpha and gamma
secretase it forms a protein called αAPP which may have effects
that protect the brain (Krishnaswamy, Verdile, Groth, Kanyenda,
& Martins, 2009). However, when beta secretase takes the place
of alpha secretase, it forms beta amyloid, which is sticky and insoluble allowing it to form plaques.The process of how beta amyloid plaque is removed from the brain is not fully understood
but it could be performed in a variety of ways including protein

transport through the blood or destruction by enzymes, such
as insulin. Beta amyloid plaque is neurotoxic and it can inhibit
synapse formation, disrupt mitochondrial action, contribute to
inflammation in the brain, and promote the hyperpolarization of
tau proteins which in turn causes neurofibrillary tangles. Beta
amyloid plaques may be more important than neurofibrillary
tangles and tau proteins in the onset of age related Alzheimer’s.
Other diseases have tangles but Alzheimer’s disease is associated with plaque formation. (Lee, Goedert, & Trojanowski, 2001)
Additionally, it is supposed that beta amyloid plaque forms earlier in the progression of Alzheimer’s disease and contributes to
the neurofibrillary tangles (Villemagne, et al., 2013). This theory,
that beta amyloid plaque is the most significant factor in the
Figure 2: Cerebral autopsy specimen
of a patient diagnosed with Alzheimer
Disease. In the HE stain numerous
plaque formations within the neuropil
background are visible. (Neurofibrillary
tangles in the Hippocampus of
a person with Alzheimer-related
pathology, HE 1.JPG) (Patho, 2015)
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pathogenesis of Alzheimer’s is called the “amyloid hypothesis”
(Burnham & Thornton, 2015).
There are two forms of Alzheimer’s and they have inherently
different causes. Early onset Alzheimer’s is when Alzheimer’s
disease occurs to people under 65. Most people with this form
of the disease have a mutation in one of three genes, APP, PSEN
1, and PSEN 2. These mutations run in families and create a
disposition to suffer from early onset Alzheimer’s. (Bird, 2015)
This is a genetic disease but it is far less common than late
onset Alzheimer’s disease and it accounts for about 5 percent of
total Alzheimer’s cases. In late onset Alzheimer’s disease, there
is also a genetic component connected with the APOE gene
but the main risk factor is age. The older someone is, the more
they are at risk of late onset Alzheimer’s disease. The reasons
why age should increase risk for Alzheimer’s disease are not yet
understood. Research is being done into the natural changes
that occur in the body with age as possible contributors to
Alzheimer’s disease. The age-related changes to the hypothalamic/pituitary/gonadal feedback loop that regulates sex hormone levels in the blood is a strong candidate for this research.
The sex hormones are produced in the context of a feedback loop with Gonadotropin-releasing hormone in the hypothalamus and the gonadotropins, luteinizing hormone and
follicle stimulating hormone which are released by the pituitary
gland. In a healthy individual, Gonadotropin-releasing hormone
is released from the hypothalamus in surges in response to internal and environmental factors. It travels to the anterior pituitary gland where it stimulates gonadotropic cells to produce
luteinizing hormone and follicle stimulating hormone These
hormones travel to the gonads, the testicles and the ovaries,
and they stimulate them to release testosterone and estrogen

respectively.To prevent too much of these hormones from being
made, testosterone and estrogen in sufficient quantities provide
negative feedback that discourages the further production of
GnRH by the hypothalamus. However, with advancing age the
process changes. Testosterone levels fall gradually in men, and in
women estrogen drops rapidly after menopause. Without the
negative feedback of the endpoint, gonadotropin levels tend to
rise, although this is not true in all cases. (Jones, 2012)
For many years it was thought that the lowered levels of
testosterone and estrogen that come with age were involved in
the cause of Alzheimer’s. It was assumed that these hormones
had neuroprotective properties and their absence allowed
Alzheimer’s disease to creep in. However, it was found that
giving testosterone or estrogen directly did not lower risk for
Alzheimer’s disease and in fact raised it. (Manly, et al., 2000)
Since supplementing with testosterone/estrogen was not useful
in preventing or understanding Alzheimer’s disease, the next
logical step was to look at the heightened levels of gonadotropins that relate to the lower sex hormone levels. However,
even in this case distinctions must be made.
Luteinizing hormone and follicle stimulating hormone are
both released by the anterior pituitary gland in response to
Gonadotropin-releasing hormone. Structurally, LH and FSH
are similar. They both are heterodimeric glycoproteins and are
composed of an alpha and beta subunit. The alpha subunit of luteinizing hormone and follicle stimulating hormone are identical,
however, the beta subunit is different and this is how they connect to different receptors and have a different scope of action.
In men, luteinizing hormone is released throughout the day and
stimulates Leydig cells to produce testosterone. Follicle stimulating hormone stimulates Sertoli cells which help sustain the

Figure 3: A feedback loop regulates the Hypothalamic – Pituitary – Gonadal axis (Boundless.com, 2017).
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maturing sperm cells. In women, follicle stimulating hormone
stimulates growth of the follicle in the ovary which increases
production of estradiol and estrogen. When the follicle is mature, there is a critical level of estrogen that is reached and that
stimulates a surge in luteinizing hormones, which in turn causes
the release of the egg from the follicle. LH and FSH are different
in both structure and function and how they interact with amyloid plaque as well. Many studies have shown links specifically
between luteinizing hormone and the levels of beta amyloid
plaque in the brain and this will be presented and evaluated.
If increased levels of luteinizing hormone contribute to
Alzheimer’s disease, it would be useful to have an explanation
for how it does so. The presence of luteinizing hormone in the
brain is not expected as it is not lipid soluble and in theory cannot cross the blood brain barrier. However luteinizing hormone
is found in the brain and it has been found that LH can pass
through this barrier in small amounts (Lukacs, Hiatt, Lei, & Rao,
1995). It is also a possible that luteinizing hormone is synthesized in the brain itself. LH receptors are found not only in the
gonads but also in the brain which would imply that it may be
active there as well. It may be that signals which are mediated by
luteinizing hormone receptors affect the processing of APP and
influence it so it is more likely to be cleaved by beta secretase
than alpha secretase. This would result in a higher level of beta
amyloid plaque formed relative to αAPP and could trigger a cascade of beta amyloid plaque buildup and ultimately Alzheimer’s
disease.

Possibility of Treatment
Since elevated levels of luteinizing hormone could be a factor in the pathogenesis of Alzheimer’s disease, they are also a
target for prevention or reversal of the disease. By lowering
levels of luteinizing hormone in the blood, the contribution luteinizing hormone is making to the disease could be negated.
A potential medicine that could be effective in this therapy is
leuprolide acetate. Leuprolide, also called leuprorelin, is a synthetic hormone that is currently prescribed under the name
Lupron to treat prostate cancer, sex hormone imbalance,
and even less serious issues such as early onset of puberty
(World Health Organization, 2015). Leuprolide acts as an agonist to the Gonadotropin-releasing hormones. It binds to the
Gonadotropin-releasing hormone receptors in the pituitary
gland and interrupts their stimulation.This results in a downregulation of luteinizing hormone and follicle stimulating hormone.
Leuprolide is delivered by injection and it can be self-administered after training. It has mild short-term side effects including
dizziness, itching, and headaches. As a long-term treatment, it
can weaken bone density (Norsigian, 2005). However, with the
research we currently have, the long-term side effects do not
seem to be very significant, specifically when weighed against
the pathology of Alzheimer’s. The effectiveness of Leuprolide as
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a treatment to lower luteinizing hormone levels, improve cognition, and prevent or even reverse the accumulation of amyloid
plaque will be discussed in this paper.

Methods
All the information that was used in this article was gathered
from online using the Touro Library search and Google Scholar.
The search terms that were used were leuprolide acetate, leuprorelin, Alzheimer’s disease, beta amyloid plaque, luteinizing
hormone, gonadotropins, hormone, gonadotropin releasing
hormone. The articles were drawn from accepted and peer reviewed scientific journals and are all available online. Websites
that were used were selected from dependable sources, government websites or scientific institutions.

Discussion:
Alzheimer’s Disease and Heightened Luteinizing
Hormone Levels in Humans
In one study, plasma samples were taken from 284 patients seen
at a tertiary care center and measured for concentrations of luteinizing hormone and follicle stimulating hormone.The patients
were divided into three groups, 134 with probable Alzheimer’s
disease, 45 with frontal temporal dementia (FTD), and 105 cognitively normal controls. The researchers logged each patient’s
score on the Mini-Mental State Examination (MMSE) to measure severity of dementia. They recorded length of sickness, the
sex and age of the subjects, and, in the case of women, if they
were taking an estrogen supplement. It was found that there
was no relationship between follicle stimulating hormone levels in men between the controls and the Alzheimer’s disease
group and although there was one with luteinizing hormone,
it was not significant when controlled for age. The important
finding was that in the women who were not taking estrogen, a
significant difference in luteinizing hormone level was observed
compared to the controls after a univariate analysis (Figure 4)
In women who were not taking any form of estrogen, this
study found elevated levels of luteinizing hormone and follicle
stimulating hormone compared to controls. The luteinizing hormone levels were higher in the Alzheimer’s group compared
to the frontotemporal dementia group which indicates that
they were not just an effect of dementia or brain deterioration. There was no significant difference found for women who
were taking estrogen but that is not unexpected, considering
that estrogen is part of a negative feedback loop that limits luteinizing hormone production. Within the men, there was no
difference found between the FTD group and the Alzheimer’s
disease group. It is possible that this is due to the small sample
size. An important part of this study found that in estrogen free
women, there was a connection between elevated levels of gonadotropins and Alzheimer’s disease.
In a previous study by the same authors, a difference was
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test specifically for gonadotropin levels. Nevertheless, the blood
that was taken was tested for it amongst other things. Some researcher reviewed the data with an eye on luteinizing hormone
and it was found that increased levels of luteinizing hormone in
the blood were correlated with beta amyloid presence in the
brain as measured by imaging techniques. This was only found in
the subjective group, which suggests that the most important link
between luteinizing hormone and beta amyloid plaque is in the
preliminary stages of Alzheimer’s disease (Ellis, et al., 2009).

Animal Trials
Figure 4: Follicle-stimulating hormone (FSH) vs luteinizing hormone
(LH) levels in women not taking estrogen. Note that some patients
with Alzheimer disease (AD) (triangles) have both higher LH and
FSH levels compared with cognitively normal (NL) controls and
patients with frontotemporal dementia (FTD) (Short, Bowen,,
O’Brien, & Graff-Radford, 2001).
found for men as well. The study tested 40 males who were
diagnosed with Alzheimer’s disease in a long-term care center
and compared them to 29 controls. The study found that the
Alzheimer’s disease patients were significantly higher in both
luteinizing hormone and follicle stimulating hormone levels relative to the control group. (Bowen, Isley, & Atkinson, 2000).
In another study, 585 normal and healthy men between the
ages of 70 and 87 years were tested for luteinizing levels to try
to find a relationship between luteinizing hormone levels and issues with memory recall. Men were chosen specifically because
in previous studies, this correlation had not been demonstrated
for men as strongly as in women. The study found that higher
levels of luteinizing hormone were related to worse performance on CVLT-II which is a test for immediate recall (Hyde,
et al., 2010).
In an even larger study that evaluated the effects of elevated levels of gonadotropins on cognition in elderly women, 649
women without dementia were given cognitive testing and
blood samples were taken. Plasma levels of luteinizing hormone,
estradiol, follicle stimulating hormone, and beta amyloid were
recorded.The study found that elevated levels of luteinizing hormone were associated with worse cognitive performance and
depression (Rodrigues, et al., 2008).
In the Australian Imaging Biomarkers and Lifestyle study of
aging, more than 1000 people were assembled to conduct a longitudinal study to aid understanding Alzheimer’s beginnings and
progression. The subjects were given full cognitive evaluation,
their blood was analyzed and many of them had their brains
imaged by MRI machines and various brain imaging technology.
The participants were grouped by cognitive issues.The categories
were healthy, subjective memory impairment, mildly impaired, and
Alzheimer’s patients. It was not the primary focus of the study to

In studying disease pathology, and possible treatment options, it
is not always possible to use humans as some potential treatments may have negative side effects, it is therefore better to
first test their potential with animals. Mice are often used because of their biological similarities to humans. Some researchers have studied ties between luteinizing hormone, beta amyloid
plaque, and cognition in transgenic mice that have genes that
lead to Alzheimer’s disease development.To test for cognition in
mice, researchers use a test known as ‘spontaneous alternation’.
It is a behavioral test which tests spatial learning and memory. In
this test, the animal is put in the center of a maze and can move
freely. Spatial memory is tested by observing whether the mouse
remembers which arms of the maze it has already explored. It
should be noted that the test results can also be influenced by
factors such as attention or sensory stimuli (Hughes, 2004).
In a study of 21, one month old transgenic Tg2576 mice, the
effects of high luteinizing hormone levels in the mice on amyloid
beta plaque deposition were tested. The animals were bred to
over-express human APP to ensure that there would be beta amyloid plaque buildup. In this breed in general, beta amyloid plaque
grows throughout the first 6 months of age and by the time they
are 10 months old, the level of beta amyloid plaque is enough to
form an accumulation. The mice were randomly split into two
groups. One was a control group that received saline solution
and the second group received leuprolide. The mice were tested
with mazes to examine spontaneous alternation and their blood
levels of luteinizing hormone were assayed to evaluate the effects
of leuprolide.The brains were sliced on the sagittal plane and preserved to find the amount of beta amyloid deposition. The mice
that were treated with leuprolide were found to have significantly
lower levels of luteinizing hormone compared to the saline group
especially 3 months after the treatment. The leuprolide-treated
mice performed better on the maze task than the control group.
Additionally, the leuprolide-treated mice had lower levels of beta
amyloid plaque and this correlated with the improved cognition
(Casadesus, et al., 2006).
Mice which were bred to have an elevated level of amyloid
beta precursor proteins had higher levels of luteinizing hormone and faster cognitive decline. The group that was treated
with leuprolide, to help lower luteinizing hormone levels, had
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less beta amyloid plaque deposition and better cognitive performance than the controls.
In another study done with mice,Tg2576 mice that were bred
to express the human amyloid precursor gene were crossed
with mice that had the genes for luteinizing hormone receptors
removed, so that they couldn’t use luteinizing hormone. There
were two control groups. One of the control groups were APP
expressing mice that were not crossbred. A second control
group was mice that had luteinizing hormone receptors and did
not express the human APP gene. Finally, a group of normal mice
was a third control. The animals were raised for 16 months,
sacrificed, and then their brains were sectioned. An imaging
software was used to compare the beta amyloid concentrations
in the brains of each group. The most important finding in this
study was that there was significantly less beta amyloid plaque
in the mice which had luteinizing hormone receptor knockout
compared to the mice with APP that did have luteinizing hormone receptors. (Lukacs, Hiatt, Lei, & Rao, 1995)
The studies mentioned above all find a correlation between
elevated luteinizing hormone levels and Alzheimer’s disease or
beta amyloid plaque deposition. If luteinizing hormone is a part
of the cause of Alzheimer’s, it presents exciting treatment possibilities through the lowering of luteinizing hormone levels especially to prevent deterioration in those at risk for Alzheimer’s. A
promising candidate for a medication that can accomplish this
safely is leuprolide.

Leuprolide as a Treatment for Alzheimer’s Disease
Leuprolide interferes with GnRH in humans and therefore
brings about lower levels of luteinizing hormone. It is not an
approved treatment for Alzheimer’s disease as of now. However,
since leuprolide is an approved treatment for prostate cancer,
some studies have observed the effect that leuprolide has had
on Alzheimer’s disease in the patients using it for other reasons. Clinical trials are currently underway to test this possibility under the code ALADDIN which is an abbreviation for
Antigonadotropin-Leuprolide in Alzheimer’s Disease Drug
Investigation
One study of the impact of leuprolide on Alzheimer’s disease
in patients with prostate cancer was done in 2010. The study
looked at the risk of death by Alzheimer’s disease in 6,647 men
who were treated for prostate cancer. In the study, 1700 men
who were treated with leuprolide were compared to 4,947
controls who were treated using other drugs that do not limit
luteinizing hormone production. After 4 years of follow up, 81
of the group in the study had died from Alzheimer’s disease.
Those who died of Alzheimer’s were found to be from the control group rather than from the group of patients who took
leuprolide for at least 4 months (D’Amico, Braccioforte, Moran,
& Chen, 2010).
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The results were that Leuprolide can aid in slower regression and improved cognition in Alzheimer’s patients. Voyager
Pharmaceuticals is not currently pursuing further research into
Lupron and most likely will not do so in the future as it declared
bankruptcy in 2012. In an interview for medicalresearch.com,
Richard Bowen cited lack of marketability to account for the
dearth in leuprolide research. “Unfortunately, there is no intellectual property protection for this treatment making it unlikely
that a pharmaceutical company will take the lead.” (R. Bowen).
It is vitally important to find a cure for Alzheimer’s and perhaps
the funding will come from a government the government or
foundation, and leuprolide research will be continued.

Conclusion
Alzheimer’s disease is a common debilitating disease that is
one of the main leading causes of death in the United States.
One of the main changes detected in the brain of a patient
with Alzheimer’s disease is beta amyloid plaque. These plaques
can only be detected after death, upon autopsy. Studies have
shown that a rise in luteinizing hormone is linked to increased
beta amyloid plaque and Alzheimer’s. Studies have been done
to lower Gonadotropin-releasing hormone levels through the
treatment of Leuprolide acetate, a Gonadotropin-releasing hormone agonist. This treatment is not being financially backed and
is therefore on hold for the time being; however, the possibility
of this treatment for Alzheimer’s disease is somewhat promising
and deserving of more research.
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